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Haemophilia A: 44 families with Haemophilia A have been studied comprising 107
males and 125 females. In 22 families there was only a single isolated affected male
whilst in the remaining 22 there was a family history of haemophilia. Of the males 53
were haemophiliacs and of these 37 had severe disease (VIII:C <0.01iu/dl), 7 had
moderate disease (VIII:C >0.01 but <0.05iu/dl) and 9 had mild disease (VIII:C
>0.05iu/dl). From pedigree analysis 40 women could be established as obligatory
carriers, 5 women were considered to be normal and the remaining 80 women were
potential carriers. Phenotypic analysis using assays of VIII:C, vWF:Ag, vWF:RCo and the
ratios VIII:C/vWF:Ag and VIII:C/vWF:RCo were used to predict carriership and the results
compared to those obtained using genotypic analysis with 3 intragenic (Bel I, Bgl I,
Xba I) and 2 extragenic (Taq I, Bgl II) restriction fragment length polymorphisms.
A control group of 31 age-matched normal females and obligatory carriers was used to
establish 'cut-off values for the VIII:C/vWF:Ag and VIII:C/vWF:RCo ratios which
correctly classified all of the normal women. Evaluation of this 'cut-off value in the
control group demonstrated the VIII:C/vWF:Ag ratio to be 'superior' to the
VIII:C/vWF:RCo ratio correctly classifying 65.2% of the obligate carriers compared to
only 21.7% using the VIII:C/vWF:RCo ratio.
Within the study, of the 40 obligate carriers identified by pedigree analysis, coagulation
data was available on 37. Using the VIII:C/vWF:Ag ratio, 21/37 (56.8%) were shown to
have an abnormal coagulation phenotype and 16 to have a normal phenotype.
Phenotypic analysis of the 80 potential carriers identified within the study showed 27 to
have an abnormal coagulation phenotype suggesting carriership, 47 to be normal and in
6 no data was available. Genotypic analysis established 23 of the obligate carriers as
informative for one or more of the intragenic polymorphisms, 15 as informative for a
linked polymorphism and 2 women were non-informative. Of the 80 potential carriers
genotypic analysis alone confirmed 7 as carriers, excluded carriership in 31 but in 42
women carrier status could not be established. However using combined
phenotypic/genotypic analysis 10 of this latter group were identified as carriers. Overall,
therefore, 48/80 (60%) potential carriers could be offered accurate genetic counselling.
In 8 of the 22 families in which there was only a single isolated affected male, RFLP
analysis implicated the maternal grandfather as a possible origin for the mutation in 5
cases.
Three families were identified in which a recombination between the DXS15 and Bel I
loci had occurred giving an overall recombination rate of 7.5%. Significant linkage
disequilibrium was demonstrated between the Xba I, Bel I and Bgl I loci.
Prenatal diagnosis using intragenic RFLP's was available to 33/89 women; using linked,
RFLP's and fetal blood sampling to a further 39 women and finally to 17 women using
fetal blood sampling alone.
Haemophilia B: 5 families with haemophilia B have been studied comprising 11 males
and 12 females. Of the males, 4 were haemophiliacs (IX:C >0.01iu/dl) and the remainder
normal. Of the 12 females, 3 could be classified as obligate carriers, 8 as potential
carriers and 1 as a probable haemophilic female. Although the mean IX:C for the
obligatory carriers was lower than that of a control group, there was a considerable
overlap of values. Only limited phenotypic data was available but 2 of 3 obligate carriers
and 3 of 4 potential carriers had IX:C assays below the lowest value obtained in a control
group of 15 normal women. No CRM+ families were identified.
Three intragenic polymorphisms (Taq I, Xmn I and Dde I) were used for gene tracking
studies. Genotypic analysis established 2 potential carriers as carriers and demonstrated
informative polymorphisms in 3 obligatory carriers. All 'at-risk' women could be
offered prenatal diagnosis using one of the intragenic polymorphisms.
Studies on the single haemophilic female showed her to be an XO/XX'nv mosaic and
additionally demonstrated a 76Valine - Glycine mutation in one FIX gene.
Adrenoleukodystrophy: Carrier detection, using the FVIII RFLP's was undertaken in a
single family with X-linked ALD. The findings confirmed a suspected male as affected
and an 'at-risk' female as unlikely to be a carrier. Additionally, a recombination
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To avoid confusion, the terminology used throughout this Thesis, is that recommended
by the International Committee on Thrombosis and Haemostasis (ICTH).1














** As no test truly reflects in vitro vWF activity, no abbreviation is recommended by the
ICTH.
FVIII/vWF: designates the factor VIII procoagulant protein/von Willebrand Factor protein
complex.
vWF:RCo: will be used to designate ristocetin-cofactor activity, the vWF-related activity
required for the aggregation of human platelets induced by the antibiotic ristocetin.
2
Factor IX.







The past twenty years has seen significant advances in technology and the development of
laboratory tests that allow the more accurate diagnosis of Haemophilia A, B and von
Willebrand disease. In addition, an explanation of the ways in which these techniques can
be used for detecting carriers of Haemophilia A and B together with advances in
obstetrics (improved dating of pregnancies by ultrasound scanning, fetoscopy and fetal
blood sampling, chorionic villus sampling) has allowed the development of antenatal
diagnosis for these disorders. The application of advances in molecular biology to
prenatal diagnosis and carrier detection promises to complement this technology further
and alleviate some of the current difficulties in carrier detection and antenatal diagnosis.
The introduction to this Thesis on the application of molecular biological techniques to
the study of carrier detection in Haemophilia A and B will, therefore, review:
1. Normal coagulation.
2. The development in our understanding of Haemophilia A, B and von Willebrand's
disease.
3. The development in technology that now allows a more accurate diagnosis of these
disorders.
4. The contribution of molecular biology to our understanding of haemophilia A and
haemophilia B.
5. Carrier detection in haemophilia A and B.
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1.1. Normal Coagulation.
Normal coagulation occurs as the result of an ordered series of reactions initiated by the
contact of blood with the extravascular tissues (Figure 1). Following injury, small blood
vessels contribute to the primary haemostatic response by transient vasoconstriction,^
whilst exposure of subendothelial fibres initiates both platelet activation^ and the
intrinsic pathway of coagulation.^ Platelet adhesion to the exposed subendothelium
involves vWF as an anchor,^>7 is rapidly followed by a change in platelet shape^ and the
subsequent release of numerous platelet constituents from both the a-granules and dense
bodies.^ Activation of the extrinsic pathway of coagulation follows the exposure of FVII
to Tissue Factor (TF), a ubiquitous glycoprotein not normally exposed to blood.^
Intrinsic Pathway Extrinsic Pathway
Fibrinogen ► Fibrin
Figure 1. The coagulation cascade illustrating the intrinsic, extrinsic and common
pathways of coagulation. HMWK = high molecular weight kininogen; PL = platelet
membrane phospholipid; Ca2+ = calcium ions.
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For many years the coagulation cascade has been divided into the extrinsic and intrinsic
pathways^ with a single, final common pathway. The cascade occurs as a series of
zymogen to enzyme conversions in which serine proteases generated from a small initial
stimulus are enzymatically amplified resulting in a localised, massive burst of thrombin
generation which rapidly cleaves fibrinogen to fibrin, thereby stabilising and reinforcing
the platelet plug.
Activation of the intrinsic pathway results in the conversion of FXI to FXIa which in turn
converts FIX to FIXa. This serine protease binds to FVIIIa and in the presence of
phospholipid (from the platelet membrane) and calcium ions, converts FX to FXa.
Factor X can also be activated by an alternative route - the extrinsic pathway. The
extrinsic pathway requires tissue factor (TF) for its activation, a protein not normally
exposed to the plasma. Exposure of FVII to TF results in the generation of activated
FVIIa; the TF-VIIa complex can then convert both inactive FX to the active serine
protease FXa and FIX to FIXa.10
Finally a complex, prothrombinase, formed from the generation of the serine protease
FXa (by either route) and FVa, calcium and phospholipid, converts prothrombin (Factor
II) to thrombin which in turn cleaves fibrinogen to fibrin.!3,14
Whilst deficiencies of all the coagulation proteins have been reported either as a single
abnormality or rarely in combination with another factor, only in the last twenty years
have the proteins involved in coagulation been purified, cloned and their DNA sequences
determined. The commonest of the inherited coagulation disorders are von Willebrand's
disease (vWD), Haemophilia A and B (Christmas disease) with approximate incidences of
1/8000,15 1/10,00016 and 1/50,000 respectively.16
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1.2. Historical Developments In Our Understanding of
Haemophilia A, B and von Willebrand's Disease (vWD).
Although the earliest description of haemophilia dates back to Babylonian times,12 it was
not until 1803 that the syndrome of a bleeding tendency occurring in males and
transmitted by females was described by Otto 18 and 25 years later Hopff1^ introduced
the term 'Haemophilia.' Later in the century, this term began to be restricted to the
inherited coagulation disorders having been previously used to describe any bleeding
disorder. Bulloch and Fildes (1911)20 restricted the term haemophilia, on the basis of an
extensive literature survey together with their own experience, to describe a 'life-long
bleeding tendency occurring only in males, with evidence of similarly affected males in
the family with transmission by apparently normal females, and characterised by a
prolonged blood clotting time but no other demonstrable abnormality.' In the same
year, Addis21 showed that the long clotting time of haemophilic blood could be
corrected by the addition of a small amount of normal plasma. It was not for another 25
years that it became generally accepted that haemophilia was due to the lack of a plasma
clotting factor which Patek and Taylor termed 'antihaemophilic globulin.'22
The suggestion that haemophilia might be due to more than one defect first arose from
the findings of Pavlovsky in 194722 that blood from two haemophilic patients was
mutually corrective, both in vitro and in vivo. Similar observations were subsequently
made by Schulman and Smith (1952)24 and in the same year, Aggeler et al2^ and Biggs
et al2^ independently described cases which although exactly resembling classical
haemophilia clinically and genetically, were shown to be due to a deficiency of another
previously unrecognised clotting factor. Aggeler called this new factor 'Plasma
Thromboplastin Component' (PTC) and the disease 'PTC deficiency,' whilst Biggs
named the bleeding disorder 'Christmas disease' after their first patient and the deficient
clotting factor, 'Christmas factor.' Subsequent studies both on the physicochemical and
biological properties of these two proteins have shown them to be identical; the
internationally agreed nomenclature for this protein is Factor IX.22
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1.3.1. The Interaction of FVIII and FIX.
Whilst the original Waterfall11 and Cascade12 hypotheses of blood coagulation
postulated that FIX directly activated FVIII generating FVIIIa which then cleaved FX to
its activated form, it is now recognised that this is incorrect and that activated FVIII
(FVIIIa) has no intrinsic enzymatic activity and serves only as a cofactor for the serine
protease FIXa.211 Factor IX is a plasma serine protease which circulates as a zymogen
and is activated by a specific proteolytic cleavage. This cleavage occurs either by FXIa
during activation of the intrinsic pathway or by the TF-VII complex of the extrinsic
pathway.
The study of coagulation in reconstituted solution indicates that FIXa has a low but
measurable FX activating capacity, which is modestly stimulated by the addition of Ca2+,
but the presence of both Ca2+ and an appropriate phospholipid, both decreases the Km
for FX and increases the reaction velocity.211 However, the addition of activated FVIII
(FVIIIa) increases the reaction velocity by at least 4000-fold.211 The increased catalytic
activity of FIXa is believed to be due to a direct association of FVIIIa with FIXa on a
phospholipid surface but in addition, it is possible that FVIIIa may play a direct role in
increasing FX binding to the phospholipid and/or in the modulation of its interaction with
FIXa.21 vWF may also protect FVIIIa from proteolysis by both FXa and activated
Protein C22 although it does not prevent thrombin induced proteolysis of Protein C.22
It is clear from the close relationship between FIX and FVIII that a deficiency or
functional abnormality of either will result in a failure of activation of the intrinsic
pathway.
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1.3.2. Definitions of Haemophilia A and B.
Based on our current understanding of the pathophysiology of haemophilia A and B,
they may be defined as follows:
Haemophilia A: an X-linked recessive disorder in which there is a lack of procoagulant
activity due to either a quantitative or qualitative abnormality of the intrinsic pathway
cofactor - FVIII.
Haemophilia B (Christmas disease): an X-linked recessive disorder due to a quantitative or
qualitative deficiency of the intrinsic pathway serine protease - FIX.
From the close relationships that exist between FVIII and FIX it can be predicted that a
deficiency of either will result in diseases with identical clinical manifestations.
1.3.3. Clinical Manifestations of Haemophilia A and B.
The normal ranges for VIITC^^ and IX:C35 in a Caucasian population are 0.50-
2.00iu/dl, and the severity of haemophilia, whilst broadly constant within a kindred is
closely related to the functional factor VIII or IX activity. The most severely affected
cases will have functional factor assay values less that O.Oliu/dl, whilst mildly affected
individuals will have values above 0.05-0.lOiu/dl. Mild cases of haemophilia may exhibit
no problems until their clotting system is stressed eg. dental extraction, surgery. In
contrast, severely affected individuals have recurrent haemorrhages into joints, muscles
and soft tissues occurring apparently spontaneously or after trivial injury. Repeated
bleeds into a joint leads to loss of movement, followed by progressive disorganisation with
crippling of the patient. Bleeding into soft tissues may cause life-threatening
complications if it occurs within a confined space eg. neck, mouth. Intracranial and
intraspinal bleeding are also commoner in haemophiliacs than in the general population
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and may be difficult to diagnose in their early stages. Mucous membrane bleeding is a
less constant feature of haemophilia but may occasionally occur without any apparent
local cause. Epistaxes and haematuria may also occur but are an infrequent cause of
bleeding in severely affected haemophiliacs. A major complication of severe
haemophilia A and to a lesser extent haemophilia B is the development of inhibitors
(antibodies) to the infused FVIII or FIX used to treat the disease.
1.4. Von Willebrand Factor (vWF) and von Willebrand's
Disease (vWD).
In 1926, Eric von Willebrand described an Aland Island family with a severe, hereditary
bleeding disorder in whom the bleeding time was prolonged but the platelet count,
coagulation time and clot retraction were all normal.36 Evaluation of this family using a
'capillary thrombometer' focused attention on platelet function, for these patients had
prolonged 'thrombometer' times. The capillary thrombometer test measured the
duration of liquidity when whole blood was pumped back and forth in a capillary tube
and since it was normal in haemophilic patients, von Willebrand concluded that the
bleeding disorder in these individuals was due to a 'constitutional thrombopathy.'^7
Over the next twenty years, many patients with 'pseudohaemophilia' as this condition was
termed, were described, the diagnosis being based upon a prolonged bleeding time, with a
normal platelet count, whole blood clotting time and an autosomal pattern of inheritance.
In 1953, a number of groups^.39,40 rep0rted that vWD was associated with a reduced
factor VIII level as well as a prolonged bleeding time. Subsequent work has shown that
despite being considered one of the hallmarks of the vWD, the bleeding time may be
normal or near-normal in mildly affected cases.^l
Although the underlying basis of vWD was unclear at this time, it became apparent that
the bleeding manifestations of the disease, the reduced FVIII levels and the prolonged
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bleeding time were readily treated by infusions of blood, plasma or plasma fractions 4^
These observations indicated that impaired haemostasis in vWD was the result of a plasma
factor deficiency and the prolonged bleeding time reflected reduced levels of a plasma
'vascular factor.'38
In 1961, Borchgrevink demonstrated a decrease in 'platelet adhesion' in vivo in patients
with vWD4^ and the in vitro analogue, the measurement of the platelet count of blood or
platelet rich plasma exposed to glass beads was widely used for many years in the
diagnosis of vWD.
A major advance in the understanding of vWF and vWD came with the purification of the
FVIII protein and the subsequent development by Zimmerman in 1971, of a specific
immunoassay for FVIII using a rabbit anti-FVIII antibody.44 The measured factor,
termed factor VHI-related antigen (VIIIR:Ag) or protein, was shown to be normal in
haemophilia A patients but reduced in individuals with vWD. The generally accepted
explanation at this time was that haemophilic patients synthesised normal amounts of a
dysfunctional factor VHI-like protein but that synthesis of normal FVIII was reduced in
vWD. (Subsequent work has shown that this assay measures vWF:Ag rather than
VIII:Ag.)
At the same time as immunological techniques were being applied to vWD, a second
diagnostic method was developed. For ten years it was known that the antibiotic ristocetin
could cause in vivo and in vitro platelet aggregation and result in severe
thrombocytopaenia, but it was not until 1971 that Howard and Firkin demonstrated that
ristocetin-induced platelet aggregation (RIPA) was normal in most individuals but not in
some patients with vWD.4^ Further study of this defect established a defective or reduced
plasma component in vWD and in addition, demonstrated that the platelet defect could be
corrected by the addition of normal plasma. In 1973, Weiss4^ modified the system and
by employing a fixed concentration of ristocetin, washed normal platelets and dilutions of
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control or test plasma, was able to develop a specific quantitative functional assay for this
plasma component - FVIII related ristocetin cofactor (vWF:RCo as it was later termed).
By the early 1970's, there was increasing evidence to suggest that FVIII consisted of a
dissociable complex. Beginning with the early work of Thelin and Wagner,47 evidence
accumulated that under suitable conditions this macromolecule could be dissociated with
the release of active small-molecular weight fragments. In 1973 Weiss and coworkers,4^
Owen et al4^ and Cooper et al^O demonstrated that at high ionic strength or with alkali
halides, detergents or 0.25M Ca2+, the FVIII complex could be dissociated resulting in a
large carrier protein and a smaller protein which retained VIII:C activity. In addition,
these separate proteins could be recombined to form a large active complex.
It is now known that FVIII circulates as a complex comprising a low molecular weight
portion - FVIII which is deficient or abnormal in patients with classical haemophilia A
and a high molecular weight portion - von Willebrand factor which constitutes 99% of the
complex and which is deficient or abnormal in patients with von Willebrand's disease.
Although these two proteins circulate as a complex in plasma, each is encoded by genes
on different chromosomes and has entirely different properties (Table 1).
12
Table 1. Properties of Factor VIII and von Willebrand Factor (vWF).
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APTT - activated partial thromboplastin time; IRMA - immunoradiometric assay;
ELISA - enzyme linked immunoadsorbent assay; CIE - crossed immunoelectrophoresis.
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1.4.1. Cloning of von Willebrand Factor (vWF).
In mid-1985, four groups independently reported the construction of partial vWF cDNA
clones using mRNA derived from human endothelial cell cultures.^ 1,52,53,54 These
cDNA clones were used to assign the vWF locus to the distal end of the short arm of
chromosome 12^ *>54 and additionally demonstrated the presence of a pseudogene on
chromosome 22.^5,56 jn 1935 full-length vWF cDNA's were constructed, sequenced and
the predicted amino acid sequencers8 shown to agree with the data obtained from
amino acid sequencing.59
1.4.2. Synthesis of von Willebrand Factor.
The vWF gene consists of at least 50 exons spread over some 200kb of DNA and codes
for a vWF mRNA of 8825 or 8830 nucleotides (a discrepancy exists as to the precise site
for the initiation of transcription and, therefore, the length of the 5' untranslated region).
The 5' untranslated region consists of either 245 or 250 nucleotides, the coding region of
8439 nucleotides and the 3' untranslated region of 136 nucleotides. vWF mRNA encodes
a pre-pro-vWF of 2813 amino acids consisting of a 22 residue signal peptide, a long 741
amino acid prosequence and the mature vWF of 2050 amino acids. The pre-pro-vWF
amino acid sequence is made up of repeated domains that are internally homologous or
of sequence similarity^,56 (Figure 2). Approximately 90% of the protein can be
accounted for by these repeated structures. A number of functional domains on the vWF
protein have been mapped and are shown in Figure 2. These include domains involved in
the binding to glycoproteins lb, (Gplb) and Ilb/IIIa (GpIIb/IIIa), collagen, heparin and
the FVIII binding site.60
More recently, a family of proteins has been recognised that have in common regions of
high sequence similarity. These common, repeated sequences were first recognised in
von Willebrand Factor and were designated A domains. A number of proteins which have
in common a variable number of these A domains have now been described.61 These
14
include proteins involved in cellular adhesion, immunity, haemostasis and various
components of the extracellular matrix and it is feasible that they are related
evolutionarily. Some of the members of this family and their possible functions are
summarised in Table 2.

























LFA - Lymphocyte Function -related Antigen; ICAM - Intracellular Adhesion Molecule;
VLA - Very Late Antigen; CMP - Collagen Matrix Protein.
After removal of the signal peptide, pro-vWF subunits dimerise by disulphide bonding
involving free cysteine residues located at the C-terminal ends of the molecules^ 2
(Figure 3). The large prosequence is cleaved from the amino terminus of the pro-subunit
which may occur after dimerisation (this prosequence is secreted as a distinct
protein64,65 an(j corresponds to the previously reported von Willebrand antigen II -
vWF:Ag 11.63 vWF:Ag II appears to be essential for intracellular multimer
formation.63,66,67 Pro-vWF dimers appear to act as promoters for the generation of
multimers, a process which probably occurs in either the Golgi bodies or a later secretory
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pathway. They are assembled into large multimers (ranging in molecular weight (MW)
from 800,000 to 20 x 10^) by the formation of interchain disulphide bonds involving the
amino termini of adjacent subunits in a head-to-head configuration (Figure 3).^8
vWF is synthesised in two sites, the endothelial cell and the megakaryocyte. The vWF
produced in endothelial cells is either secreted^ or stored in the Weibel-Palade bodies
for future release.69 The vascular endothelium is thought to be the site of synthesis of
plasma vWF but it is unclear how the complex of vWF and FVIII is formed. Platelet vWF
has been located in the granules, cytosol and platelet membrane and various assays of
subcellular fractions shows that virtually all vWF is found in the a-granules. Platelet vWF
is secreted from the a-granules during the release reaction.7^ The multimeric structure
of vWF in platelets is similar to that of plasma although even larger multimers are found.
The analysis of the complex multimeric structure of both platelet and plasma vWF71
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Figure 2. vWF gene transcription and translation products. The functional binding

















C C c c
>c
||vWF:AgII dimer
Figure 3. Assembly of the vWF subunit and multimer formation.
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1.4.3. Role of von Willebrand Factor.
Although it has no inherent enzymatic activity, vWF is essential for normal coagulation as
it promotes haemostasis by anchoring platelets to the vascular endothelium and in
addition, serves as a carrier protein for FVIII preventing its proteolytic degradation in
plasma.
At shear rates comparable to those that occur in vivo, platelets will not adhere to the
subendothelium in the absence of functionally active plasma vWF.73 Two binding sites
for vWF have been identified on platelets. The first, associated with the platelet membrane
glycoprotein lb (Gplb) is involved in ristocetin-induced binding of VWF,74,75,76 whilst
the second is associated with the glycoprotein Ilb/IIIa complex (GpIIb/IIIa) and binding
to this site is induced by both thrombin and ADP.77,78,79,80 |n the subendothelium
vWF binds to collagen types I and m81,82 an(j t0 another, as yet undefined,
component.83 VWF may also be involved in platelet-platelet interaction.
vWF acts as a carrier protein for FVIII preventing its proteolytic degradation in plasma**4
and ensures that it is rapidly carried to any site of injury thereby maximising its low
concentration in the plasma. The binding site for FVIII lies between residues 1 and 272
on the vWF protein and the actual binding appears to involve calcium ions.85,86
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1.5. The Development of Quantitative Assays for FVIII, FIX
and vWF.
1.5.1. Factors VIII and IX.
In 1893 Wright demonstrated that haemophilic blood had a prolonged clotting time**7
and in 1911 Addis showed that this could be corrected by the addition of a small amount
of normal plasma.^8 Brinkhous in 1939 showed that after the coagulation of
haemophilic blood was apparently complete it still contained large amounts of
unconsumed prothrombin which could then be activated to thrombin by the addition of
tissue thromboplastin.89 The prothrombin consumption test as it was named, though not
specific for haemophilia, was more sensitive than the simple clotting time and proved
useful in the diagnosis and assessment of the severity of haemophilia. However, such tests
were relatively crude, abnormal only in severe disease and failed to differentiate between
haemophilia A and B.
In 1951, Merskey^O described a test in which the calcium clotting time was performed on
mixtures (in varying proportions) of normal and haemophilic plasma. In this way a curve
relating the clotting time to the dilution of the plasma was obtained and from which, by
comparison with an unknown, an estimate of the amount of FVIII present could be
obtained. This was the forerunner of a number of tests including the partial
thromboplastin time, the activated partial thromboplastin time and the one-stage factor
assay.
In 1953 Biggs and Douglas devised a relatively simple test - the thromboplastin
generation test^l in which the formation of 'intrinsic prothrombin activator' ie.
prothrombinase was measured. Subsequent modifications of this test have been used to
assay both FVIII and FIX - the so-called two-stage factor assay. By substituting the
various components of the test with samples obtained from haemophiliacs, Biggs and
Douglas were able to demonstrate that haemophilia comprised two separate disorders with
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different aetiologies - they called this second disease 'Christmas disease' after their first
patient.26
FVIII and FIX are now generally measured by one of these two methods - the one-stage
or two-stage assay. One-stage assays are widely used and have the advantage of simplicity
although the two-stage assay has been shown to be more precise in the measurement of
FVIII.92 a serious drawback to the use of one-stage factor assays is the need for factor
deficient plasma. Originally derived from haemophilic plasma the potential infective
risks associated with its use make it dangerous although the introduction of heat treated
deficient or depleted plasma have reduced these risks.
A number of variables have been shown to affect the accurate assay of VIII:C and IX:C,
these include the specimen acquisition and handling, the choice of reagents, standards and
buffers, the individual performing the assay and the final analysis of the data.93,94 This
is illustrated by the findings of the College of American Pathologists (CAP) whose survey
in 1980 reported that a plasma sample with a target VIII:C activity of 40% when assayed
in a number of laboratories by a variety of techniques, resulted in an interlaboratory
variation that ranged between 27% and 78%.95
Although the introduction of National and International biological standards has
considerably improved the standardisation of both VIII:C and IX:C assays some problems
in assay reliability still remain.
1.5.2. Von Willebrand Factor.
The introduction in 1970, by Zimmerman and co-workers of a specific immunoassay for
FVIII related antigen (or protein) (FVIIIR:Ag)44 was followed shortly by the
demonstration that normal platelets could be aggregated both in vivo and in vitro by the
antibiotic ristocetin.46,96,97 This led to the finding that both FVIIIR:Ag and ristocetin
cofactor activity are present in the blood of haemophiliacs as well as normal individuals,
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whilst being absent or reduced in the blood of patients with vWD and led to improvements
in the diagnosis of both haemophilia A and vWD. Subsequent modifications to the
measurement of ristocetin induced platelet aggregation (RIPA) have allowed the
development of a quantitative functional assay for vWF using either platelets^,99 an(j
more recently of an ELISA assay that reflects function.100
With the finding that FVIII comprised two proteins - FVIII and vWF circulating as a
covalently linked complex, it was recognised that Zimmerman's original assay measured
vWF:Ag (FVIIIR:Ag) rather than VIII:Ag (VIIIC:Ag). However, the assay has proved
invaluable both in the investigation of vWD and in the detection of carriers of
haemophilia A.
vWF is known to exist in platelets and plasma as a series of multimers of various
molecular weight. The diagnosis and classification of the vWD variants is dependent
upon the characterisation of these multimers. Two techniques are now widely used for
this - crossed-immunoelectrophoresis (CIE)1111 and sodium dodecyl sulphate polyacryl-
amide (SDS-PAGE) or agarose gel electrophoresis.102
In CIE a plasma sample is electrophoresed through a 'first dimension' agarose strip in
which no antibody is present. Because vWF is so large the agarose acts as a molecular
sieve and separation occurs primarily on the basis of size. Smaller multimers, therefore,
migrate more rapidly to the anode than the larger multimers. After the first dimension
electrophoresis has been run, a 'second dimension' of agarose gel is poured containing
antibody to the vWF:Ag. The plate is turned so that the direction of electrophoresis is
perpendicular to the first dimension. The vWF:Ag now migrates into the antibody-
containing gel and a precipitate forms, the shape of which reflects the partial separation of
multimers produced by electrophoresis in the first dimension. The alteration in the
multimeric structure of vWF results in an altered pattern of migration.
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A more precise method of resolving the multimeric structure of vWF requires SDS-
electrophoresis of either plasma or of platelet lysate using various concentrations of
agarose or composite agarose-polyacrylamide gels. Electrophoresis separates the
multimers by size, the gels are fixed and reacted with anti-vWF antibodies and the
bands subsequently visualised with autoradiography. Multimeric analysis has a superior
resolving power compared to CIE and in addition by varying the concentration of
agarose in the electrophoresis, various abnormalities of multimeric structure can be
highlighted. For example, using a 1% agarose gel each low molecular weight multimer
appears as a single band whereas with 2% gels they appear as a triplet with a predominant
central band and two satellite bands symmetrically positioned and with even higher
resolution gels the multimers migrate as a group of five bands.^3
Although more recently various other techniques for investigating vWD have become
available eg. proteolytic degradation of the vWF subunit, vWF cDNA gene probes, these
remain, at present the province of specialised research laboratories.
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1.5.2.1. Classification of von Willebrand's Disease.
The classification of von Willebrand's disease is frequently altered as new variants are
added but on the basis of vWF:Ag, vWF:RCo and multimeric analysis, they may be
categorised as shown in Table 3.
Type I variants are the most frequent form accounting for 60-70% of cases and are due
to quantitative defects of vWF with no functional abnormality. All multimers are present
but in reduced amounts. Inheritance shows an autosomal dominant pattern and a number
of subtypes have been reported.
Type II variants are the qualitative variants of vWF. Inheritance is dependent upon the
subtype but usually autosomal dominant. Multimeric analysis shows a lack of the large
and intermediate size multimers with variable sub-band abnormalities according to
subtype.
Type III is the most severe form of vWD with undetectable vWF. Inheritance is autosomal
recessive and affected individuals are usually compound heterozygotes.
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1.5.3. IX:Ag and the Classification of Haemophilia B.
In 1956 FantI and colleagues * **4 ancj Roberts and co-workers in 1966*05 use(j a human
antibody to demonstrate that the plasma from some patients with haemophilia B
contained material that cross-reacted with a specific FIX antibody. The factor IX:Ag was
termed cross-reacting material (CRM). Patients with virtually normal levels of IX:Ag were
termed CRM+. Patients with a proportionate reduction in both factor IX activity and
antigen levels were termed CRM* and those patients with reduced factor IX antigen and a
greater, disproproportionate reduction of factor IX activity were called CRMrec*uce<*
(CRM1).
Heterogeneity amongst all the categories has been described ie. some patients who have
normal IX:Ag levels are very severely affected whilst others are only mildly affected.
A small group of individuals with CRM+ disease - haemophilia Bm,***6 have been shown
to have prolonged ox brain prothrombin times - the hallmark of the disease. A general
classification of haemophilia B based upon the measurements of IX:Ag, IX:C and the ox
brain prothrombin time is shown in Table 4.***7
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Table 4. A classification for haemophilia B based upon measurements of IX:C, IX:Ag
and the ox brain prothrombin time.
CRM status IX:Ag
(iu/dl)
IX :C Ox brain Clinical
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The assays for VIII:Ag are based upon similar principles to those for vWF:Ag although
the Laurell techniquel is not applicable as no suitable antibody has been found which
results in a visible antigen-antibody precipitate. In initial assays the antibody was derived
from severely affected haemophiliacs who had developed inhibitors (antibodies) to
infused replacement FVIII.109 More recently alternative approaches using monoclonal
antibodies been employed.1 ^
The IRMA assay for VIII:Ag reported in 1979 by Peake et al, used an IgG anti-VIII:C
antibody arising in a multi-transfused severe haemophiliac. *09 Using this assay they
were able to demonstrate that measurements of VIII:C and VIII:Ag correlated well in the
majority of normal and haemophilic individuals but in occasional patients normal levels
of VIII:Ag were found but reduced or absent VIII:C - CRM+ haemophilia A. In patients
with vWD the levels of VIII:C and VIII:Ag were in good agreement. VIII:Ag was also
detectable in serum, cord blood samples and fetal serum and the assay was, therefore, of
potential value for both carrier detection and prenatal diagnosis in haemophilia A
families.
Despite these initial encouraging reports, there has been little commercial interest in the
development of assays for VIII:Ag and currently no widely available commercial kit is
obtainable.
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1.6. The Contribution of Molecular Biology to our
Understanding of Haemophilia A and B.
The contribution of molecular biology to our understanding of the haemophilias has
been considerable. With the cloning and sequencing of the two genes, it has become
possible to characterise specific mutations within affected individuals, to improve the
accuracy and availability of carrier detection to 'at risk' females and more recently to
begin to produce sufficient recombinant FVIII and FIX for clinical trials.
1.6.1. The Factor IX Gene.
Historically, FIX was the first of the two proteins to be cloned and sequenced although
some 20% of the humanUl and all of the bovine amino acid sequence1 12 had been
determined by the time the first FIX cDNA clones became available in 1982. The relative
ease with which FIX could be purified provided sufficient material to allow amino acid
sequencing and the data derived from this proved invaluable in subsequent cloning
experiments.
The two groups responsible for cloning the human FIX gene used similar approaches.
Kurachi and DavieH3 screened a cDNA library derived from human liver using two
different probes. The first probe was derived from baboon liver mRNA enriched for FIX
whilst the second comprised a number of synthetic oligonucleotide probes (12), based
upon the amino acid sequence Met-Lys-Gly-Lys-Tyr - the sequence having been derived
earlier. Using these probes, four positive clones were identified from which a single clone
was isolated containing 1,466 base pairs encoding human FIX.
Choo et all 14 use(j a slightly different approach by using FIX enriched bovine mRNA to
synthesise the cDNA isolating positive clones by screening with two sets of synthetic
oligonucleotide probes based upon the bovine sequence. The bovine cDNA was then
used to probe a human cDNA library, a positive clone was isolated and characterised.
The following year, Jaye et all 15 use(j a more novel approach by designing a 52-base
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synthetic oligonucleotide probe again deduced from the amino sequence of bovine FIX,
to screen a human cDNA library and subsequently characterising the positive clones.
In 1984, Anson et al reported the entire mRNA sequence of human FIX,116 characterised
the promoter region and defined the mRNA start, the eight intron-exon boundaries and
the mRNA stop point. The following year, Yoshitake published the entire genomic
sequence for FIX* 19 completing the work started by Kurachi and Davie three years
earlier.
The cloning of the FIX gene allowed its localisation to the long arm of the X-
chromosome at Xq26-27l 18,119,120 centromeric to the Fragile X and FVIII loci. In
addition a number of groups identified intragenic polymorphisms which have proved
useful in carrier detection studies in haemophilia B families. Cloning has also allowed the
development of recombinant FIX although the post-translational modifications necessary
to produce functional FIX has made it necessary to employ transformed mammalian cell
lines with very low yields (<lmg/litre culture).^1
The gene for FIX is substantially smaller than that of FVIII but still spans 34kb of
genomic DNA,H",117 although only 4% of the sequence codes for protein. It
comprises eight exons which account for 1/12 of the gene, the primary transcript being
processed down to a mRNA of 2802 residues (Figure 4) consisting of:
1. A 5' non-translated leader of 29 residues
2. The protein coding sequences
3. A non-translated 3' tail of 1390 residues starting with a double stop translator
terminator UAAUAG and ending 15 residues beyond the AAUAAA polyadenylation
signal.
The exons of the FIX gene appear to correspond broadly with the domains of the factor
























Figure 4. Schematic diagram of the human FIX gene and protein.
The first exon, A, codes for the 5' non-coding region of the mRNA and hydrophobic
signal domain of the precursor molecule. Exon B codes for the hydrophilic pro-
sequence of the precursor molecule and also for the calcium binding domain (contains
11/12 y-carboxy glutamyl residues), the so-called 'Gla' region. Exon C, the smallest
exon, contains the remaining y-carboxy glutamyl residue. Exons D and E form the
connecting peptide of the protein and have some homology to human epidermal growth
factor (EGF). Exon F, encodes the activation peptide whilst the last two exons, G and H
code for the serine protease catalytic region of the molecule.
Comparison of the gene structure of FIX with the other vitamin-K-dependent proteins
suggests that factors VII, IX, X and Protein C are homologues and presumably represent
duplication of the same ancestral gene whilst prothrombin (Factor II) is more distantly
related to FIX. 122
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1.6.2. Synthesis of FIX.
FIX, a vitamin K dependent glycoprotein is synthesised exclusively by the liver
parenchymal cells resulting in a normal plasma concentration of 3-5pg/ml with a half-life
of about 24 hours.35 Synthesis of FIX is dependent on sufficient amounts of vitamin K
in the liver. A vitamin K-dependent carboxylase is responsible for the attachment of the
12 carboxyl-groups to the amino-terminal part of the FIX protein. 123 in the absence of
sufficient amounts of vitamin K, acarboxy FIX is produced which may be demonstrated
by electrophoresis in the presence of Ca2+ ions (migration increased 124) The levels of
FIX are known to be influenced by a number of drugs including oestrogen-containing
compounds,124 anabolic steroids 125,126 Vitamin-K antagonists.123,127,128
1.6.3. The Development of FIX Gene Probes.
With the cloning and sequencing of the FIX gene it became possible to characterise the
underlying genetic mutations in affected individuals, although until recently such an
approach was time consuming and only applicable to small numbers of individuals.
More important was the search for polymorphic markers to track mutant genes within a
kindred, allowing accurate carrier detection and prenatal diagnosis.
1.6.4. Restriction Fragment Length Polymorphisms (RFLP's).
Polymorphic markers have been used by geneticists for many years to follow the
inheritance of genes within a family. If two alleles of a marker can be distinguished by
some means then the inheritance of the adjacent linked disease allele can be inferred.
Classically the marker gene was a protein eg. glucose-6-phosphate dehydrogenase
(G6PD) or Complement 3 (C3) where the different isoforms could be readily
distinguished eg. by isoelectric focusing. Such polymorphisms are inherited in a strictly
Mendelian manner and allow a mutant gene to be tracked within a family. Such an
approach has been used to determine carrier status in haemophilia A using glucose-6-
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phosphate dehydrogenase (G6PD) isoenzymes. 129
Such tracking, however, is dependent upon the marker gene and the disease allele being
inherited as a stable unit which is not always so. During the formation of a gamete, a
stage in meiosis occurs when DNA is exchanged between the maternal and paternal
chromosomes. If this crossing-over occurs between a marker and its linked disease allele
then the two will no longer be inherited as a pair and recombination has taken place. The
further apart the two markers are on a chromosome the more likely recombination is to
occur. To be useful, therefore, a marker should lie within 10 centimorgans (cM) of the
disease allele, resulting in an approximate recombination frequency of 10% - a
centimorgan is not a measure of physical distance but represents a probability of
recombination occurring - lcM equals a probability of recombination of 1%.^0
In 1978 Kan and Dozy demonstrated useful polymorphic markers at the DNA level using
restriction enzymes. ^1 The vast majority of these changes appear to be neutral and
many occur in the intronic, non-coding regions of genes. Such polymorphisms may
result in the creation or loss of a restriction endonuclease cleavage site and therefore, alter
the length of DNA fragments generated using specific enzymes (Figure 5). These so-
called restriction fragment length polymorphisms (RFLP's) have proved invaluable in
tracking genes in many diseases in whom the underlying genetic defect is unknown eg.
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Figure 5. Diagrammatic representation of carrier detection using RFLP analysis. In this
kindred the mother (1) is an obligate carrier of an X-linked recessive disease and her two
daughters (3 and 4) seek advice to try and establish their carrier status. The probe detects
a intragenic polymorphic site (RP) situated on the X-chromosome. In the absence of the
restriction site (RP), the probe hybridises to a 12kb fragment but when the site is present
the probe detects a 7kb fragment. When DNA from each family member is digested and
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hybridised with the probe, the mother (1) and daughter (3) are both heterozygous for the
polymorphism. The father (2) has a single band of 12kb from his normal gene. An
affected son (5) has a single 7kb band which he has inherited from his mother. His sister
(4) has only a single band of 12kb, representing a normal 12kb fragment from her father
and the abnormal 12kb fragment from her mother and she is, therefore, a carrier. The
remaining son (6) has inherited the normal 7kb fragment from his mother and is,
therefore, unaffected. The remaining daughter (3) who is heterozygous for the RFLP
must have inherited a normal 12kb fragment from her father and a normal 7kb fragment
from her mother and she is, therefore, normal.
RFLP's may be divided into two groups depending upon whether they occur within a
gene or in regions of DNA closely linked to it:
1. Intragenic polymorphisms
2. Extragenic or linked polymorphisms
1. Intragenic polymorphisms.
Intragenic polymorphisms occur within a gene either within the coding sequences or,
more commonly within the non-coding, intronic sequences. Recombination with
intragenic markers is a major problem with the analysis of some genes. For example in
the case of the dystrophin gene, the chances of intragenic recombination have been
estimated at 12%. 132
2. Extragenic or linked polymorphisms.
Extragenic or linked polymorphisms map close to the gene of interest but are associated
with a risk of recombination, the probability of which depends upon the distance between
the polymorphic site and the gene.
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Although RFLP's have proved invaluable in carrier detection and antenatal diagnosis, their
use is associated with many potential problems:
1. A crucial family member may be missing and as a result it is impossible to determine
which marker (RFLP) is associated with the disease allele.
2. Non-paternity within a kindred may lead to errors and paternity testing should,
therefore, be ascertained whenever paternal RFLP's have to be examined to reach a
diagnostic conclusion.
3. Recombination may take place.
4. New mutations may occur.
5. Closely positioned RFLP's exhibit linkage disequilibrium. The finding that certain
RFLP's occur more frequently in a population is termed linkage disequilibrium and
represents a non-random distribution of alleles at two or more linked loci.
Polymorphic protein markers that are in linkage disequilibrium with certain diseases
have been known for some time eg. HLA-B27 and ankylosing spondylitis but was first
observed in the human genome by Kan and Dozy in 1978 with the B-globin gene.131
The rate of change towards equilibrium can be estimated mathematically. If two
genetic markers are loosely linked then frequent crossing-over will eventually
randomise both forms of one polymorphism with both forms of the other. Eventually
all four haplotypes will be present at frequencies proportional to the gene frequencies
and the condition of linkage equilibrium will have been reached. However, when the
two sites are very close ie. intragenic, the rate of change towards linkage equilibrium
due to crossing-over may be very slow and take many thousands of years.
6. The frequency of polymorphisms appears to be lower in the X-chromosome than in
other chromosomes.^33
7. A female may be non-informative ie. homozygous for all available RFLP's.
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1.6.4.1. The Detection of Restriction Fragment Length
Polymorphisms (RFLP's).
The most commonly used method for detecting RFLP's is known as 'Southern blotting'
after its originator Dr. EM Southern134 (Figure 6). DNA is extracted from, for example,
peripheral blood leucocytes, digested with the appropriate restriction enzyme(s) and the
fragments separated by agarose gel electrophoresis. The DNA fragments separate in
agarose on the basis of their size, very large fragments migrating only slowly whilst
smaller fragments move more rapidly. The gel is then soaked in alkali, denaturing the
DNA and making it single stranded.
The DNA fragments contained within the matrix of the agarose gel are relatively difficult
to probe and are, therefore, transferred to either nitrocellulose or nylon membranes by
capillary blotting. The DNA is immobilised on the membrane by either baking
(nitrocellulose) or exposure to UV light (nylon).
The hybridisation membranes have a great capacity to non-specifically bind DNA,
resulting in a large amount of background radio-activity. This non-specific binding is
eliminated by soaking the membrane in non-homologous DNA eg. salmon sperm and
then incubating it with the appropriate radio-labelled probe. In the presence of a single-
stranded radio-labelled probe, hybridisation occurs only when a complementary sequence
is present. Following washing and developing (autoradiography) a signal is observed
where complementary sequences are present.
By varying the temperature, pH and ionic strength of the washing buffers (stringency) the
degree of mismatch that will be allowed can be varied. At high stringencies, only perfect
or near-perfect complementary sequences will hybridise whereas at low stringencies, a























Figure 6. Detection of RFLP's by Southern blotting. Explained in detail in text.
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1.6.5. The FIX Gene and RFLP's.
Following the cloning of the FIX gene, Camerino et al in 1984 demonstrated a Taq I
polymorphism^20 ancj jn the same year winship et al established the presence of two
further polymorphic markers, Xmn I and Dde 1.135 Figure 7 shows the positions of the
currently reported intragenic and flanking RFLP's within or close to FIX gene whilst
Tables 5-6 tabulates further information and shows their approximate allelic frequencies






t it t t
H
t
5' I—-h—I 1—I 3'
B C D E F G H
XII XIII VIII II
Figure 7. The FIX gene and the location of the currently reported intragenic RFLP's.
B(a), B(b) = BamH I sites; X = Xmn I site; T = Taq I site; M = Msp I site; H = Hha I site
located 8kb 3' to the FIX gene. The 50bp insertion detected by Dde I (or Hinf I) and the
AlanineTThreonine dimorphism are also included. Roman numerals below the genomic
map indicate the positions of the genomic probes used in the detection of the various
polymorphisms.
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Table 6. Factor IX RFLP's - racial variation.
White
RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Taq I 73 1.3/1.8 0.29/0.71 42 120
Xmn I 72 6.5/11.5 0.29/0.71 42 135
Dde I 74 1.70/1.75 0.24/0.76 37 135
Msp I 74 2.4/5.8 0.20/0.80 32 137
BamH I (a) 96 23/25 0.06//0.94 11 138
BamH I (b) 32 13/15 0/1.0 0 139
Ala/Thr 73 0.126+0.120 0.33/0.67 44 140/145
Dimorphism + 0.159/
(Mnl I/PCR) 0.126+0.279
Hha I 59 0.15+0.080/ 0.39/0.61 48 144
0.230
Taq I 1.65(or 0.15/0.85 26 150
(Extragenic) 3.9)/l1.8
Sst I Not recorded 5.9/8.8 0.43/0.57 49 153
(Extragenic)
American Blacks
RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
139
Taq I 63 1.3/1.8 0.14/0.86 21 139
Xmn I 60 6.5/11.5 0.12/0.88 21 139
Dde I 40 1.70/1.75 0.64/0.36 46 139
Msp I 49 2.4/5.8 0.61/0.39 48 139
BamH I (a) 21 23/25 0.48/0.52 50 139
BamH I (b) 61 13/15 0.13/0.87 23 139




Hha I 91 0.15+0.08/ 0.57/0.43 49 145
0.230
Japanese
RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Taq I 81 1.3/1.8 0/1.0 0 146
Xmn I 81 6.5/11.5 0/1.0 0 146
Dde I 81 1.70/1.75 0/1.0 0 146
Msp I 81 2.4/5.8 0/1.0 0 146




RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Taq I 68 1.3/1.8 0.03/0.97 6 147
Xmn I 56 6.5/11.5 0.04/0.96 8 147
BamH I (a) 67 23/25 0/1.0 0 145




Hha I 68 0.15+0.08/ 0.18/0.82 30 145
0.230
Asian
RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Taq I 80 1.3/1.8 0.09/0.91 16 147
Xmn I 78 6.5/11.5 0.06/0.94 11 147
BamH I (a) 23/25 0/1.0 0 148




Hha I 80 0.15+0.08/ 0.18/0.82 30 145
0.230
Malay
RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Taq I 69 1.3/1.8 0.01/0.99 2 145
Xmn I 69 6.5/11.5 0/1.0 0 145
BamH I (a) 67 23/25 0/1.0 0 145




Hha I 66 0.15+0.08/ 0.06/0.94 11 145
0.230
Maori
RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Taq I 72 1.3/1.8 0.07/0.93 13 152
Xmn I 120 6.5/11.5 0.008/0.992 1.6 152
Polynesian
RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Taq I 72 1.3/1.8 0/1.0 0 152
Xmn I 116 6.5/11.5 0/1.0 0 152
Heterozygosity - predicted from allelic frequencies (2pq x 100: where p and q represent
the frequencies of the two alleles.
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1.6.5.1. Intragenic Polymorphisms.
The following intragenic polymorphisms have been used for RFLP studies in haemo¬
philia B:
1. Taq I: situated 3' to exon D and detected by either genomic probe VIII or the FIX
cDNA. It detects a two allele system with bands of 1.8kb or 1.3kb.
2. Xmn I: situated 3' of exon C, this polymorphism is detected by the same probes as the
Taq I polymorphism and again is a two allele system generating bands of 11.5kb and
6.5kb. However, the two polymorphisms are in strong linkage disequilibrium and little
additional information is obtained by the use of the Xmn I polymorphism although
occasional families informative for only the latter have been reported.
3. Dde I: situated 5' of exon B and detected by genomic probe XIII or the FIX cDNA
probe. This detects a two allele system with polymorphic bands of 1.75kb and 1.70kb.
The actual polymorphism represents a small 50bp insert situated in intron 1 of the FIX
gene at residues 5505-5554 and which alters the size of the fragments generated by
digestion with Dde I. The same polymorphism is also detected with Hinf I but produces
fragments of 0.70kb and 0.75kb.
4. Msp I: situated within lOkb of the Taq I site, the polymorphism is detected by either
the FIX cDNA probe or a genomic probe and again is a two allele system with bands of
5.8kb and 2.4kb.
5. Alanine/Threonine dimorphism: situated at amino acid 148 in exon F this poly¬
morphism results in the substitution of an alanine for the more common threonine
residue. This dimorphism has been detected using a number of approaches including
antibodies,oligonucleotide probes^ and PCR.^3
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6. BamH I (b): Situated 5' to the Xmn I site in intron 3 and detected using the FIX
genomic probe - Probe VIII. This again is a two allele system with bands of 15kb and
13kb.
Unfortunately, these intragenic RFLP's are clustered within the FIX gene and as a result
their overall usefulness is reduced due to linkage disequilibrium.
1.6.5.2. Linked or Extragenic RFLP's.
A number of linked RFLP's have proved useful in carrier detection studies in
haemophilia B.
1. BamH I (a): situated in the 5' flanking sequence of the FIX gene and detected by
genomic probe VIII. This is a two allele system with polymorphic fragments of 23kb and
25kb. This RFLP is present in Caucasians but from the allelic frequencies only 11 % of
females would be expected to be informative whereas in American Blacks the predicted
heterozygosity rate is 50%.
2. Hha I: located 8kb 3' to the factor IX gene and detected by PCR. Under normal
conditions, the restriction endonuclease Hha I will not cleave at sites where the cytosine
residue is methylated. The amplification of specific regions of DNA results in large
amounts of non-methylated DNA which can then be cleaved by Hha I permitting its use
in the detection of a highly informative polymorphism. Although extragenic the greatest
distance between this marker and any potential mutation (assuming all mutations occur
within the coding regions or promoter sequences) is 43kb and therefore, the chances of a
recombination event occurring are small.
3. Taq I: this polymorphism is detected using the probe pCX38.1 at the DXS102 locus
centromeric to the FIX gene.150 generates bands of 1.65kb (or 3.9kb) and 11.8kb.
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The precise recombination frequency between this extragenic polymorphic marker and
the FIX gene is unclear.
4. Sst I/Sac I: this polymorphism is detected using the probe pX58dIIIc at the DXS99
locus which maps telomeric to the FIX gene. 155 it generates bands of 5.9kb or 8.8kb.
Again the precise recombination frequency between this extragenic polymorphic marker
and the FIX gene is unclear although at least one recombination has been reported. 154
Summary.
Striking racial differences exist in the prevalence of the FIX polymorphic sites (Table 6).
People of Asian and Oriental ancestry show a low frequency of heterozygosity for the
Taq I and Xmn I polymorphisms but an increased frequency of heterozygosity for the
Hha I polymorphism and in the Japanese for the linked Sstl/Sac I polymorphism.
The linked Bgl I has proved to an extremely useful marker in American Blacks where the
predicted heterozygosity rate is 50% compared to only 11 % in Caucasians.
Overall, the four intragenic RFLP's (Taq I, Xmn I, Dde I, BamH I) and the
Alanine/Threonine dimorphism) will be informative in approximately 79% of individuals.
By using the data derived from analysis of the Hha I polymorphism the number of
informative individuals increases to 89%. 144 it is possible to increase this figure further
by using either the extragenic Taq I and/or Sac I/Sst I RFLP's. However, the risks of
recombination leading to errors in diagnosis make such an approach unattractive.
Improvements in the detection of kindred-specific mutations allowing more accurate
carrier detection studies, make the use of these 'distant' linked, extragenic
polymorphisms unnecessary.
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1.6.6. Kindred specific defects.
Haemophilia B patients may be divided into CRM+ and CRM". The former might be
expected to have point mutations in regions of the gene coding for the FIX protein whilst
in the latter mutations and deletions critical for the biosynthesis of the mRNA or of the
protein may be more common. Approximately 1/3 of cases of haemophilia B are due to
a dysfunctional protein and direct sequencing of such variants led to the identification of
the first mutant FIXChapel Hill (145 Arg-His) in 1978.^6,157
Mutations and small deletions/insertions within the FIX gene have recently been
comprehensively reviewed by Giannelli et al.158 Of 216 known mutations, there were
114 unique molecular events the remainder being repeats. The majority of these
mutations occurred at CpG dinucleotides, a known 'hotspot' for mutation in the factor IX
gene1^9 and in the human genome. 160,161 such mutations arise because the cytosine
residue in the CpG sequence is readily methylated generating 5'-methylcytosine. This
can spontaneously dcaminate to form thymine, resulting in a cytosine to thymine (C-T)
mutation.
1.6.6.1. Haemophilia B and the development of inhibitors.
Although a clear association has been shown to exist between the development of
inhibitors to infused FIX and deletions within the gene, 162 a number of cases have been
reported in which the gene appears normal (by Southern blotting techniques) in the
presence of high titre antibodies. 163 Presumably in these cases, small point mutations,
deletions/insertions are present. Table 7 shows a number of the reported deletions within
the FIX gene and whether they are associated with the development of inhibitors. These
are more comprehensively reviewed by Giannelli et al.l"
The finding that not all deletions are associated with the formation of inhibitors suggests
that other factors must be involved in the immune response to therapeutic factor IX.
Highly polymorphic immune response genes within the HLA locus in Man are known to
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be involved in the presentation of antigens by macrophages and other accessory cells to T
lymphocytes as part of the process by which the proliferation of a specific B cell occurs
producing antibody. It is possible that individual variations in this system may affect the
response to a foreign antigen eg. factor IX replacement and therefore, the formation of
antibodies.
Table 7. Deletions and insertions within the FIX gene.
Mutation Size Defect Ir
Manchester il62,164 >250kb Complete +
Manchester n 162,164 >250kb Complete +
London 1162,165 27kb Exons F,G,H +
Jersey 1^63 >114kb Complete +
Boston 1^3 >114kb Complete +
Seattle 166 11.6kb Exons E,F +
Strasbourg! 67 5.0kb Exon D -
Chicago 163 5.0kb Exons E,G,H +
9-29kb
Pisa168 >35kb Complete +
Baril54 >3kb Exons A-H +
Unnamed 169 NR At least exon D +
" 170 NR Complete +
" 170 NR Complete +
» 170 NR Complete +
»171 >150kb Complete +
» 172 NR Exons A,B,C +
- 173 NR At least exon H +
Nara 1174 >33kb +
Nara 2174 >33kb +
El Salvadorl75 6kb Insertion Exon D/intron D -
nhibitors
NR = not reported.
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1.6.7. Haemophilia B Leyden.
An interesting subgroup of unrelated haemophilia B patients are characterised by a
similarly altered developmental expression of FIX - the so-called haemophilia B Leyden
phenotype, characterised by both low IX:Ag and IX:C before the age of 15 years but with
a gradual increase in the parameters after puberty. 176 A number of such cases have been
characterised and shown to be due to mutations in the promoter sequence of the FIX
gene. 177'178 This has led to the hypothesis that this variant FIX results from a promoter
mutation and that sequence elements very close to the putative start site of the
transcription are crucial for constitutive FIX transcription. In addition, the results suggest
that single-point mutations may suffice to switch from constitutive to hormone-dependent
gene expression.
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1.7. The Contribution of Molecular Biology to our
Understanding of Haemophilia A.
1.7.1. Structure of the FVIII Gene.
It is now recognised that the early preparations of FVIII were purifications of the
FVIII/vWF complex and only with the introduction of methods that have allowed the
selective purification of the FVIII protein did cloning of the gene become a possibility.
This was achieved in 1984 by two Biotechnology companies, Genentech Inc. 179 and
Genetics Institute Inc. 180 an(j represented a remarkable achievement.
Purification of homogeneous FVIII, free of vWF was the necessary preliminary to
biochemical characterisation. Tuddenham and his co-workers were able to produce a
small amount of highly purified human FVIII protein permitting limited amino acid
sequencing. Using this purified protein, Genentech Inc. isolated and sequenced a
nonapeptide and from this data, designed a 36-base synthetic oligonucleotide probe
based on known codon preferences. This was then used to probe a human genomic
library derived from an individual with 4X chromosomes (karyotype 49.XXXXY). The
initial clones obtained spanned 28kb of genomic DNA but were subsequently expanded
to contain 200kb of DNA encompassing the entire FVIII gene.
The approach taken by Genetics Institute differed slightly. Microsequencing of highly
purified porcine factor FVIII yielded sufficient amino acid sequence data to construct
oligonucleotide probes which were then used to screen a porcine genomic DNA library.
A positive clone was isolated, used to probe a human genomic library and a single
recombinant phage of 16kb isolated. Sequencing of the two clones revealed approximate
80% homology and indicated that the human clone represented part of the human FVIII
gene. Using fragments of the human clones as probes to screen a human lymphoblastoid
cell line (karyotype 49,XXXXY) a number of overlapping clones covering some 200kb
of DNA were isolated and shown to contain the whole of the human FVIII gene. The
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isolation of genomic and cDNA clones allowed the complete amino acid sequence to be
derived.
The gene for FVIII is situated at the tip of the long arm of the X chromosome (Xq28)181
and comprises 186kb of DNA (0.1% of the human X-chromosome) spread over 26
exons (ranging in size from 69-3106bp) and 25 introns, the six largest of which each
contain over 14kb of DNA. 179 This codes for a mRNA of 9,029bp and a precursor
polypeptide of 2351 amino acids (Figure 8). The complete nucleotide sequence of the
coding regions, the promoter elements, and the intron-exon boundaries have been
determined and the amino acid sequence of the protein has been deduced. 179,180,182
Analysis of the mRNA shows a probable 5' start site at position -170 which is preceded in
the genomic sequence by the sequence GATAAA that conforms with sequences required
for precise initiation of transcriptionJ 79 jhe 5' untranslated region is followed by a
single, continuous open reading frame coding for the polypeptide protein of 2351 amino
acids comprising a 19-amino acid hydrophobic signal peptide which is removed during
secretion of the mature protein and the mature protein of 2332 residues. The 3'
untranslated region is 1805 residues long and contains the AATAAA and CATTG
polyadenylation signals starting 19 bases upstream from the poly(A)+ tail.
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1.7.2. Amino Acid Homology Studies.
Computer analysis of the predicted amino acid sequence of FVIII reveals a complex




































Figure 8. Domain structure and processing of FVIII. The hatched areas represent
regions with a high density of acidic amino acids. The thrombin, activated Protein C
(APC) and factor Xa cleavage sites are shown.
There are 3 replicated 'A' domains, a single 'B' domain and 2 'C' domains: ^2,183





The 'A' domain repeats consist of approximately 350 amino acids with 30% amino acid
homology between repeats. The third A domain is found at the amino acid terminus of
the light chain following a short segment of 41 predominantly acidic amino acids and it is
this region which is thought to contain the binding site for vWF.
2. Duplicated C domain:
CI: residues 2020-2172
C2: residues 2173-2332
The C domain occurs as a tandem repeat at the carboxyl terminus of the molecule and
each contains approximately 150 amino acids with 37% amino acid homology.
3. Single B domain:
B: residues 712-1648
The single B domain is coded for entirely by exon 14, as are parts of the A2 and A3
repeats and is presumed to be an ancient insertion.
The mature polypeptide, therefore, has the structure: AJ-A2-B-A3-C1-C2. The deduced
sequence of FVIII contains regions of homology with the known amino acid sequences
of bovine factor V and human caeruloplasmin, 180,182 supporting the suggestion that
these three proteins are related by evolution. The significance of the repeating
homologous units in these three proteins is unclear but may reflect duplications and
triplications of some smaller ancestral gene.
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1.7.3. Synthesis and Release of FVIII.
Early studies undertaken to identify the source of FVIII production included
transplantation studies in which normal organs were transplanted into haemophilic
animals.I84 These studies indicated that the liver was the probable source of FVIII
production but it was not until the gene was cloned that this was confirmed. Wion and
colleagues *85 using FVIII gene probes identified FVIII mRNA in liver, spleen, kidney
and lymphocytes and fractionation of liver revealed mRNA in the hepatocyte fraction but
not the sinusoidal fraction, indicating the actual hepatocyte as the source of FVIII
production rather than other cells within the liver. Endothelial cells which synthesise vWF
do not produce FVIII although they may provide a temporary storage site.186 The
control of FVIII synthesis is poorly understood. It is known that hormonal influences
can increase the plasma level of FVIII and that vasopressin and its analogues can be used
both for diagnostic purposes!87 an(j jn the treatment of mild haemophilia.!88,189
Whether vasopressin acts at the levels of transcription, translation or storage is unclear but
the rapidity of its response suggests the latter.
1.7.4. Processing of FVIII.
FVIII serves as a cofactor to FIXa in the activation of FX in the presence of calcium ions
and phospholipid from platelets. The rate of FXa production is greatly increased by
FVIII whose catalytic efficiency is, in turn, greatly increased by thrombin. Activation and
subsequent inactivation of FVIII by thrombin are associated with a series of polypeptide
cleavages (Figure 8).
FVIII consists of a heterodimer processed from the larger precursor polypeptide and is
stabilised in plasma by complexing with von Willebrand factor. The activation of FVIII
coincides with proteolysis of both the heavy and light chains. Cleavage within the heavy
chain after Arginine 740 generates a 90kDa polypeptide that is subsequently cleaved after
Arginine 372 to generate polypeptides of 50 and 43kDa. Concomitantly the 80kDa light
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chain is cleaved after Arginine 1689 to generate a 73kDa polypeptide. Each thrombin
cleavage site is bordered by acidic residues and presumably these act as thrombin binding
domains. Factor VIII can be inactivated by activated Protein C through proteolytic
cleavage within the heavy chain at Arginine 336. Factor Xa and thrombin can also
inactivate FVIII by cleavage at Arginine 336.
1.7.5. The Development of FVIII Gene Probes.
Following cloning and sequencing of the FVIII gene in 1984, carrier detection and
antenatal diagnosis has involved both RFLP analysis and the detection of kindred specific
mutations. However, the much of the work involving carrier detection has, until very
recently, made use of RFLP analysis - the size of the FVIII gene making the detection of
specific mutations, except in certain individuals, an immense task.
1.7.6. Restriction Fragment Length Polymorphisms and the
FVIII Gene.
Despite the size of the FVIII gene, the frequency of polymorphisms appears, as elsewhere
on the X-chromosome to be low. In 1984, Harper et al^O identified a Bgl II
polymorphism adjacent to the DNA probe DX13 (DXS15) situated some 5cM from the
FVIII gene but tightly linked to it and in the following year Oberld et al^l reported a
Taq I/Msp I polymorphism associated with the probe ST14 (DXS52), again adjacent to
but tightly linked to the FVIII gene. Although both of these polymorphisms have proven
extremely useful for in carrier detection and antenatal diagnosis in haemophilia A, their
use is associated with a 5% risk of recombination. *92 Q0ning of the FVIII gene allowed
the search for intragenic polymorphisms and in 1985 Gitschier et al^3 reported a Bel I
site situated in intron 18. In the same year a Bgl I polymorphism was identified^4 ancj
the following year an Xba I site recognised. 195 Tables 8/9 show the currently reported
FVIII intragenic and extragenic polymorphisms and tabulates their allelic frequencies in a
number of populations. Figure 9 maps their position within the FVIII gene.
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Table 9. Factor VIII RFLP's - racial variation.
White
RFLP No. X chromo- Alleles Frequency Heterozygosity Reference
somes analysed (kb) (% )
Bell 133 0.8/1.1
Bgl I 52 5.0/20
Xba I 88 4.8/6.2
Hind III 56 2.6/2.7
Msp I (a) 67 4.3+3.2/
7.5
Msp I (b) 42 3.8/4.0
Bgl II NR 2.8/5.8
Taq I/Msp I NR Multiple






BstX I 51 4.25/6.4
Taq I NR 4.0/9.5
Intron 7 225 'G' or
'A'
Intron 13 159 Variable -
VNTR
American Black
































RFLP No. X chromo- Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Bell 33 0.8/1.1 0.66/0.34 45 194
Bgl I 36 5.0/20 0.94/0.06 8 194
Hind III 80 2.6/2.7 0.29/0.71 41 203
Msp I (b) 28 3.8/4.0 0.93/0.07 13 198
Chinese
RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Bel I 133 0.8/1.1 0.82/0.18 30 207
Xba I 49 4.8/6.2 0.57/0.43 49 207
Bgl I 54 5.0/20 1.0/0 0 207




RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Bell 144 0.8/1.1 0.70/0.30 42 208
Xba I 130 4.8/6.2 0.59/0.41 48 208
Bgl I 138 5.0/20 0.91/0.09 16 208
Msp I (b) 49 3.8/4.0 0.65/0.35 45 198
Bgl II 108 2.8/5.8 0.84/0.16 27 208
Taq I/Msp I 112 Multiple - 76 (Observed) 208
Malay
RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Bell 68 0.8/1.1 0.79/0.21 33 203
Hind III 64 2.6/2.7 0.24/0.76 36 203
Polynesian
RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Bell 121 0.8/1.1 0.55/0.45 49 209
Xba I 115 4.8/6.2 0.5/0.5 50 209
Bgl I 120 5.0/20 0.01/0.99 2 209
Maori
RFLP No. X chromo¬ Alleles Frequency Heterozygosity Reference
somes analysed (kb) (%)
Bell 72 0.8/1.1 0.66/0.44 44 209
Xba I 72 4.8/6.2 0.57/0.63 49 209
Bgl I 72 5.0/20 0.06/0.94 11 209
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Msp I (b) Msp I (a)
Figure 9. Map of the FVIII gene showing the approximate positions of the intragenic
and flanking RFLP's.
1.7.6.1. Intragenic RFLP's.
A number of intragenic polymorphisms have been reported within the FVIII gene
although they show linkage disequilibrium and racial segregation and their use is,
therefore, dependent upon the allelic frequencies within the population studied.
1. Bel I: situated within intron 18 and comprising a two allele system. The polymorphism
is an excellent marker as over 40% of Caucasian women are predicted to be heterozygotes
(Table 9).
2. Bgl I: situated within intron 25, 2kb 5' of exon 26 it detects a two allele system. It is
useful for carrier detection studies particularly in the American Black population. In
Europeans, a degree of linkage disequilibrium exists between the Bgl I and Bel I sites with
the result that the combined use of both polymorphisms does not significantly increase
the yield of informative families.
3. Xba I: situated within intron 22, approximately 18kb 3' to the Bel I site it again detects
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a two allele system. A degree of linkage disequilibrium exists between this site and the
Bel I polymorphism but approximately 25% of females homozygous at the Bel I site will
be informative. Unfortunately the 9.6kb FVIII genomic probe (p482.6) cross-hybridises
to a non-FVIII region. Therefore, a double digestion with Kpn I and Xba I is required to
move the polymorphic FVIII band away from the non-FVIII band.
4. Hind HI: situated within intron 19 it detects a two allele system. The polymorphism is
found in approximately 30% of Caucasians but a high degree of linkage disequilibrium
exists between this site and the Bel I site making it of limited use.
5. Intron 7: situated in intron 7 of the FVIII gene, this polymorphism ('A' or 'G') is
detected only by PCR. The allelic frequencies are:'G' - 79%; 'A' - 21%). This poly¬
morphism shows strong linkage disequilibrium with both the Bel I and Xba I poly¬
morphisms and, therefore, yields little additional information.
6. Msp I (b): situated in intron 22 - it detects a two allele system with bands of 4.0 and
3.8kb. This polymorphism is useful only in Japanese families as Caucasians are
homozygous.
7. Intron 13 VNTR: a recently reported tandem repeat (CA)n situated in intron 13 has
been shown to be highly informative with 91% of females being heterozygotes. This
VNTR is analysed by PCR amplification followed by electrophoresis in polyacrylamide
gels. Analysis reveals 8 allelic bands with the number of repeats varying from 16-24.
Excluding the intron 13 VNTR, approximately 70% of females will be heterozygous for
one or more polymorphisms with an extremely small risk (<0.1 %) of recombination and
therefore, of misdiagnosis. If the VNTR is analysed exclusively, then over 90% of women
will be informative and it represents the most useful polymorphic marker currently
available.
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1.7.6.2. Extragenic (Linked) RFLP's.
A number of linked polymorphic markers have proved useful in carrier detection studies
in haemophilia A:
1. Bgl II: this was the first of the polymorphic markers to be used in carrier detection and
prenatal diagnosis in haemophilia A. Although tightly linked to the FVIII gene, there is a
risk of recombination of 5%.
2. Taq I/Msp I: Taq I digestion of genomic DNA and probing with the ST14 probe
reveals two distinct polymorphic systems. The primary system is composed of at least 24
alleles ranging in size from 15kb to 3.0kb. The secondary system involves the presence
of a Taq I site in a 5.5kb band which gives rise to two bands of 4.0kb and 1.5kb although
in the Caucasian population this extra Taq I site is rare. In an unrelated black population,
84% heterozygosity was observed. In addition the ST14 probe is known to recognise a
two allele Msp I RFLP in the Caucasian population.
3. Msp I (a): situated 3' to exon 26, and 9kb 3' to the Bgl I RFLP, it detects a two allele
system with DNA fragments of 7.5 and 4.3/3.2kb. This Msp I polymorphism is in
linkage disequilibrium with all previously described polymorphic sites suggesting it may
be of limited value.
3. Taq I: situated 17kb 5' to exon 1, it detects a two allele system with bands of 4.0 and
9kb. However, it shows strong linkage disequilibrium with the Bel I polymorphism.
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Summary.
As with the FIX RFLP's, racial differences exist in the prevalence of the various FVIII
polymorphic sites (Table 9). The Bgl I polymorphism is unhelpful in the Chinese but has
been shown to be particularly useful in the American Black population. Similarly, the
Msp 1(b) RFLP is unhelpful in Caucasians and American Blacks but extremely useful in
the Japanese population. These differences emphasise the importance of using RFLP's
appropriate to the population under study.
The intron 13 VNTR should prove to be extremely useful in carrier detection studies in
haemophilia A and in particular may eliminate the need to analyse extragenic markers in
some families. No information is available on the combined use of the VNTR with the
other intragenic RFLP's although it is probable that they will show some linkage
disequilibrium. However, in non-informative females the linked Bgl II and Taq I RFLP's
may still prove useful.
1.7.7. Kindred Specific Defects.
Defective synthesis of FVIII may result from a number of gene defects, a number of
which are shown in Tables 10 and 11. Early studies used biased techniques eg. screening
with Taq I which contains within its recognition sequence the CpG sequence and which,
therefore, detected repetitive mutations at a few CpG sites. Tuddenham and colleagues
have recently published a comprehensive review of mutations in haemophilia A and
report an enormous diversity of mutations ranging from single base-pair substitutions to
major deletions.-^ ^
Although over 150 different mutations have now been reported in Haemophilia A, in a
recent paper approximately 50% of the mutations in severe haemophilia A did not occur
within the promoter region, the splice junctions, the coding sequence or the
polyadenylation site.211 It is probable that the mutations in these individuals occur
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outside the regions studied and the authors speculate that these may include sequences
deep within introns, other sequences outside the gene that are important for its expression
or another gene involved in factor VIII expression that is closely linked to the factor VIII
gene. The molecular basis of haemophilia A is likely, therefore, to be more complex than
solely mutations within the FVIII gene.
1.7.8. Mutations in the FVIII gene and Inhibitor Formation.
In the review by Tuddenham et al, inhibitors were found in 12 patients with point
mutations.jen 0f these had nonsense mutations and were associated with severe
disease whilst the remaining two point mutations (2209 Arg-Gln and 2229 Trp-Cys)
resulted in a mild-moderate phenotype. Although there appears to be some association
between specific mutations and the presence of inhibitors eg. 8 of the 12 inhibitor
patients had nonsense mutations at either 1941 or 2147, it is clear that possession of a
mutation by itself is insufficient to specify inhibitor formation and the reasons for this are
unclear. However, it is apparent that deletions within the FVIII gene appear to be
associated with an approximate five-fold higher risk of developing inhibitors compared to
other severe haemophiliacs without gene deletions.
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Table 10. Deletions/Insertions and the FVIII gene.
Mutation Exon VIII:C Inhibitors
(iu/dl)
39kb212 23-25 <0.01 +
60kb213 11-19 <0.01 +
7kb214 6 <0.01 -
2.5kb214 14 <0.01 -
5.5kb1214 22 <0.05 -
16kb214 23-25 <0.01 -
7kb214 24-25 <0.01 _
>35kb216 1-5 <0.01 -
2.0kb217 3 <0.01 -
15-20kb217 7-10 <0.01 +
2.0kb217 14 <0.01 -
12-14kb217 14 <0.01 +
NR217 26 <0.01 -
NR218 23-26 <0.01 +
>210kb219 1-26 <0.01 -
15kb220 15-18 <0.01 +
>127kb221 1-22 <0.01 +
>2kb222 26 <0.01 _
22kb223 26 <0.01 -
Insertion of LI Sequence
3.8kb224 14 NR NR
2.3kb224 14 NR NR
NR - not recorded.
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Table 11. Point mutations within the FVIII gene.
Mutation/Codon Intron/Exon VIII:C Inhibitors
(iu/dl)
TCGA-TCAA225 4/- 0.05-0.10 _
TCGA-TTGA212 2/- <0.01 -
TCAA-TCGA212 25/- <0.01 -
CGAA-CGGA Glu-Gly272226 n 0.12 -
CGA-TGA Arg-Stop 336227 78 <0.01 -
CGC-TGC Arg-Cys 372228 78 0.04 -
CGC-TGC Arg-Cys 1689227 -/14 <0.01 -
CGA-TGA Arg-Stop I960229 718 <0.01 +
CGA-TGA Arg-Stop I960194 718 <0.01 -
CGA-TGA Arg-Stop 2147230 -/23 <0.01 NR
CGA-CCA Arg-Pro 2116230 722 <0.01 NR
CGA-TGA Arg-Stop 2147231 723 <0.01 +
CGA-TGA Arg-Stop 2209212 724 <0.01 -
CGA-TGA Arg-Stop 2209211 724 <0.01 -
CGA-TGA Arg-Stop 2209197 724 <0.01 -
CGA-TGA Arg-Stop 2209231 -PA <0.01 +
CGA-CAA Arg-Gln 2209231 - /24 <0.01 -
CGA-CAA Arg-Gln 2209232 724 <0.01 -
CGA-CAA Arg-Gln 2209233 724 <0.01 -
CGA-TGA Arg-Stop 2307212 726 <0.01 +
CGA-TGA Arg-Stop 2307234 726 <0.01 -
CGA-TGA Arg-Glu 2307234 726 0.09 -
NR - not recorded; Arg - arginine; Gin - glutamine; Pro - proline; Cys - cysteine; Glu -
glutamic acid; Gly - glycine; Stop - stop codon.
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1.8. Recent Advances in Molecular Biology.
In the last 4-5 years, a number of techniques have been developed which have
considerably simplified both the molecular characterisation of FVIII and FIX mutations
and the detection of carriers by either RFLP analysis or direct detection of the underlying
mutations.
Such techniques can be grouped into: (1) methods for detecting large deletions or major
rearrangements within a gene eg. multiplex amplification;235 (2) methods which define
the approximate site of mutation eg. Ribonuclease A (RNAse) cleavage,236 denaturing
gradient gel electrophoresis (DGGE),237 chemical mismatch analysis;238 and (3)
sequencing methods that delineate the exact base alterations responsible for the disease
eg. direct sequencing of amplified DNA.239 Many of the these techniques use the
Polymerase Chain Reaction (PCR) technique^O to selectively amplify small regions of
the gene.
1.8.1. Polymerase Chain Reaction (PCR).
Southern blotting although superior to previously described molecular hybridisation
techniques relies upon many steps: restriction enzyme digestion, agarose gel
electrophoresis, blotting, preparation of probes etc.. Such a technique, whilst producing
excellent results, is time consuming, labour intensive and relatively costly in terms of
reagents. In late 1985, Saiki et al, reported a technique by which specific DNA fragments
are enzymatically amplified in vitro by a DNA polymerase using short synthetic
oligonucleotide primers flanking the area of interest to direct the enzyme to the
appropriate region. Repeated cycles of amplification result in an exponential increase in
DNA. The use of a heat-stable DNA polymerase (Thermus aquaticus) not only reduces
background amplification due to non-specific binding of oligonucleotide primers but
permits longer segments of DNA to be amplified. The technique allows the use of small
amounts of DNA eg. chorionic villi without purification and is readily automated.
Amplified products may be analysed in a number of ways including electrophoresis in
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agarose and polyacrylamide gels, restriction mapping and direct sequencing.
1.8.2.1. The Use of PCR in Haemophilia A.
In 1987, Kogan et al202 described the use of the PCR technique to amplify the regions of
the FVIII gene containing the Bel I and Xba I polymorphisms and subsequently to
directly analyse a polymorphism in intron 7.205 Following amplification the DNA is
digested with the appropriate enzyme, electrophoresed, stained with ethidium bromide
and visualised with UV light. Depending upon the presence or absence of the appropriate
restriction site and the sex of the individual either one or more bands are observed.
Although the technique is valuable in carrier detection and the prenatal diagnosis of
haemophilia A, its use is limited for the same reasons as Southern blotting, namely that
30% of women will be homozygous for either the Bel I or Xba I RFLP's. In addition, the
Xba I amplifications generate a non-FVIII band which masks one of the polymorphic
bands making its use with PCR limited. However, alternative strategies for carrier
detection using PCR may be possible eg. detecting polymorphisms that do not alter
restriction sites.241 a number of the FVIII polymorphisms can now be analysed by PCR
(see Table 8).
In addition to studying FVIII gene polymorphisms, Kogan and colleagues were also able
to sex individuals using Y-specific primers allowing the rapid sexing of fetuses in 'at-
risk' pregnancies.202
Subsequent developments of the PCR technique have allowed the identification of a
number of mutations within the FVIII gene. In 1988, Gitschier and colleagues used the
PCR technique to screen haemophiliacs for mutations at FVIII cleavage sites.227 Codons
encoding four of the six arginine residues present at these sites contained CpG
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dinucleotides and were, therefore, considered potential hotspots for mutation. This
approach led to the discovery of mutations at both the activated Protein C and thrombin
cleavage sites in haemophilia A patients.
1.8.2.2. The Use of PCR in Haemophilia B.
The PCR technique can be used in the detection of haemophilia B carriers in one of
several ways:
1. The amplification of specific polymorphisms (see Table 5).
2. Direct detection of mutations. The relatively small size of the FIX gene allows the
design of primers to selectively amplify all of the FIX gene, generating sufficient material
for direct sequence analysis. This is superior to the use of RFLP's but requires
considerably more time and effort. However, the use of this technique should allow
accurate detection of carriers and rapid antenatal diagnosis in almost all 'at-risk' females.
3. Chemical mismatch analysis. This technique permits rapid screening for mutations by
detecting the formation of heteroduplexes. Briefly, radio-labelled amplified wild-type
DNA and amplified mutant DNA are mixed, denatured and allowed to reanneal. If a
mutation is present, a mismatch occurs which after chemical modification is chemically
cleaved and the products of the cleavage detected by electrophoresis. The extra bands
generated by the cleavage indicating the approximate position of the mutation which can
then be confirmed by direct sequencing. Such a technique is readily applicable to the
study of mutations in the FIX genes of haemophilia B families.242
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1.9. Carrier Detection in the Haemophilias.
Haemophilia A and B are both X-linked recessive diseases and as a result genetic
counselling should be offered to 'at-risk' females. Carrier detection is generally
undertaken for 2 reasons:
1. An affected individual exists within a family and other female members wish to know
whether they may be carriers and, therefore, at risk of producing a similarly affected
child.
2. A female with no family history of haemophilia gives birth to an affected child and
wishes to know whether there is a risk to subsequent children.
Carrier detection is approached by:
A. Pedigree analysis
B. Phenotypic analysis
C. Genotypic analysis (reviewed in Chapter 4: Discussion)
and by combining these results it may be possible to establish the probability of
carriership in a specific female.
1.9.1. Pedigree Analysis.
An accurate family pedigree forms an essential part of the initial investigation of any
family with a bleeding diathesis. As well as information about possible linkage of the
haemophilic gene, details about other X-linked traits eg. G6PD deficiency, colour
blindness should be sought.
On the basis of this pedigree data a female may be classified as either an obligate carrier,
a potential carrier or normal.
Obligate carriers include:
a. The daughter of a haemophiliac.
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b. A mother with two affected children.
c. A mother with one affected child plus a family history of haemophilia.
d. The mother of two daughters, each of whom has an affected male (assuming their
father is normal).
Possible carriers include:
a. A female who has no affected children but a male haemophilic relative on the
maternal side.
b. The mother of a single haemophilic child.
An accurate pedigree, therefore, forms an essential part of genetic counselling and may in
some families, allow a female to be excluded as a carrier.
1.9.2. Phenotypic Analysis.
Traditionally, the laboratory detection of carriers of haemophilia A and B has depended
upon the results of coagulation testing. The earliest attempts at carrier detection involved
the measurement of FVIII and FIX clotting activity. In normal individuals the levels of
VIII:C and IX:C are generally within the range 0.5-2iu/dl with a mean value of l.Oiu/dl.
In male haemophiliacs the levels are reduced in proportion to the severity of the disease.
Consistent with this, levels of VIII:C and IX:C will tend to be lower in carriers with average
levels of 0.5iu/dl. However, the actual levels can vary widely depending upon the degree
of X-chromosome inactivation which has occurred - Lyon's hypothesis.243 Lyon's
hypothesis of random X-chromosome inactivation postulates that at an early stage in
embryological development one of the X-chromosomes becomes inactivated, a process
which is random and is irrevocable for the descendants of each cell after the decision has
been made. Lyonisation, therefore, results in some carriers with a markedly reduced level
of VIII:C and others with a value in the normal range (Figure 10). It is this latter group
in whom carrier detection, based upon phenotypic data, is extremely difficult. Recently, a
report has appeared in which X-chromosome inactivation has occurred in affected
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females but which does not appear to be random ie. preferential inactivation of the
normal X-chromosome.244 It is possible that this apparent non-random X-inactivation
represents an ascertainment bias. Such biases arise when the study sample is ascertained
through affected individuals (as usually happens in studies of diseases) rather than by
analysing a random sample of the population. In this case, therefore, the suggestion that
there is preferential inactivation of the normal X-chromosome may be a chance finding
rather than a true abnormality.
VIII :C or IX:C
Figure 10. VIII:C (or IX:C) values in normal women and obligatory carriers of
haemophilia demonstrating the overlap that occurs between normal women with low
VIII:C (or IX:C) and obligatory carriers with normal VIII:C (or IX:C).
In addition to Lyonisation a number of other factors have been shown to affect the
measurement of VIII:C, IX:C and vWF in plasma and must be considered when
interpreting the results of coagulation testing:24^
1. Age - VIII:C levels increase with age with the highest values being found in the very
young and very old and the lowest values are found in the 25-30 year-old age range.
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An International Co-operative study in 1986-246 concluded that age had a significant
effect on both VIII:C and vWF:Ag with the values being highest at the extremes of age.
2. ABO blood group - females with blood groups A, B and AB, both normal and
carriers have significantly higher levels of both FVIII and vWF although the primary
effect is upon vWF.246 js unclear how the genes coding for the ABO blood group
system (located on chromosome 9) can affect the expression of a different
chromosome although it is possible that the effect may occur post-translationally.
3. Oestrogen therapy/pregnancy are well recognised to increase both VIII:C and
vWF.247
4. Laboratory variation - a number of variables have been shown to affect the assay of
VIII:C, IX:C and vWF and these include:
A. The collection of the sample and its subsequent processing. VIII:C is relatively
labile and samples must, therefore, be assayed immediately. VIII:Ag appears to
be more stable, samples can be frozen and processed in the future. Samples for
IX:C and vWF assays can also both be safely frozen.
B. Method of assay ie. one-stage or two-stage assay for VIII:C.
C. The choice of reagents/standards.
D. Analyst.
It is important, therefore, for individual laboratories to establish both normal ranges for
their own local population and to standardise their assays using the various national and
international standards available.
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1.9.2.1. Historical Review of Carrier Detection in
Haemophilia A.
The first attempt at carrier detection in the female relatives of haemophiliacs was reported
by Schloessmann in 1930^48 wh0 examined 34 carriers of haemophilia of whom 16 had
an abnormal bleeding tendency. In 13 he measured the coagulation time and found it to
be abnormal in 11. Andreassen in 1943249 aigo found a tendency to haemorrhage in
female carriers and demonstrated abnormal coagulation in 30 out of 31 cases. Skold,
however, in 19442^0 measured the whole blood clotting time and was unable to
demonstrate any difference between carriers and normal females. In 1951, Merskey et
ai251 using the whole blood clotting time, prothrombin consumption test and an AHF
titration test (to measure VIII:C) failed to demonstrate any abnormality between obligate
carriers and a control group of normal females. Two years later the first accurate
quantitative measurement of VIII:C was published by Graham,2^2 wh0 found low levels
in six out of ten carriers of mild haemophilia in a single large family and attributed this to
a peculiarity of the haemophilic gene responsible for the disease. In apparent
confirmation, Gardikas et al2^3 reported normal levels of VIII:C in ten obligatory
carriers of severe haemophilia whilst Margolius and Ratnoff in 19562^4 detected an
abnormal value in only one of nineteen carriers.
Numerous subsequent studies by many groups have demonstrated that diminished levels
of VIII:C may be found in some carriers of both mild and severe haemophilia but that
there is a wide variation in the results obtained with some obligate carriers having entirely
normal activity and some normal women having borderline low VIII:C values. It is now
accepted that the measurement of VIII:C alone provides a poor means of carrier
detection.
The results of the published studies of VIII:C levels in carriers of haemophilia A are
shown in Table 12. Of interest are the widely differing VIII:C values obtained by many
workers; the differences in activity values between races; the discrepancies between 1-
stage and 2-stage assays and whether the samples were assayed immediately or after
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freeze/thawing. These results emphasise the importance of standardising laboratory
techniques to minimise such errors.
Following the introduction of specific assays for VIII:C the next significant advance in
the detection of haemophilia A carriers was the report in 1971^55 0f a specific assay for
FVIII related antigen (VIIIR:Ag=vWF:Ag) or protein. Zimmerman found the ratio
between VIII:C and vWF:Ag (VIIIR:Ag) in female carriers of haemophilia A was
significantly lower than in normal females and that this ratio (VIII:C/vWF:Ag) provided a
better criterion for detecting carriers than VIII:C alone. Zimmerman's results were
particularly interesting as they showed that carriers with an VIII:C of more than 100%
had a proportional increase in their vWF:Ag (VIIIR:Ag) level. Nevertheless, the ratio of
activity to antigen was still considerably less than in normal women and on the basis of
this carriers could still be distinguished. Although subsequent work has confirmed the
validity of these measurements in the clarification of carrier status, there continues to exist
a wide variation in the observed differences in carrier detection between various
laboratories.
A co-operative study in 1977 suggested that variation in the laboratory estimation of
VIII:C and vWF:Ag was related to laboratory technique rather than statistical methods.256
Seligshon in 1979^57 suggested that in cases where carrier status was in doubt the
repeated measurement of VIII:C and vWF:Ag was necessary to eliminate errors inherent
in the assays. Graham in 1980258 showed that discriminants useful for detecting carriers
of severe haemophilia A were associated with large error rates when applied to carriers of
mild haemophilia A because of the greater overlap between the factor-VIII related
activities of mild and normal women. In 1977 a WHO Memorandum on carrier detection
in haemophilia245 suggested that the measurement of vWF:RCo might replace vWF:Ag
whilst Marshall and Stenhouse in 1979259 advocated that all three tests be used. Shen in
1982260 compared the predictive ability of 28 different discriminant equations which he
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calculated from various ratios of the three tests. He found that vWF:RCo was not as good
as vWF:Ag for carrier detection and these findings were confirmed by Duncan in
1984.261
The results of carrier detection studies using the measurement of VIII:C, vWF:Ag and
vWF:RCo together with the various methods of statistical analysis are reviewed and
summarised in Table 13.
1.9.2.2. The Value of VIII:Ag Assays in the Detection of
Haemophilia A Carriers.
In 1978, Peake et al^^ described an immunoassay for VIIIrAg and reported its
subsequent use in carrier detection. They found that a comparison of VIII:Ag/vWF:Ag
(VIIIC:Ag/VIIIR:Ag) ratios and VIII:C/vWF:Ag (VIII:C/VIIIR:Ag) ratios gave the same
proportional misclassification of carriers as normal (4/23) but that the former ratio
showed greater discriminatory power. There was no statistical difference between the two
ratios obtained in carriers of mild or severe haemophilia. An advantage of the VIII:Ag
measurement is its relative stability in plasma allowing samples to be batched and
processed at a later date. Hoyer in 1982^62 used the measurement of VIII:Ag and
vWF:Ag in the detection of pregnant haemophilia carriers and was able to demonstrate
that it was as useful in discriminating between carriers and non-carriers as the
measurement of the VIII:C/vWF:Ag ratio.
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1.9.2.3. Summary of Phenotypic Methods for the Detection of
Carriers of Haemophilia A.
It is generally accepted than the measurement of VIII:C alone does not provide sufficient
discrimination between normal and obligatory carriers of haemophilia A. Currently
phenotypically based carrier detection using the measurement of VIII:C and vWF:Ag
allows the classification of 85% of potential haemophilia A carriers. However, it is clear
that in some true carriers, Lyonisation will result in normal VIII:C values, a normal
VIII:C/vWF:Ag ratio and therefore, in misclassification. It is these individuals in whom
molecular based methods of carrier detection are likely to play an important role.
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1.9.3. Haemophilia B.
Haemophilia B is a more heterogeneous disorder than haemophilia A with roughly one-
third of patients having CRM+ disease. A low IX:C in obligatory carriers of haemophilia
B has been shown in a number of studies (Table 14) but as with carriers of haemophilia
A, the overlap between normal and reduced activity is wide. To overcome these
limitations, the measurement of IX:Ag has been suggested as a method of improving the
accuracy of phenotypic based carrier detection. A number of techniques have been
employed to measure IX:Ag including electroimmunoassay (EIA),308,309,310 antibody
neutralization 10-312 and radioimmunoassay (RIA).313
Elodi313 foun(j that jn 8 obligate carriers of haemophilia (CRM"), there was good
correlation between IX:C and IX:Ag but that the additional measurement of IX:Ag did
not improve the detection of carriers. Matsuzo308 reported that the levels of IX:C in
obligate carriers of haemophilia B were significantly lower than those of VIII:C in
obligate carriers of haemophilia A. In addition, he noted the discrepancy between IX:C
and IX:Ag in haemophilia Bm and CRM+ patients and carriers and pointed out the value
of these measurements in the detection of carriers with these disorders. Thompson309
found the mean values for both IX:C and IX:Ag significantly lower in heterozygotes
compared to a control group but felt that IX:Ag was of limited value in improving
detection rates but that it might serve as an independent method to confirm the results of
clotting activity assays.
Graham in 1979314 showed that the most efficient and cost-effective method for
classifying CRM" carriers was univariate discrimination based upon assay of IX:Ag alone.
For CRM"1" carriers, bivariate linear discrimination utilising both IX:C and IX:Ag assays
was preferable. 0rstavik in the same year315 concluded that the quantitative
determination of both factor IX antigen and factor IX activity was of value in establishing
the risk of carriership in both CRM" and CRM+ haemophilia B families.
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1.10. Bayesian Methods in Risk Estimation.
Bayesian statistics is a method of combining probabilities which is widely used in
estimating genetic risks and is, therefore, applicable to the study of both haemophilia A
and B.245 The theorem or law was originally formulated by the Reverend Bayes^22 an(j
enables the overall probability of an event, C such as carrier status to be calculated taking
into account the family pedigree data and data derived from various tests eg. biochemical
assays, RFLP analyses.
Bayes's theorem may be stated as follows;323
1. If the prior probability of an event C occurring is denoted as P(C) and
2. the prior probability of an event C not occurring is denoted as P(NC) and
3. the conditional probability of an observation O occurring if C occurs equals P(0|C)
and
4. the conditional probability of observation O occurring if C does not occur equals
P(0|NC), then the overall probability of event C given O is observed equals:
P(C) xP(OlC)
[P(C) x POIC)] + P(NC) x P(OINC)]
This is more clearly shown in the Bayesian table on the following page.
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[P(C) x P(OIC)] + [P(NC) x P(OINC)] [P(C) x P(OIC)] + [P(NC) x P(OINC)]
The application of this approach to the prediction of carrier status in X-linked recessive







In this Pedigree, II-3 is the daughter of an obligate carrier of Haemophilia A and wishes
to know whether she is a carrier or not. The prior probability that she is a carrier (from
the pedigree data) is 1/2 and the prior probability that she is not a carrier is also 1/2. II-3
has three normal sons - if she is a carrier the conditional probability that all three would
be normal is 1/2 x 1/2 x 1/2 = 1/8; if she is not a carrier, the conditional probability that
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all three sons would be normal is very nearly 1. It not exactly 1 as there is a risk that a
son could be affected because of a new mutation. If she is not a carrier, the conditional
probability that all three sons would be normal is, therefore, 1-p where p. is the mutation
rate in females. (For clarity in these examples p is assumed to extremely small and
therefore, ignored).
If we consider the joint probability ie. the product of the prior and conditional
probabilities; then the joint probability that she is a carrier is 1/2 x 1/8 = 1/16 and the joint
probability that she is not a carrier is 1/2x1 = 1/2. The final risk or posterior probability
that she is a carrier is, therefore:
1/16 _1
1/16 + 1/2 9
and the final risk or posterior probability that she is a not a carrier is:
1/2
_ 8
1/16 + 1/2 ~9
Tabulating the above information:
Probability II-3 carrier II-3 not a carrier
Prior Probability 1/2 1/2
Conditional Probability
3 normal children 1/8 1
Joint Probability 1/2 x 1/8 = 1/16 1/2x1 = 1/2
Final Risk or Posterior 1/9 8/9
probability
This information can then be used to advise II-3 of the risks of having an affected child.
The risk that her next child will be an affected male is: 1/9 (the final risk that II-3 is a
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carrier) x 1/4 ( the chances of a child being both male and inheriting the abnormal X-
chromosome) = 1/36. If the information provided by the three normal children is not
taken into account then the risk of having an affected child is 1/2 (the risk that II-3 is a
carrier from the pedigree) x 1/4 = 1/8.
The conditional probability can be further modified if any carrier tests are available. For
example in the pedigree described the VIII:C/vWF:Ag ratio in II-3 was 0.65. From
previous analyses of the VIII:C/vWF:Ag ratio in both obligatory carriers of haemophilia A
and normal women, 3/4 obligate carriers were found to have a ratio equal to or below
0.65 but only 1/16 normal women. These results are shown in the table below and
illustrate that the addition of this extra information increases the risks that II-3 is carrier
and reduces the probability that she is normal.
Probability II-3 carrier II-3 not a carrier
Prior Probability 1/2 1/2
Conditional Probability
- of 3 normal sons 1/8 1
- of Vm:C/vWF:Ag ratio
= 0.65 3/4 1/16
Joint Probability 1/2 x 1/8 x 3/4 = 3/64 1/2 x 1 x 1/16 = 1/32
Final Risk or Posterior 3/5 2/5
probability
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Bayesian analysis can also be applied to pedigrees in which only an isolated affected male






In the Pedigree shown above, there is single haemophilic male (II-1) and III-3 seeks
advice as to her carrier status.
The prior probability for III-3 is quite different to the prior probability established for II-
3 in the previous Pedigree.
The probability that any female is a carrier can be derived from the formula:
Probability = 2p + 2v + 2 \xf
w
where p. is the mutation rate in females, v is the mutation rate in males and / is the
biological fitness.323 Biological fitness is the capacity to reproduce and have healthy
children. In some sex-linked recessive disorders eg. Duchenne Muscular Dystrophy the
biological fitness approaches or equals zero but in other conditions such as haemophilia,
fitness is reduced but above zero. In conditions in which biological fitness is only mildly
impaired this will have a major influence when estimating the prior probability that any
female is a carrier as she may have inherited the abnormal gene from her father.
In haemophilia the biological fitness of affected males is estimated to lie between 0.3 -
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0.7. The mutation rate in males (v) is thought to be about 10 times that in females
(|i).324 if we assume for the pedigree above that /=0.5 and v = lOp then the prior
probability of female being a carrier is:






In order to derive the risks for III-3 the risks of 1-2 and II-3 being carriers must be
calculated. The Bayesian table below calculates the risks for 1-2:





































The final or posterior probability that II-3 is a carrier equals:
23|X
16 23
+ + M 131
16 4
and the prior probability that III-3 is a carrier equals
23 1
_ 23
131 X 2 ~ 262
Additional information from, for example coagulation testing might alter these
probabilities quite dramatically.
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Bayesian analysis allows many variables to be included in the final risk analysis eg, coag¬
ulation data, other biochemical data eg. G6PD isoelectric focusing results, and the results
of RFLP analysis.
In the following pedigree, RFLP analysis using a linked polymorphism was available.
€>
II-1 is an obligate carrier of haemophilia A as she has a brother who is a haemophiliac
and she also has two affected sons. Her daughter III-3 wished to know if she is a carrier.
Genotypic analysis was carried out using a single RFLP and showed that she (III-3) had
inherited the same allele as all three affected haemophiliacs and was, therefore, highly
likely to be a carrier. Although this RFLP is closely linked to the FVIII gene there is a
chance of a recombination occurring. The recombination fraction (0) is an estimate of
the likelihood of recombination taking place.
Therefore, if we construct a table as before:
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Probability III-3 carrier III-3 not a carrier
Prior Probability 1/2 1/2
Conditional Probability
2 normal sons 1/2 x 1/2 = 1/4 1
RFLP data 1-0 0
Joint Probability 1/2 x 1/4 x (1-0) 1/2x1x0
= (l-0)/8 0/2
Final Risk or Posterior 91 —
8 l~e 2 40
probability +i (1-0)+ 40 Hz21 + 2. (1-0)+ 40
8 2 8 2
where 0 is the chance of a recombination event occurring.




and the chances of III-3 not being a carrier are:
4 x 0 05
= 0.18
(l-0.05)+(4x0.05)
Bayesian analysis allows the risk of carriership to be determined taking into account
many variables. However, as the size of the Pedigree increases and the amount of data
available grows, the complexity of the analysis increases dramatically. Such tasks are,






2. Materials and Methods.
2.1. Patients.
Families studied had either one or more diagnosed haemophilic members and were,
therefore, offered carrier detection as part of a genetic counselling service or alternatively,
counselling was requested because of a history of haemophilia in previous generations.
Families were seen either at the Birmingham Children's Hospital, The Queen Elizabeth
Hospital, Birmingham or Addenbrooke's Hospital, Cambridge.
At an initial interview, an accurate family pedigree was plotted and samples taken for
DNA studies and coagulation assays.
2.2. Historical Controls.
Haemophilia A: Phcnotypic data on 31 normal females and 31 obligatory carriers of
haemophilia A was available and shown in Table 15. Obligatory carriers and normal
controls matched for age and their oral contraceptive status had previously been studied.
For each women three assays for VIII:C and vWF:Ag were performed on separate
occasions and the mean calculated. In the majority of cases vWF:RCo was also measured.
The ratios of VIII:C/vWF:Ag and where appropriate the VIII:C/vWF:RCo were calculated.
This information is used in the results section to interpret the results from phenotypic
analysis on the study subjects (Chapter 3: Results).
Haemophilia B: No historical controls were available for haemophilia B. However, 15
normal females were studied to allow a comparison with results obtained from the study.
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2.3. Analysis of Phenotypic Data.
Haemophilia A: the ratios for VIII:C/vWF:Ag and VIII:C/vWF:RCo (where possible) were
derived for normal females and obligatory carriers within the control group. In women
in whom both results were available the VIII:C/vWF:Ag ratio was plotted against the
VIII:C/vWF:RCo ratio (Chapter 3: Results). From this graph a 'cut-off value for each
ratio was found which correctly classified all of the normal women. These ratios were
then used to analyse the data derived from the phenotypic studies of both the study
obligatory and potential carriers. In the obligate carriers, the number correctly classified
from these ratios was determined whilst for the potential carriers, a prediction was made
based, on the ratios, as to whether they were likely to be carriers or normal.
In some of the study obligatory and potential carriers only a single ratio could be
calculated. In these cases, although they are not presented graphically, the original data
has been reanalysed and a prediction of carriership made. These graphs and tables are
reported in Chapter 3.
Haemophilia B: only limited phenotypic data was available on families with
haemophilia B. The measurement of IX:C was used to predict carrier status where
possible and IX:Ag assays were used to establish CRM status.
In the analysis of the data reference is made to 'unrelated females' when reporting the
frequency of heterozygotes. This was performed by alphabetically sorting each family
and recording the results obtained for the first female member.
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Table 15. Summary of VIII:C, vWF:Ag, vWF:RCo, VIII:C/vWF:Ag and VIII:C/vWF:RCo
values in 31 normal women and 31 obligatory carriers of haemophilia A used as a control
group in this study.
Vni:C vWF:Ag vWF:RCo VHItC/ VHI:C/
(iu/dl) (iu/dl) (iu/dl) vWF:Ag vWFrRCo
Normal women
On oral contraceptive pill (n=13)
No. 13 13 9 13 9
Mean 1.10 1.17 1.12 0.98 1.21
Max. 2.22 2.06 1.93 1.26 2.25
Min. 0.62 0.54 0.48 0.59 0.50
SD 0.42 0.48 0.64 0.34 0.71
Not on oral contraceptive pill (n=18)
No. 18 18 10 18 10
Mean 1.14 1.13 1.23 1.06 1.03
Max. 1.68 2.18 2.00 1.38 2.13
Min. 0.67 0.65 0.55 0.60 0.62
SD 0.46 0.49 0.62 0.26 0.44
Obligatory carriers of haemophilia A
On oral contraceptive pill (n=13)
No. 13 13 11 13 11
Mean 0.52 1.02 1.02 0.54 0.66
Max 1.04 2.21 1.61 0.80 0.79
Min 0.17 0.42 0.82 0.36 0.28
SD 0.26 0.55 0.53 0.20 0.39
Not on oral contraceptive pill (n=18)
No. 18 18 12 18 12
Mean 0.64 1.24 1.01 0.54 0.84
Max. 0.93 2.06 1.69 0.71 1.82
Min. 0.27 0.64 0.33 0.21 0.26
SD 0.23 0.39 0.51 0.20 0.52
NB. No. - number analysed; Mean - the mean of three samples collected on separate




All reagents unless otherwise stated were obtained from either Sigma Chemical Co., Poole,
Dorset or BDH Chemical Ltd., Bristol. All reagents were Analar grade or equivalent.
DNA Reagents.
Proteinase K, lysozyme, RNAse, bovine serum albumin (BSA), large fragment DNA
polymerase I (Klenow) and dNTP's were obtained from BCL, Lewes. Restriction
endonucleases, lambda DNA/Hind III and 0X174/Hae III markers, were obtained from
Gibco-BRL, Paisley Scotland. Hybond-N membrane and [32p]dCTP were from
Amersham International, Amersham and Saran Wrap from Du Pont (UK) Ltd., Stevenage.
Hybridisation bags were obtained from Hybaid Ltd, Teddington, Middx.
Hexaribonucleotides and Sephadex G50 (DNA Grade) were from Pharmacia-LKB,
Milton Keynes. Fuji RX X-ray film and X-ray cassettes were obtained from Genetic
Research Instrumentation Ltd., Dunmow, Essex. Whatman 3M chromatography paper
was obtained from Whatman International Ltd., Maidstone, Kent. Thermus aquaticus
'Taq' polymerase was obtained from Perkin-Elmer Cetus.
Coagulation reagents.
Rabbit anti-human factor VIII and FIX, peroxidase anti-FVIII and anti-FIX conjugates
were obtained from DAKO Ltd., High Wycombe, Bucks. Coagulation standards were
obtained from The National Institute for Biological Standards and Controls (NIBSC),
London. Other reference and factor depleted plasma were obtained from Immuno Ltd.,
Sevenoaks, Kent.
Buffers.
All buffers referred to in the methods section are listed at the end of this chapter.
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2.5. Coagulation Methods.
2.5.1. Collection and Preparation of Samples for Coagulation
Assays.
Samples for coagulation studies were collected into 3.8% trisodium citrate in a ratio 1:9
anticoagulant to blood. Platelet poor plasma (PPP) was prepared by centrifuging whole
blood samples at 1500g for 15 minutes at 4° C and removing the plasma. Functional
VIII:C assays were performed immediately; for assays of vWF and FIX, samples were
frozen and stored at -50° C for processing in batches at a later date.
2.5.2. Two-stage Factor VIII:C Assay.
A modified commercial kit (Diagen Kit, Diagnostic Reagents Ltd.) based on a 2-stage
factor assay was used for VIII:C assays.
Reagents:
1. Test plasma: platelet poor plasma prepared as above.
2. Standard: (NIBSC) reference plasma for VIII:C reconstituted to give l.OOiu/ml,
stored at -20° C until required and warmed to 37° C for 10 minutes prior to use.
3. Factor VIII reagent: reconstituted with 5ml of isotonic saline and 5ml of
0.025M CaCl2.
4. Substrate plasma: reconstituted in 5ml distilled water and kept at 37° C whilst
performing the assay.
5. Citrate saline: 1 part 3.8% trisodium citrate + 4 parts isotonic saline.
6. Aluminium hydroxide: lg Al(OH)3 in 4ml distilled water.
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Method:
A) Adsorbed plasma: 200pl of plasma was mixed with 20(0.1 of Al(OH)3 and incubated at
37° C for 3 minutes, spun in a microfuge for 2 minutes at 12,000 rpm and the
supernatant removed.
B) Plasma dilutions: Using 3" x 1/2" plastic tubes, dilutions (1/10, 1/20, 1/50, 1/100, 1/400)
of standard and test plasma were prepared in citrate-saline buffer and stored on ice until
required.
C) Incubation: Sufficient glass clotting tubes required for the assay were placed in an ice-
block and 400pl of the factor VIII reagent added to each tube. Tubes were placed in the
water bath at 37° C, allowed to warm, lOOp.1 of the first standard dilution added and the
master clock started. At 1 minute intervals, 100(0.1 samples of the remaining standard and
test dilutions were added to the prewarmed glass clotting tubes. Finally, lOOp.1 of citrate-
saline was added to the last tube as a blank.
D) Clotting: At 12 minutes on the master clock, 200(0.1 of substrate plasma was added to
the first tube and the clotting time recorded. At 1 minute intervals this was repeated with
the remaining tubes.
E) Results: Clotting times were plotted against plasma dilutions on double logarithmic
scale graph paper and two best-fit parallel lines drawn through each set of points. From
this the VIII:C concentration in the test plasma could be determined.
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2.5.3. Immunological Assay of vWF (vWF:Ag) by ELISA.
An 'in-house' ELISA method^25 was used for vWF:Ag assays.
Reagents:
1. DAKO rabbit anti-human FVIII.
2. DAKO peroxidase anti-FVIII conjugate.
3. Coating buffer - 0.05M carbonate buffer pH9.6.
4. Incubation buffer - PBS + 0.1% Tween 20.
5. Washing buffer - PBS + 0.05% Tween 20.
6. Citrate phosphate buffer (CPB) pH5.0.
7. Substrate solution - 80mg of 1,2 orthophenylenediamine dihydrochloride
(OPD) + 15ml of CPB + 10pl of fresh H2O2 (20 volumes) prepared immediately
before use.
8. NIBSC human vWF:Ag standard.
9. Normal control plasma.
Method:
A) Plate coating: 100pl of anti-human FVIII (diluted 1/500 with carbonate buffer) was
added to each well of a 96 well microtitre plate using a multi-channel pipette and the plate
incubated for 1 hour at 20° C. The plate was then inverted to remove the antibody and
washed three times in 0.05% washing solution.
B) Antigen Incubation:
I. Standards, tests and control plasma samples were diluted 1/10, 1/20, 1/40 and
1/80 in incubation buffer.
II. lOOpl of buffer alone was added to the first column of the plate to serve as a
negative control and 100pl of each dilution of standard, control and tests in
duplicate to the remaining wells.
III. The plate was then incubated in a moist chamber for 1 hour at 20° C then
washed as above.
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C) Conjugate Incubation: Peroxidase anti-FVIII conjugate was diluted 1/500 with
incubation buffer and lOOpl added to each well using a multi-channel pipette. The plate
was incubated for a further 1 hour at 20° C, inverted to remove the conjugate and washed
twice with washing solution and once with CPB.
D) Substrate Incubation: The substrate was prepared immediately before use and lOOpl
added to each well and the plate incubated on the bench. Periodically the microtitre
reader was blanked using the blank wells and the OD492 of the 1/10 dilution checked.
When the OD reading reached 0.2-0.22, the reactions were stopped by adding 150pl of
1M sulphuric acid to each well.
E) Results: The OD492 reading for each well was plotted on a linear scale against the
standard dilution on a logarithmic scale. A standard curve was plotted and a parallel line
drawn against it for each test. The value for each test sample could then be derived.
2.5.4. Measurement of von Willebrand Factor (vWF) using a
2-site Monoclonal Antibody ELISA.
vWF activity was measured using a 2-site monoclonal antibody ELISA assay. ^0 This
assay has been shown to detect the presence of an epitope on the vWF molecule that
reflects its function. 100,326
Reagents:
1. Primary antibody: RFF-VIII:R/1 - diluted in coating buffer.
2. Secondary antibody: RFF-VIII:R/2- alkaline phosphatase conjugate - diluted in
dilution buffer.
3. Coating buffer - 0.05M carbonate buffer pH9.6.
4. Dilution buffer - PBS + 0.05% Tween 20 + 0.1% BSA.
5. Washing buffer - PBS + 0.1% Tween 20.
6. Substrate buffer - see buffers.
7. Substrate solution - p-nitrophenyl phosphate (lmg/ml) in substrate buffer.
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8. vWF standard - NIBSC.
Method:
A) Plate coating: RFF-VIII:R/1 antibody was diluted in coating buffer to lpg/ml and
220pl added to each well of a 96 well Nunc Immunoplate. The plate was incubated at
20° C for 1 hour and then overnight at 4° C. Before use the plate was washed three times
with washing buffer.
B) Antigen preparation: Standard and test plasma samples were diluted in dilution buffer
and 200pl added to duplicate wells. For the standard curve, the following dilutions were
used: 0, 1/10, 1/20, 1/40, 1/80, 1/160, 1/320, 1/640. Test samples were diluted 1/10, 1/20
and 1/40. The plates were incubated for 2 hours at 20° C and then washed three times
with washing buffer.
C) Conjugate Incubation: RFF-VIII:R/2-alkaline phosphatase conjugate was diluted 1/100
and 200pl was added to each well using a multi-channel pipette. The plate was incubated
for a further 2 hours at 20° C then washed three times with washing solution.
D) Substrate Incubation: The substrate was prepared immediately before use and 200pl
added to each well and the plate incubated on the bench. Exactly 30 minutes after
adding the substrate solution, 50pl of 3M NaOH was added to each well to stop the
reactions and the OD405 for each well read.
E) Results: The OD4Q5 for each well was plotted on a linear scale against standard
dilutions on a logarithmic scale. A standard curve was derived for the control and a
parallel line drawn against it for each test. The value for the test could then be derived.
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2.5.5. Functional FIX Assay - One Stage IX:C Assay.




2. FIX reference plasma - NIBSC.
3. FIX deficient plasma - Immuno Ltd.
4. Light kaolin suspension (0.5%).
5. Platelet substitute (Bell & Alton).
6. Tris-buffercd saline pH7.4.
7. 0.025M calcium chloride.
Method:
A) Plasma dilutions: Using 3" x 1/2" plastic tubes suitable dilutions (1/10, 1/40, 1/160) of
standard and test plasma were prepared in Tris-buffered saline and stored on ice.
B) Incubation: 0.1ml kaolin, 0.1ml platelet substitute and 0.1ml deficient plasma were
added to each of an appropriate number of glass clotting tubes and placed in a water bath
at 37° C.
C) Clotting: In quick succession 0.1ml of the 1/10 dilution of reference plasma was added
to tube 1, 0.1ml of 1/40 dilution to tube 2 and 0.1ml of 1/160 to tube 3 and a 'master'
clock started. At 3 minutes the procedure was repeated for the test plasma. At 10
minutes 0.1ml of 0.025M calcium chloride at 37° C was added to each of the three
reference plasma tubes and the clotting times for each determined. At 13 minutes this
step was repeated for the test plasma.
D) Results: Using logarithmic-linear graph paper, the clotting reference times obtained
for each dilution were plotted against the log of the corresponding plasma concentration
using the 1/10 dilution as equivalent to l.Ou/ml. A straight line was then drawn through
the points. The clotting times for the test plasma were then plotted and the best line
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parallel to the control plasma obtained. The IX:C concentration of the test plasma could
then be derived by interpolation of the line.
2.5.6. Immunological FIX (IX:Ag) Assay.
An ELISA assay was used to measure IX:Ag; the primary antibody was a rabbit anti-
human IX:Ag and the secondary antibody a rabbit anti-human IX:Ag peroxidase
conjugated.
Reagents:
1. Primary antibody - Rabbit anti-human IX:Ag (DAKO Ltd.).
2. Secondary antibody - Rabbit anti-human IX:Ag peroxidase conjugated
(DAKO Ltd.).
3. Coating buffer - 0.05M carbonate buffer pH9.6.
4. Dilution buffer - PBS + 0.05% Tween 20 + 0.1% BSA.
5. Washing buffer - PBS + 0.05% Tween 20.
6. Citrate phosphate buffer (CPB) pH5.0.
7. Substrate solution - 30mg of 1,2 orthophenylenediamine dihydrochloride
(OPD) + 10ml of CPB + 10pl of fresh H2O2 (20 volumes) prepared immediately
before use.
8. Reference IX:Ag plasma - Immuno Ltd.
9. Normal control plasma.
Method:
A) Plate coating: The primary antibody was diluted 1/300 in carbonate buffer and 100|al
added to each well of a 96 well microtitre plate leaving columns 1 and 12 empty to serve
as blanks. Antibody was added to well 96 - the antigen blank. The plate was covered
with parafilm and incubated overnight at 4° C, the antibody was then tipped out and the
plate blotted onto absorbent paper. 200pl of wash buffer was added to each well and the
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plate incubated for 2 minutes. The plate was inverted to remove the buffer, drained by
gently tapping on absorbent paper and the washing step repeated twice.
B) Sample Dilutions - A standard curve was derived using the dilutions shown:
Dilution Reference plasma Diluting buffer
100% lOpl 1.0ml
80 0.8 of 1/100 dilution 0.2ml
60 0.6 of 1/100 dilution 0.4ml
40 0.4 of 1/100 dilution 0.6ml
20 0.2 of 1/100 dilution 0.8ml
Test and control plasma were diluted 1/150 in dilution buffer. lOOpl of each sample
dilution was added to duplicate wells. lOOpl of dilution buffer was added to well 96
(H12). The plate was covered with parafilm and incubated at 37° C for 60 minutes and
the washing step carried out earlier, repeated.
C) Substrate conjugation: The secondary antibody was diluted 1/1000 in dilution buffer
and 100|il added to each well using a multi-channel pipette. The plate was incubated for
2hrs at 37° C. (During this time 80mg of 1,2 orthophenylenediamine dihydrochloride
(OPD) was dissolved in 10ml of CPB.) The plate was then washed twice with washing
buffer and once with CPB.
D) Substrate incubation: lOpl of H2O2 (20 Vols) was added to the OPD solution
immediately before use. 100pi of the OPD/H2O2 solution was added to each well and the
colour allowed to develop at 37° C. When the colour had developed sufficiently
(approximately 4 minutes) the reaction was stopped by adding 150pl of 1M sulphuric
acid to each well.
E) Results: The plate was then read on a microtitre plate reader (492nm), a standard curve
established by plotting dilution against OD492 on single log paper. The IX:Ag values in
the test samples were then established from the standard curve.
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2.6. DNA Methodology.
FVIII and FIX Gene Probes.
The FVIII and FIX gene probes used for the genotypic analyses are listed at the end of
this chapter.
2.6.1. Collection of Whole Blood Samples for DNA Studies.
Whole blood was collected into 3.8% trisodium citrate (1:9 blood:anticoagulant). The
DNA was either extracted immediately or the samples stored at -30° C for processing at a
later date.
2.6.2. DNA Extraction.
The method of Bell et al^28 was use(j wjth modifications. 10ml of anticoagulated blood
was added to 90ml of ice-cold cell lysis buffer and stored on ice for 15 minutes. The
sample was centrifuged at lOOOg for 10 minutes at 4° C to obtain a pellet which was then
re-suspended in 4.5ml of TE pH8.0. The nuclei were lysed by adding 10ml of nuclear
lysis buffer and gently rotating the sample on a mechanical rotator at 250rpm until a
clear viscous solution was obtained. This was then extracted with 5ml of TE (pH8.0)
saturated phenol followed by 5ml of chloroform :i soamyl alcohol (24:1) and the phases
separated by centrifugation at lOOOg for 5 minutes at 20° C. The upper phase was re-
extracted with 5ml of phenol/chloroform followed by a single chloroform extraction.
The DNA was precipitated by adding 2 1/2 volumes of ethanol, the DNA collected on a
sealed sterile glass Pasteur pipette, washed in 70% ethanol, dried and finally re-suspended
in 500pl of distilled water.
2.6.3. Quantitation of Genomic and Plasmid DNA.
Genomic and plasmid DNA was quantitated by measuring its optical density (OD) at
260nm. The degree of phenol and protein contamination was determined by measuring
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the OD260 and OD28q.
From the formula:
1 OD260nm = 50jj.g double stranded DNA - the DNA concentration could be
determined.
The ratio of the OD's at 260/280 also gives an indication of DNA purity (should exceed
1.8).
2.6.4. Restriction Enzyme Digests.
Restriction enzyme digests were performed according to the manufacturer's instructions
supplied with each enzyme. 10pg of DNA was used in each digest, 2units/p.g of enzyme
and the appropriate volume of a 10X buffer. Samples were digested for at least 2 hours
and usually overnight (12-16 hours).
2.6.5. Submarine Gel Electrophoresis.
Following restriction enzyme digestion, DNA samples were size fractionated by
submarine gel electrophoresis in IX Tris-Borate-EDTA (TBE). 20 x 17cm agarose gels
(0.8%) in IX TBE containing ethidium bromide (0.5pg/ml) were poured and allowed to
set. Sufficient IX TBE buffer to cover the gel by 2-3mm was added. One-sixth volume
of 6X loading buffer was added to each DNA sample and the samples loaded using a
micropipette. Up to twenty samples could be run on a single gel. Electrophoresis was
carried out at a constant voltage of 1.5V/cm until the bromophenol blue front had
migrated to the end of the gel.
Size markers (lpg of Lambda DNA digested with Hind III) were included in each
electrophoresis from which the sizes of individual fragments could be determined (the
migration of a fragment being inversely proportional to its molecular weight). In
addition by incorporating radio-labelled markers, the efficiency of transfer could be
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monitored and markers were then easily visible on the final autoradiograph.
2.6.6. Preparation of 32p_Labeueci Molecular Weight
Markers.
The large fragment of DNA polymerase I (Klenow) was used to radio-label the recessed
3' ends of Lambda DNA digested with Hind III.
The following were combined:
Lambda DNA/Hind III fragments
10X labelling buffer
Unlabelled dNTP's (minus dCTP)









and incubated at 20° C for 30 minutes. The reaction was stopped by the adding lpl of
0.5M EDTA (pH8.0) and the unincorporated [32P]dCTP removed by Sephadex G50
column chromatography (see 2.6.17).32^ Labelled markers were stored at -20° C and
could be used for several months before losing activity.
2.6.7. Southern (Capillary) Blotting.
DNA fragments following separation by electrophoresis were transferred to nylon
membranes by capillary blotting.^34 After electrophoresis the gel was placed in
denaturing solution for 15 minutes to produce single-stranded DNA. This was repeated
twice leaving the final solution for 30 minutes. Denaturing buffer was replaced with
neutralising buffer left for 30 minutes and repeated twice. If fragments greater than 20kb
were to be transferred then the gel was placed in 0.25M HC1 at room temperature for 15
minutes prior to denaturation to hydrolyse the fragments and improve the transfer.
The transfer apparatus consisted of a glass plate suspended over a reservoir of transfer
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buffer (10X SSC). A sheet of filter paper (Whatman 3M) was cut to the same width as the
gel but long enough to form a wick from the glass plate into the buffer. The gel was
placed onto the filter paper and all air bubbles excluded. A sheet of nylon membrane
(Hybond N) previously cut to fit the gel, was placed on the gel and all air bubbles
excluded. Three sheets of filter paper were then cut slightly larger than the gel, soaked in
transfer buffer and placed on top of the membrane followed by a stack of absorbent
paper towels. A glass plate and a 0.5kg weight were used to compress the stack. Transfer
with 10X SSC was allowed to proceed for 12-16 hours, after which the membrane was
removed, rinsed briefly in 2X SSC to remove any adhering agarose and allowed to dry at
room temperature. The membrane was then wrapped in 'Saran Wrap' and the DNA
immobilised by exposing it to UV light (305nM) for 3 minutes.
2.6.8. Pre-Hybridisation and Hybridisation of Southern Blots.
Detection of specific gene sequences in immobilised DNA involved an initial pre-
hybridisation step to block non-specific binding of radio-labelled probe during
subsequent hybridisation. This was then followed by the actual hybridisation with the
radio-labelled probe.
Membranes were heat sealed into plastic bags (Hybaid Ltd.) with sealable inlet/outlet
ports. 25ml of buffer was used in each pre-hybridisation/hybridisation and consisted of:
Solution Volume Final Concentration
20X SSC 7.5ml SSC X6
Denhardt's solution 50X 2.5ml X5
10% SDS 1.25ml 0.5%
Dextran Sulphate 25% 5ml 10%
Distilled water 8.75ml
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Denatured Salmon Sperm 200p,l 0.08mg/ml
(lOmg/ml)
Final volume: 25ml
Salmon sperm was used as a source of non-homologous DNA to reduce non-specific
binding of the radio-labelled probe and was denatured by boiling for 5 minutes followed
by rapid chilling on ice. Pre-hybridisation was carried out with shaking at 65° C for 6-7
hours after which the pre-hybridisation buffer was drained, added to the labelled
denatured probe and readded to the membrane ensuring all air bubbles were expelled.
Hybridisation was carried out with constant shaking for 24-48 hours at 65° C.
2.6.9. Washing of Hybridisation Membranes (Southern Blots).
Following hybridisation membranes were washed to remove any non-hybridised probe.
Three washes were used with increasing temperature and stringency:
1. SSC X2 + 0.1% SDS at 20° C for 15 minutes
2. SSC X2 + 0.1% SDS at 65° C for 15 minutes
3. SSC X0.2 + 0.1% SDS at 65° C for 30 minutes
Filters were blotted to remove excess fluid but not allowed to dry and wrapped in Saran
Wrap. Autoradiography was carried out for 1-5 days at -70° C using Fuji RX film,
Kodak cassettes and two intensifying screens.
2.6.10. Reprobing of Hybridisation Membranes (Southern
blots).
Hybridised membranes could be re-probed by stripping in dcnaturation buffer for 1
minute, followed by a wash in distilled water for 30 seconds and then 2 minutes in
neutralisation buffer. Filters were then washed briefly in distilled water, wrapped in Saran
Wrap and autoradiographed for 3 days to ensure stripping was complete. The filters were
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then pre-hybridised and hybridised as before.
2.6.11. Growth, Maintenance and Preservation of Bacterial
Strains.
E. coli strain DH5 was a gift from Dr. I. Peake (Dept. of Haematology, Welsh National
School of Medicine, Cardiff) and was used for all transformation experiments.
2.6.11.1. Short-term Storage of Bacteria/clones.
Bacteria were stored inverted on tightly sealed agar plates at 4° C until required. Colonies
could be maintained for 2-4 weeks by this technique,
2.6.11.2. Long-term Storage of Bacteria/clones.
A single bacterial colony was inoculated into a culture flask containing 10ml of 2XTY
(Bacto-tryptone, Bacto-yeast extract, NaCl) and grown overnight at 37° C with vigorous
agitation. 0.85ml of the overnight culture was then transferred to a sterile pre-chilled
Eppendorf containing 0.15ml of freezing buffer, vortexed briefly, snap frozen in liquid
nitrogen and stored at -70° C. Bacteria were recovered by scratching the surface of the
frozen stock with a sterile platinum loop and either streaking an agar plate or inoculating
a flask containing the appropriate culture media.
2.6.12. Transformation of E.coli by Plasmid DNA.
The FVIII and FIX gene probes were received cloned into plasmids and required to be
transfected into a suitable strain of E.coli to provide sufficient amounts for use as probes.
The method used was based upon that of Mandel and Higa330 who demonstrated that the
uptake of bacteriophage Lambda is enhanced by treatment with calcium chloride. This
technique was subsequently was shown to work for plasmid DNA.331
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100ml of 2XTY was inoculated with 1ml of an overnight bacterial culture and the cells
grown until they reached a density of 5 x 10^/ml. Cell density was calculated by
measuring the OD^qo of the culture. At the correct cell density the culture was chilled on
ice for 10 minutes and then centrifuged at 4000g for 5 minutes at 4° C. The supernatant
was discarded, the cells resuspended in 50ml of ice cold lOOmM CaCl2 and stored on ice
for 15 minutes. The cells were then centrifuged at 4000g for 5 minutes at 4° C, the
supernatant discarded and the cells resuspended in 6ml of ice-cold lOOmM CaCl2-
Aliquots of 0.2ml were dispensed into pre-chilled, sterile, glass tubes and the cells stored
at 4° C for 24 hours. Plasmid DNA was diluted in TE (pH8.0) to a concentration of
lng/pl and 40ng added to 0.2ml of competent cells and stored on ice for 30 minutes.
The tubes were then heat shocked in a water bath at 42° C for 2 minutes, 1.0ml of 2XTY
was then added to each tube and the cells incubated at 37° C for 60 minutes without
shaking to allow the bacteria to recover. Each tube was then mixed with 3ml of top agar
(Bacto-agar 7g/l + agarose 7g/l) and poured onto pre-heated agar plates (Bacto-agar 15g/l
+ agarose 15g/l) containing the appropriate selective agent (usually ampicillin 50pg/ml)
and incubated at 37° C for 16-24 hours. This method yielded approximately 10^-10^
transformants per pg of intact plasmid.
2.6.13. Rapid, Small-scale Isolation of Plasmid DNA.
A small-scale plasmid preparation was performed following each transformation to check
the insert before proceeding to a large scale preparation. A single bacterial colony was
inoculated into 5ml of 2XTY (containing the appropriate selective agent eg. ampicillin
50pg/ml) and the cells grown at 37° C overnight with vigorous agitation. 1.5ml of this
overnight culture was transferred to an Eppendorf and centrifuged for 60 seconds to






containing lysozyme (lOmg/ml in lOmM Tris-HCl pH8.0) and the cells vortexed to mix.
The tube was placed in a boiling water bath for 40 seconds and then centrifuged for 10
minutes at room temperature at 12,000rpm in a microfuge. The pellet was removed, 40pl
of 2.5M sodium acetate and 420pl of isopropanol added and the sample placed in a dry-
ice/ethanol bath for 15 minutes to precipitate the plasmid DNA. Samples were
centrifuged again for 15 minutes at 4° C, the supernatant removed and the plasmid pellet
resuspended in 50ptl of TE pH8.0 containing DNAse free RNAse (50|Xg/ml) and
incubated at 37° C for 10 minutes. 10(0.1 of the solution was then added to 1.2|ol of the
appropriate 10X buffer and digested with 1-2 units of the desired restriction enzyme.
Samples were analysed by agarose gel electrophoresis in a 'minigel' system and
fragments visualised on a UV transilluminator. When a 'mini-prep' demonstrated that
the correct sized insert was present then a large scale isolation of the plasmid was
performed.
2.6.14. Large Scale Isolation of Plasmid DNA.
500ml of 2XTY in a 2 litre flask was inoculated with a single bacterial colony containing
the appropriate plasmid and grown overnight at 37° C with vigorous agitation. The cells
were pelleted by centrifugation at 4000g for 10 minutes at 4° C, re-suspended in 3ml of
glucose buffer containing lysozyme (20mg/ml in glucose buffer) and stored on ice for 30
minutes. 4ml of 0.2M NaOH/1% SDS (freshly made) was added and the mixture inverted
gently to mix. The sample was stored on ice for 5 minutes, 3ml of 3M NaOAc (pH4.8)
added and the sample incubated on ice for 60 minutes. The sample was then spun at
3000g for 30 minutes at 4° C to pellet the cellular DNA and bacterial debris leaving the
plasmid DNA in the supernatant. The supernatant was aspirated, 2.5 volumes of absolute
alcohol added and the sample placed at -70° C for 30 minutes to allow the plasmid DNA
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to precipitate. The sample was spun at 10,000g for 30 minutes at 20° C to pellet the
plasmid DNA. The plasmid DNA was re-suspended in 400pl of NEST buffer, transferred
to a 1.5ml Eppendorf, lOOpl of proteinase K (lOmg/ml) and lOOp.1 of 10% SDS added,
and the sample incubated at 55° C for 60 minutes. The DNA was extracted once with
phenol and once with chloroform and the DNA re-precipitated with 2.5 volumes of
absolute alcohol and 1/10 volume of 3M NaOAc pH4.8 and left at -70° C for 30 minutes.
The DNA was pelleted by spinning at 12,000rpm in a microfuge for 10 minutes at 4° C,
re-suspended in 380 pi of distilled water, 20pl of DNAse free RNAse (lOmg/ml in TE)
added and the sample incubated at 37° C for 30 minutes. The DNA was precipitated by
adding 2.5 volumes of ethanol and 1/10 volume of 4M NaOAc and left at -20° C for 10
minutes. The DNA was pelleted in a microfuge for 10 minutes, washed in 70% ethanol
and finally re-suspended in 100-200pl of TE (pH8.0) and the concentration determined.
2.6.15. Gel Purification of Plasmid Inserts.
Following the preparation of plasmid DNA, the insert was excised from the vector by
digestion with the appropriate restriction enzymes(s) (see Probe Data) and separated by
electrophoresis in 1% low melting point (LMP) agarose in IX TAE (Tris-Acetate-EDTA)
containing ethidium bromide (0.5pg/ml). The band of interest was visualised under UV
light and excised.
2.6.16. Labelling of Probes with [32p]dCTP.
Probes were radio-labelled with 32p_dCTP using the method of Feinberg and
Vogelstein.332,333 f^e desired band was cleanly excised from LMP agarose and placed
into a pre-weighcd 1.5ml Eppendorf tube. Water was added at a ratio of 3ml F^O/gram
of gel. The tube was boiled for 7 minutes to melt the gel and denature the DNA
aliquoted into 20pl samples and stored at -20° C. Prior to labelling the tube was reboiled
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for 3 minutes and then incubated at 37° C for 10-60 minutes. Samples were re-boiled a
maximum of three times. The concentration of the probe could be calculated knowing
the amount of plasmid plus probe which was initially digested together with the sizes of
both the vector and insert. The labelling reaction was carried out at room temperature by
adding the following reagents:
Oligo-labelling buffer (OLB) lOpl
BSA 20mg/ml lpl
DNA in agarose (maximum 33.5pl) Xpl
[32P]dCTP (Amersham PB10205) 4000Ci/mmol) 5gl
Klenow DNA polymerase (1unit/pl) 2\xl
dH20 to: 50nl
Generally, 20-30ng of DNA was used in each labelling reaction and the incubation
carried out overnight. The unincorporated [32P]dCTP was separated from the labelled
product on a 5ml Scphadex G50 column.
2.6.17. Sephadex G50 Chromatography.329
A 5ml disposable plastic pipette was filled with Scphadex G50 (Pharmacia-LKB Ltd.) pre-
swollen with TE pH8.0. The column was washed several times with TE (pH8.0), the
labelled probe applied in a lOOpl volume and the column further washed with TE. By
closely monitoring the column with a mini-monitor two radioactive peaks could be
detected. The first peak (representing the labelled probe) was collected whilst the second
(the unincorporated [32P]dCTP) was discarded.
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2.6.18. Polymerase Chain Reaction (PCR).
2.6.18. Enzymatic Amplification of the Bel I and Xba I
Polymorphisms.
Using the polymerase chain reaction (PCR)240 the regions flanking the Bel I and Xba I
polymorphisms were amplified, digested with the restriction enzymes Bel I and Xba I
respectively and RFLP analysis performed.
The primer sequences used in the PCR amplifications were as published by Kogan et
ai 202
Bel I: 5'- TAAAAGCTTTAAATGGTCTAGGC and
5'- TTCGAATTCTGAAATTATCTTGTTC
Xba I: 5'- CACGAGCTCTCCATCTGAACATG and
5'- GGGCTGCAGGGGGGGGGGACAACAG
Amplification primers were synthesised on an Applied Biosystems synthesiser and were
not purified before use. Amplifications were performed in lOOpl reaction volumes
containing lpg of genomic DNA, lOOpmoles of each amplification primer, 200pM of
each dNTP (previously adjusted to pH7.0 with 0.05M Tris base in distilled water) and
10pl of 10X PCR buffer. Samples were heated to 100° C for 5 minutes to denature the
DNA, briefly spun and placed in a programmable heating block (Hybaid Ltd., Intelligent
Heating Block) at the appropriate annealing temperature for 2 minutes. Two units of
Thermus aquaticus ('Taq' polymerase) was added to each sample and the tubes overlaid
with lOOpl of light mineral oil.
For the Bel I polymorphism, samples were subjected to 35 cycles in a programmable
heating block (Intelligent Heating Block, Hybaid Ltd, Middx.) consisting of a 65° C
annealing step for 1 second, a 76° C extension step for 15 seconds and a 94° C
denaturation step for 1 second. On the final cycle the extension step was increased to 10
minutes. The Xba I amplifications were identical but the extension time was reduced to
10 seconds. The timing for each temperature represents the time at that particular
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temperature.
After the amplifications were completed, 18pl of each reaction was analysed on a 1.5%
agarose gel containing ethidium bromide (0.5pg/ml) to check the quality of the amplified
product. If a satisfactory amplification was achieved, 18pl of the amplified material was
digested with 5 units of the appropriate enzyme. The samples were incubated at either
55° C (Bel I) or 37° C (Xba I) for 4 hours and the digests analysed by electrophoresis.
The Bel I digests were analysed on 1.5% agarose gels containing ethidium bromide
(0.5pg/ml) whilst the Xba I amplifications required electrophoresis in 12% nondenaturing
acrylamide gels followed by immersion for 15 minutes in IX TBE containing ethidium
bromide 0.5pg/ml. The gels were then viewed under UV light and photographed.
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Cell lysis buffer (CLB):
2.7. Table 16. Buffers.
Aluminium hydroxide: 25g of aluminium hydroxide was dissolved in 100ml
distilled water and stored in aliquots at 4° C
Carbonate buffer (0.05M): Sodium carbonate 1.59g
Sodium bicarbonate 2.93g
Sodium azide 0.2g
Distilled water to 1L (final pH9.6)
Sucrose (Analar) 11 Og
Tris-HCl 1M pH8.0 lOmls
MgCl2 1M 5mls
Triton X-100 lOmls
Made up to 1L with distilled water and stored at 4° C.
1:4 3.8% trisodium citrate:isotonic saline
Citric acid 7.3g
Na2HP04. 12H20 23.87g
Distilled water to 1L (final pH 5.0)
Sodium chloride 1.5M
Sodium hydroxide 0.5M
Bovine serum albumin (BSA) 2% (w/v)
Ficoll 400 2% (w/v)
Polyvinyl pyrollidone (PVP) 2% (w/v)





































0.5g of light Kaolin was suspended in 100ml 0.9% saline


















pH adjusted to 4.8 with glacial acetic acid.
Neutralising buffer: Sodium chloride 1.5M
Tris-HCl pH7.2 0.5M
Na2EDTA 0.001 M




Phenol: Chromatography grade phenol was melted at 68° C and
one-fifth the volume of TE pH8.0 added + 8-hydroxy-

























(each dNTP dissolved in 3mM Tris-HCl pH7.0/0.2mM
EDTA at a concentration of 0.1M
Solution B:
Hepes pH6.6. 2M
Solution C: Hexaribonucleotides (Pharmacia-LKB) evenly
suspended in TE at 90 OD26O units/ml).
Solutions A, B and C were mixed in a ratio 100:250:150 and
stored at -20° C.




Phosphate buffered saline: NaH2P04. 2H20 0.37g
(PBS) Na2HP04. 12H20 2.68g
Sodium chloride 8.47g
Distilled water to 1L
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RNAse free of DNAse: Ribonuclease A was dissolved in TE pH8.0, boiled for 15






















pH adjusted to 8.0 with HC1.
Tris-Acetate-EDTA (50X): Tris base 242g
Glacial acetic acid 57.1ml
Na2EDTA 0.5M pH8.0 100ml
Distilled water to 1L.
Tris-Borate-EDTA (10X): Tris base 108g
Boric acid 55g
Na2EDTA 9.3g
Distilled water to 1L.
Tris-buffered saline (pH7.4): Tris base 1.6g
Sodium chloride 2.2g
HC1 42ml
Distilled water to 1L.
Washing buffer: PBS 0.01M pH7.2
Tween 20 0.05%
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The Results of Carrier Detection Studies in Haemophilia.
Introduction.
This section presents the results of the phenotypic and genotypic analyses performed on
families with haemophilia A and B. The phenotypic, genotypic and pedigree data for
each family are contained in the Appendices together with an analysis of the results for
each individual. The results obtained for haemophilia A and B will be presented
separately. A summary of the findings for each family is presented at the end of this
Chapter in Tables 34-37.
3. Section 1.
3.1.1. The Results of Carrier Detection Studies in
Haemophilia A.
Forty-four families with haemophilia A were investigated (Table 19). A family history of
haemophilia affecting more than one generation was obtained in 21 families, whilst in 22
families the disease appeared to have arisen spontaneously. In 3 families from this latter
group (Pedigrees Nos. 7, 12 and 24), the birth of a second affected child established the
mothers as obligatory carriers. In 1 family (Pedigree No. 29) with two affected offspring
the mother was adopted and no family history was obtainable, although she is, by
definition an obligate carrier.
The 44 families studied comprised 232 individuals, 107 were males and 125 females. Of
the males, 53 were haemophiliacs and of these 37 had severe disease (VIII:C <0.01iu/dl),
7 had moderately severe disease (VIII:C>0.01 but <0.05iu/dl) and 9 had mild disease
(VIII:C >0.05iu/dl). When the 125 females from these families were analysed with their
respective family pedigrees, 40 were identified as obligate carriers, 80 could not be
excluded as carriers ie. were potential carriers and 5 could be classified as normal females
as in each case they were wives of haemophiliacs and from families in which there was no
history of haemophilia.
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Table 19. Numerical summary on 232 individuals from 44 families with haemophilia A.
Number of males studied.
Normal: 54










3.1.2. Analysis and Interpretation of the Phenotypic Data
from the Haemophilia A Kindred.
3.1.2.1. VIII:C, vWF:Ag, vWF:RCo, VIII:C/vWF:Ag and
VIII:C/vWF:RCo Values in Obligatory and Potential Carriers
from 44 Families with Haemophilia A.
The levels of VIII:C, vWF:Ag, vWF:RCo and the VIII:C/vWF:Ag and VIII:C/vWF:RCo
ratios together with their ranges, means and standard deviations for the 80 potential
carriers and 40 obligate carriers identified in the study are shown in Table 20. When
VIII:C, vWF:Ag and vWF:RCo data is not given it was generally because these individuals
were bled at other centres and the samples sent by post for DNA analysis.
1. VIII:C Assays.
The measurement of VIII:C has been shown to be a poor discriminant for determining
carriership in families with Haemophilia A. However, its measurement can identify those
women with low levels of VIII:C and, therefore, at risk of bleeding and in addition allows
the VIII:C/vWF:Ag and VIII:C/vWF:RCo ratios to be derived. The results of the VIII:C
assays are shown in Table 20 and Figure 11.
i. Normal females: 5 women, wives of haemophilic men and without any family history
of haemophilia were bled primarily for genotypic studies. All of these women had
normal VIII:C, vWF:Ag and vWF:RCo results.
ii. Obligate carriers: of the 40 obligate carriers available for analysis, VIII:C assays were
available on 37. The mean VIII:C was 0.60iu/dl with a range of 0.15-1.5iu/dl.
iii. Potential carriers: of the 80 potential carriers, VIII:C assays were available on 74.
The mean VIII:C was 0.83iu/dl with a range of 0.16-2.05iu/dl.
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Potential Ca-riers Obligatory carriers
Study Data
Figure 11. Scattergram showing the distribution of VIII:C in the study obligatory
carriers and potential carriers of haemophilia A compared to the historical controls
(normal women and obligatory carriers). The mean value for each group is indicated.
The results show that the mean VIII:C for the historical obligatory carriers and the
obligatory carriers identified within the study are similar and lower than the mean VIII:C
for the normal historical female controls, whilst the mean for the potential carriers lies
between these two groups.
127
2. Assessment of Haemostatic Risk in Females from Families with Haemophilia A
using VIII:C Assays.
The incidence of VIII:C values below 0.40iu/dl was 7/31 in the historical obligatory
carrier group, 13/37 in the study obligate carriers and 11/74 in the study potential
carriers. Except when VIII:C assays are very low, this information if of little help in
carrier detection but is important as females with low VIII:C levels may have abnormal
bleeding in association with invasive procedures including those used for antenatal
diagnosis.
3. vWF:Ag, vWFrRCo Assays and VIII:C/vWF:Ag and VIII:C/vWF:RCo ratios.
The ratios of VIII:C to vWF.Ag and possibly VIII:C to vWF:RCo have been shown to be
better discriminants of carriership than measurements of VIII:C alone. These ratios have,
therefore, been calculated for the potential carriers and obligatory carriers identified
within the study and compared to the mean values for the historical normal and




The values obtained from the measurement of the VIII:C/vWF:Ag ratio in the control and
study obligatory carriers are similar although the range is larger in the latter group. The
mean ratios of both groups of obligatory carriers are lower than those for the normal
female control group. The mean ratio for the potential carriers lies between that of the












Normal women Obligatory carriers
Historical controls.
Obligatory carriers Potential carriers
Study data.
Figure 12. Scattergram showing the distribution of the VIII:C/vWF:Ag ratio in the study
obligatory carriers and potential carriers of haemophilia A compared to the historical




The mean values obtained from the measurement of the VIII:C/vWF:RCo ratio in the
control obligatory carriers and the study obligatory carriers are again similar but the
range is much wider than that seen with the VIII:C/vWF:Ag ratio. The means are again
lower than those seen for the normal female controls. The mean ratio for the potential
carriers lies between that of the normal women and the obligatory carriers.
Normal Women Obligatory carriers
Historical controls
Obligatory carriers Potential Carriers
Study data.
Figure 13. Scattergram showing the distribution of the VIII:C/vWF:RCo ratio in the study
obligatory carriers and potential carriers of haemophilia A compared to the historical
controls (normal women and obligatory carriers). The mean value for each group is
indicated.
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3.1.3. Discrimination between Obligate Carriers and Normal
Women and the Classification of Potential Carriers of
Haemophilia A using the Ratios VIII:C/vWF:Ag and
VIII:C/vWF:RCo.
The value of the VIII:C/vWF:Ag and VIII:C/vWF:RCo ratios as discriminants of
carriership, are shown in Figures 14-16 where the VIII:C/vWF:Ag ratio is plotted against
the VIII:C/vWF:RCo ratio for:
- the historical controls ie. obligate carriers and normal females - Figure 14.
- the study obligate carriers and the historical normal controls - Figure 15.
- the study potential carriers and the historical normal controls - Figure 16.
Lines which completely separate the control groups of normal females and obligatory
carriers have been drawn and the ratios at which these lines intercept the axes have been
used to assign a phenotype to obligate and potential carriers identified by pedigree
analysis within the study. (The limitations of this approach will be discussed in Chapter
4). Only individuals in whom both the ratios could be calculated are shown in these
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Figure 14. VIII:C/vWF:Ag ratio plotted against VIII:C/vWF:RCo ratio for the historical
obligate carriers and historical normal female control group. A line for each ratio has been
drawn which separates the normal females from the obligate carriers.
NB. The ratios that separate normal females from obligatory carriers are 0.58
(VIII:C/vWF:Ag) and 0.49 (VIII:C/vWF:RCo). The VIII:C/vWF:Ag ratio of 0.58
misclassifies 8/23 (34.8%) of the obligatory carriers as normal whilst the VIII:C/vWF:RCo
ratio of 0.49 misclassifies 18/23 (78.3%) as normal - the VIII:C/vWF:Ag ratio, therefore,
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Figure 15. VIII:C/vWF:Ag ratio plotted against VIII:C/vWF:RCo ratio for the historical
normal female controls (mean of 3 samples) and the obligate carriers identified within the
study (single sample). The lines represent the ratios derived from Figure 14.
NB. The VIII:C/vWF:Ag ratio (<0.58) misclassifies 15/30 of the study obligatory carriers as
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Figure 16. VIII:C/vWF:Ag ratio plotted against VIII:C/vWF:RCo ratio for the normal
female controls and the study potential carriers. The lines represent the ratios derived from
Figure 14.
NB. Of the potential carriers, 41/53 are identified as normal with the VIII:C/vWF:Ag ratio
(<0.58) and 43/53 with the VIII:C/vWF:RCo ratio (<0.49).
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3.1.4. Summary of Data and Interpretation of Results from
Figures 14-16.
The data from Figures 14-16 is summarised in Table 21. For the historical controls, data
for measurements of both VIII:C/vWF:Ag and VIII:C/vWF:RCo were available but for
women within the study, it was not always possible to determine both ratios eg. missing
vWF:RCo data. From the results in Figure 14 the ratios were determined that correctly
classified all of the normal female controls. Using these ratios to analyse both the
obligate carriers (controls and study) and the potential carriers showed:
1. Historical obligate carriers
The VIII:C/vWF:Ag ratio correctly identified 15/23 (65.2%) of the historical obligate
carriers, misclassifying 8/23 (34.8%) whilst the VIII:C/vWF:RCo ratio correctly identified
only 5/23 (21.7%), misclassifying 18/23 (78.3%). From these findings the
VIII:C/vWF:Ag ratio appeared to be a more sensitive discriminant.
2. Obligate Carriers and Potential carriers identified within the Study.
A. Obligate carriers - the VIII:C/vWF:Ag ratio correctly identified 15/30 (50%) of
carriers, misclassifying 50%. When the VIII:C/vWF:Ag ratio of 0.58 was used to screen all
obligate carriers irrespective of whether the VIII:C/vWF:RCo ratio had been measured,
then 21/37 (56.8%) were correctly classified. When the VIII:C/vWF:RCo ratio was used
the number of obligate carriers correctly classified fell to 43.4%. These findings support
those found for the historical controls in that the VIII:C/vWF:Ag ratio appears to be a
more sensitive discriminant of carriership.
B. Potential carriers - using the VIII:C/vWF:Ag ratio of 0.58, predicted that 41/53
(77.4%) of the potential carriers would be normal and 12/53 (22.6%) would be carriers
whilst the VIII:C/vWF:RCo ratio predicted that 43/53 (81.1%) would be normal and 10/53
(18.9%) would be carriers. When the VIII:C/vWF:Ag and VIII:C/vWF:RCo ratios were
used to screen all potential carriers (irrespective of whether results for both assays were
available) the numbers predicted to be carriers were 20/74 (27%) for VIII:C/vWF:Ag and
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11/61 (18%) for VIII:C/vWF:RCo.
Phenotypic analysis in families with haemophilia A is invaluable for a number of reasons
- it can identify those women with low VIII:C values and, therefore, at risk of bleeding
and it can establish which potential carriers are likely to be true carriers but it cannot
exclude carriership in potential carriers with normal VIII:C/vWF:Ag and VIII:C/vWF:RCo
ratios. However, phenotypic analysis can prove invaluable in the interpretation of the
genotypic data and in women in whom genotypic analysis is unhelpful.
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3.2. Genotypic Analysis in Haemophilia A.
3.2.1. Intragenic and Extragenic Polymorphisms.
Carrier detection was attempted in 80 'at-risk' females from 44 families with haemo¬
philia A using three intragenic (Bel I, Xba I, Bgl I) and two extragenic (Bgl II, Taq I)
polymorphisms. Forty obligate carriers of haemophilia A were also studied to identify
informative RFLP's for use in prenatal diagnosis.
The first probes to be obtained allowed analyses for the Bgl II and Bel I polymorphisms
to be performed and were, therefore, carried out on the majority of families. Families
which were informative with only the linked Bgl II marker or non-informative for the
Bel I polymorphism were studied further to determine heterozygosity for the Xba I
and/or Bgl I polymorphisms. In cases which were otherwise non-informative, the multi-
allelic, extragenic Taq I polymorphism was analysed.
Intragenic Polymorphisms.
1. Bel I polymorphism.
The Bel I polymorphism, located within intron 18, produces a band of 0.8kb when the
site is present and a l.lkb band when the site is absent after digestion of genomic DNA
with Bel I and probing with pi 14.12. In initial studies this polymorphism was analysed
by Southern blotting but subsequently analyses were performed by enzymatic
amplification using the polymerase chain reaction (PCR). Two other polymorphisms are
in complete linkage disequilibrium with the Bel I intron 18 polymorphism - a Hind III
polymorphism situated in intron 19196,233, an(i an ]yjSp j polymorphism situated in 3'
flanking regionJ 97 a resuit of this strong linkage disequilibrium they offer no
advantages over the readily analysed Bel I marker.
Figure 17 shows an auto radiograph from a family in which there was a single affected
male and in which the Bel I polymorphism was informative. From the pedigree (Pedigree
No. 43 - Appendix 1), 1-1 and II-2 are both potential carriers. Genotypic analysis shows
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that the gene in haemophilic II-1 is marked by the 0.8kb fragment of the Bel I
polymorphism; II-2 is homozygous for the 1.1 kb fragment, having inherited a 1.1 kb
fragment from her father (1-2) and the normal 1.1 kb fragment from her mother (1-1) and
is, therefore, not a carrier.
Figure 17. Autoradiograph of leucocyte DNA digested with Bel I and hybridised with
the genomic probe pi 14.12. The polymorphic bands at 0.8kb and l.lkb are indicated.
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Figure 18 shows part of Pedigree No. 10 (Appendix 1) in which the Bel I polymorphism
has been identified using the Polymerase Chain Reaction. The region containing the
Bel I site was amplified, digested with Bel I and electrophoresed in a 1.5% agarose gel
containing ethidium bromide. Amplification generates a single fragment of 142bp.
After digestion with Bel I if the polymorphic site is present two bands are seen at 99bp
and 43bp whilst if the site is absent only a single band of 142bp is visible.
In this pedigree the abnormal gene is associated with the 99/43bp bands (0.8kb by
Southern blotting) of the Bel I polymorphism (III-5). Both 1-2 and II-6 are obligatory
carriers but only II-6 is heterozygous for the Bel I polymorphism. II-6's son, III-6 has
inherited the normal 142bp fragment and is, therefore, normal. As II-6 is informative for
the Bel I polymorphism this could be used for prenatal diagnosis.
in
Figure 18. 18pl of a Bel I amplification was digested with lOunits of Bel I and
electrophoresed in a 1.5% agarose gel containing ethidium bromide (0.5pg/ml). A single
band of 142bp is seen when the Bel I site is absent and two fragments at 99bp and 43bp if
the site is present. M - 0X174/Hae III markers.
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The Bel I polymorphism proved useful in a number of situations.
1. No coagulation data available
Intragenic polymorphisms are useful in establishing carrier status in families in which
coagulation data is not available on potential carriers and their use is preferred to
extragenic polymorphisms as the latter carry a risk of recombination and, therefore, of
misdiagnosis.
In Pedigree No. 43 (Appendix 1), although no coagulation data was available it was
possible to exclude the 'at-risk' daughter (II-2) as a haemophilia A carrier on the basis of
the results obtained by Bel I analysis even though it was not possible to confirm her
mother (1-1) as a carrier.
2. Identifying the origin of the haemophilic mutation.
(See also - Sporadic Haemophilia A).
In some families, the presence of an identical haplotype in brothers, one a normal male
and the other a haemophiliac, indicated that the mutation was unique to the affected male
and excluded other females within the kindred as carriers. For example, in Pedigree No.
20 (Appendix 1), there are 3 potential carriers although all have a normal coagulation
phenotype. The haemophilic gene is marked by the 0.8kb (and 2.8kb Bgl II) allele
which both III-1 and III-2 have inherited from their mother. This suggests that the
mutation is unique to III-1 although it is possible that II-2 could be a germ line mosaic.
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2. Xba I polymorphism.
The Xba I polymorphism, situated in intron 22, detects a two allele system after a double
digestion of genomic DNA with Xba I and Kpn I and probing with p482.6. A double
digestion is required to separate the polymorphic FVIII gene hybridising bands away
from a non-FVIII hybridising band.
Figure 19 shows Pedigree No. 35 (Appendix 1) in which the Xba I polymorphism has
been analysed by Southern blotting using a EcoR I/Sst I fragment of the genomic clone
p482.6 as a probe. This results in two polymorphic fragments of either 6.2kb or 4.8kb
and a non-FVIII hybridising band at 6.6kb. In lanes A1-5 5pg of genomic DNA was
digested with Xba I and Kpn I whilst in lanes Bl-5 10pg of DNA was digested. The
polymorphic bands at 4.8kb and 6.2kb are visible as is the non-FVIII hybridising band at
6.6kb. These are more easily seen in panel A than panel B, although the additional
polymorphic band at 4.8kb in II-2 is clearer in panel B. The figure illustrates that to
resolve the polymorphic 6.2kb fragment from the 6.6kb fragment, the amount of DNA
loaded onto the gel is critical and it is, therefore, advisable to perform two digests with
varying amounts of DNA.
In Pedigree No. 35, III-1 and III-3 who are both obligate carriers of haemophilia A,
sought advice concerning prenatal diagnosis of the disease. The mutant gene is marked
by the 6.2kb fragment of the Xba I polymorphism which both III-1 and III-3 must
inherit. Ill-1 is heterozygous for the Xba I polymorphism and can, therefore, be offered
antenatal diagnosis but her sister (III-3) is homozygous for this marker and another,
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Figure 19. Autoradiograph of leucocyte DNA digested with Xba I/Kpn I and hybridised
with an EcoR I/Sst I fragment of the genomic probe p482.6. In panel A, lanes 1-5
contain 5pg of DNA and in panel B lOpg.
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With developments in technology it has become possible to analyse the Xba I
polymorphisms by means of PCR and this is illustrated in Figure 20. The results are
complicated by a non-FVIII sequence which is also amplified and masks the 96bp
polymorphic fragment. In some females, depending upon which other family members
are available, the Xba I site on the second chromosome may be inferred and in males with
only a single X chromosome the Xba I polymorphism can be established. The ease by
which families can be screened for heterozygosity at the Xba I polymorphism by PCR is
such that all families non-informative for the Bel I polymorphism are now screened using
this technique and those in which Xba I appears to be informative are then reanalysed by
Southern blotting.
Figure 20 shows a 12% non-denaturing polyacrylamide gel stained with ethidium
bromide showing Pedigree No. 40 (Appendix 1) which was informative for the Xba I
polymorphism. The haemophilic gene in this kindred is marked by the 96bp fragment
(II-1). Males 1-1 and II-1 show only a single band of 96bp and we can infer that they
lack the Xba I site ie. 6.2kb by Southern blotting. 1-2 and II-2 both show bands at 96bp
and 68bp/28bp indicating the presence of an Xba I site. However, it is not clear whether
these two females are heterozygotes or homozygotes as the co-amplifying non-FVIII
96bp band masks the other polymorphic site. However, 1-2 must be heterozygous as she
has a son (II-1) who lacks the Xba I polymorphism and II-2 must also be heterozygous as
she must inherit an X-chromosome from her father (1-1) who lacks the Xba I site. This
assumes correct paternity.
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Figure 20. 18|al of a 100(0.1 Xba I amplification was digested with lOunits of Xba I and
electrophoresed in a 12% non-denaturing polyacrylamide gel in IX TBE. After
electrophoresis the gel was soaked for 20 minutes in IX TBE containing ethidium
bromide (0.5pg/ml). The constant band at 96bp which masks one of the polymorphic
fragments is seen as are the two fragments of 68bp and 28bp generated when the Xba I
site is present.
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3. Bgl I polymorphism.
The Bgl I polymorphism, adjacent to exon 26 detects a two allele system after digestion
with Bgl I and probing with the FVIII cDNA probe - Probe C. A band of 20.0kb is seen
when the site is absent and 5.0kb when the site is present.
Figure 21 shows an autoradiograph obtained from one of the few families (Pedigree No.
42 - Appendix 1) in which the Bgl I polymorphism was helpful. II-2 is a potential carrier
of haemophilia A with an abnormal coagulation phenotype. As her son, (III-1) is
phenotypically normal, we can deduce that the haemophilic gene is marked by the 5.0kb
fragment. Her daughter III-2 is homozygous for the 5.0kb allele; she must have
inherited one allele from her father (II-1) and the other from her mother. Although this
does not establish the carrier status of III-2, the finding of abnormal coagulation
phenotypes in both mother and daughter supports the suggestion that they are both
carriers. Although reported here in the context of haemophilia A, it is possible that this
family has a variant of von Willebrand's disease in which there is a mutation in the vWF
protein affecting binding of the FVIII molecule. This is discussed in greater detail in
Chapter 4.
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Figure 21. Autoradiograph of leucocyte DNA digested with Bgl I and hybridised with
the FVIII cDNA clone - Probe C. The polymorphic fragments at 20.0kb and 5.0kb are
clearly visible. M - Lambda DNA/Hind III markers.
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3.2.2. Linked or Extragenic Polymorphisms.
Wherever possible informative intragenic polymorphisms were sought to identify carriers.
However, a number of women will be non-informative ie. homozygous for all these
markers and in these cases, the linked extragenic polymorphisms may be useful. Two
extragenic markers were used in the genotypic studies - the Bgl II and Taq I
polymorphisms both situated centromeric to the FVIII gene.
1. Bgl II polymorphism.
The probe for this polymorphism became available early in the study and was used to
study a number of families before the intragenic markers became available. This
extragenic polymorphism detected with the probe DX13 (DXS15) yields fragments of
either 2.8kb or 5.8kb and up to 4 constant non-polymorphic bands.
Figure 22 shows Pedigree No. 14 (Appendix 1) in which the intragenic markers were
unhelpful but which was informative for the Bgl II polymorphism. The haemophilic
gene is marked by the 2.8kb fragment (III-1) for which II-1 is heterozygous. Although
this could be used in prenatal diagnosis there would be a 5% chance of error due to
possible recombination.
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Figure 22. Autoradiograph of leucocyte DNA digested with Bgl II and hybridised with
the genomic probe DX13 (DXS15). The polymorphic fragments at 2.8kb and 5.8kb are
clearly visible. M - Lambda DNA/Hind III markers.
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2. Taq I polymorphism.
The extragenic Taq I marker detected by the probe ST14 (DXS52), yields up to ten
polymorphic bands after digestion with Taq I and is of use when the other
polymorphisms are non-informative. However, because it is extragenic it is associated
with a risk of recombination and, therefore, of misdiagnosis. This polymorphism was
analysed in women who were non-informative for the other markers both intra- and
extragenic. A major problem with the Taq I polymorphism is the interpretation of blots
with supposedly constant fragments migrating together with the polymorphic fragments.
Figure 23 shows Pedigree No. CI (Appendix 3), a pedigree in which there was no history
of haemophilia A or B but in which help was sought in identifying potential carriers in a
family with X-linked adrenoleukodystrophy, using the FVIII gene probes. This family is
described in more detail at the end of this Chapter. As this disease is X-linked the
interpretation of the results is identical to those obtained for haemophilia A and B.
Within this family the disease is associated with the 4.5kb allele of the Taq I
polymorphism (III-l). III-2 has inherited the same allele from his mother and might be
expected to be affected by the disease - a suggestion recently confirmed both clinically
and from biochemical analyses. Their mother (II-l) must, therefore, be an obligatory
carrier of the disease and this is confirmed by the finding of abnormal long chain fatty
acids, in keeping with a carrier state for the disease. She is heterozygous for the Taq I
polymorphism having inherited a 4.1kb allele from her father (I-1) and a 4.5kb allele
from her mother (1-2). 1-2 is a potential carrier of the disease, although no long chain
fatty acid studies were available. Her son, II-3 has inherited the 3.9kb allele and is
clinically normal but her daughter, II-4 is heterozygous for the Taq I allele having
inherited a 4.1kb allele from her father and the 3.9kb allele from her mother. Even
though the carrier status of 1-2 cannot be definitively established, the haplotype of II-4 is
against her being a carrier. The linkage of the ST14 marker to the ALD gene is discussed
in greater detail at the end this chapter.
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Figure 23. Autoradiograph of leucocyte DNA digested with Taq I and hybridised to the
ST14 (DXS52) probe. The polymorphic bands at 4.5kb, 4.1kb and 3.9kb are clearly
visible.
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3.2.3. Heterozygosity Frequencies for the Intragenic and
Extragenic Polymorphisms.
The frequencies of the allelic DNA fragments and the number of heterozygous females
for the three intragenic and the two extragenic polymorphisms are summarised in Table
22. This shows the data obtained for all women and does not exclude related individuals.
Data for unrelated individuals is shown in Table 23 and gives a more accurate indication
of the frequency of heterozygotes.
Not all the available polymorphisms were analysed for each female. As the probes for the
Bgl II and Bel I polymorphisms became available early in the study these analyses were
carried out on most women. The Xba I polymorphism was analysed only in women in
whom the Bel 1 and Bgl 1 polymorphisms were unhelpful. The Bgl I polymorphism was
studied in most women to determine the frequency of the various haplotypes in the local
population. Lastly, the Taq I polymorphism was analysed only in women who were non-
informative for all other markers.
1. All females (Table 22).
51 of 122 women (41.8%) were heterozygous for the Bel I polymorphism, 36 of 63
women (57.1%) were heterozygous for the Xba I polymorphism, 10 of 75 women
(13.4%) were heterozygous for Bgl I. Of the linked, extragenic markers, 66 of 112
women (58.9%) were heterozygous for the Bgl II polymorphism and all but two women
examined for the Taq I polymorphism were heterozygous although only 10 women were
analysed.
152
Table 22. Frequencies of allelic DNA fragments at three intragenic and two extragenic
polymorphic sites in or close to the FVIII gene for all women in whom data was available.
Heterozygosity
No. of X
chromo- Alleles Allele Alleles Observed Predicted
RFLP somes (kb) Frequency (kb) (%) (%)
analysed
Intragenic polymorphisms
Bel I 346 0.8 0.76 0.8/1.1 41.8 36.5
1.1 0.24
Xba I 184 4.8 0.58 4.8/6.2 57.1 48.8
6.2 0.42
Bgl I 210 5.0 0.90 5.0/20.0 13.4 18
20.0 0.10
Extragenic polymorphisms
Bgl II 325 2.8 0.41 2.5/5.8 58.9 48.4
5.8 0.59
Taq I 25 Multiple 80 -
The predicted and observed heterozygosity frequencies are also shown. The predicted
heterozygote frequencies are calculated from 2pq x 100 where p and q are the
frequencies of the respective alleles eg. for Bel I the predicted frequency is 2 x 0.759 x
0.241 x 100 = 36.5%.
NB. Heterozygosity frequencies greater than 50% represent sampling errors as the
number of heterozygotes cannot exceed 50% in a two allele system.
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2. Unrelated females.
Forty-three unrelated women which included obligate carriers, potential carriers and
normal females were also studied to determine the heterozygosity frequency in this group
(Table 23). The figures are similar to those shown in Table 22.
Table 23. Observed heterozygote frequency for the three intragenic and two extragenic
polymorphic sites in or close to the FVIII gene in unrelated women (includes potential
carriers, obligate carriers and normal females).
Heterozygosity
No. of X
chromo- Alleles Allele Alleles Observed Predicted
RFLP somes (kb) Frequency (kb) (%) (%)
analysed
Intragenic polymorphisms
Bel I 44 0.8 0.75 0.8/1.1 36.4 37.5
1.1 0.25
Xba I 27 4.8 0.50 4.8/6.2 55.5 50
6.2 0.50
Bgl I 31 5.0 0.94 5.0/20.0 13 11.3
20.0 0.06
Extragenic polymorphisms
Bgl II 43 2.8 0.37 2.5/5.8 67 47
5.8 0.63
Taq I 4 Multiple - - 100 -
NB. Heterozygosity frequencies greater than 50% represent sampling errors as the
number of heterozygotes cannot exceed 50% in a 2-allele system
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3. Obligatory carriers.
Twenty-four unrelated obligate carriers from the study were also analysed to determine
the frequency of hcterozygotes in this group (Table 24). The figures are similar to those
reported in Tables 22 and 23, although the frequency of heterozygotes is less for the
Bgl I polymorphism.
Table 24. Heterozygote frequency for the three intragenic and two extragenic




chromo- Alleles Alleles Observed
RFLP somes (kb) (kb) (%)
analysed
Intragenic polymorphisms
Bel 1 24 0.8
1.1
Xba I 19 4.8
6.2
Bgl I 16 5.0
20.0
Extragenic polymorphisms
Bgl II 23 2.8 2.5/5.8 65
5.8





Summary of Tables 22-24.
Tables 22-24 indicate that the intragenic Bel I and Xba I polymorphisms will be useful in
genotypic studies ie. carrier detection and prenatal diagnosis, in both obligate carriers and
potential carriers as the observed heterozygosity rate in unrelated females is between 36%
(Bel I) and 55% (Xba I). The Bgl I polymorphism is unlikely to add greatly to the
number of women heterozygous for this additional intragenic marker as the frequency of
the 20kb allele is low suggesting that the majority of females will be homozygous 5.0/5.0.
This is confirmed by the low number of observed heterozygotes (13%). However, the
linked Bgl II and the multi-allelic Taq I polymorphisms will be useful in those women in
whom the intragenic markers are non-informative. They are unlikely to show linkage
disequilibrium with the intragenic markers because of their distance from the FVIII gene
and in addition, the numbers of observed heterozygotes in unrelated women is high.
3.2.4. Multiple Heterozygosity.
Some women were heterozygous for more than one polymorphism and this data is shown
in Table 25. Ten women were heterozygous for both the Bel I and Xba I polymorphisms,
9 women for the Bel I and Bgl I polymorphisms and 26 women for both the Bel I and
Bgl II polymorphisms. Five women were heterozygous for the Bel I, Xba I and Bgl II
polymorphisms and 8 women for the Bel I, Xba I and Bgl II polymorphisms.
A single woman was informative for the three intragenic polymorphisms and the linked
Bgl II marker. No data is available for the Taq I polymorphism as this was only analysed
when other markers were non-informative.
156
Table 25. Number of women heterozygous for more than one polymorphism.
Heterozygous
Number























Bel I + Xba I +
Bgl I
49 1 2.0
NB. Data shown includes related women.
3.2.5. Frequency of Heterozygotes in Both Unrelated and
Related Females, if Non-Informative at the Bel I and/or
Xba I Loci.
The intragenic Bel I polymorphism was informative in 36.4% of unrelated women (Table
23) and 41.8% of all women (Table 22). Women who were non-informative for this
marker were then screened for heterozygosity at the Xba I and Bgl I sites and if these
were unhelpful the linked polymorphisms were analysed. The number of women who
were informative for both the intragenic and extragenic polymorphisms when either the
Bel I or the Bel I/Xba I polymorphisms were non-informative are shown in Table 26.
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Table 26. Observed frequency of heterozygotes at two intragenic and two extragenic
polymorphic sites, when either the Bel I polymorphism or both the Bel I and Xba I
polymorphisms were non-informative.
Bel I non-informative Bel I and Xba I non-informative
All women Unrelated All women Unrelated
RFLP No. % No. % No. % No. %
Xba I 23/50 46 12/23 52.1 - - - -
Bgl I 1/54 1.9 1/21 4.8 0/50 - 0/50 -
Bgl II 39/66 59 17/25 68 17/55 31.5 14/25 56
Taq I - - 4/4 100 4/5 80 4/4 100
In all women who were non-informative for the Bel I polymorphism, 46% were
informative for the Xba I polymorphism, less than 2% for the Bgl I marker but 59% for
the linked Bgl II polymorphism. In all women who were non-informative for both the
Bel I and Xba I polymorphisms, the Bgl I polymorphism was unhelpful as all women
were homozygous, however 31.5% of women were heterozygous for the linked Bgl II
marker.
The Xba I polymorphism, therefore, proved extremely useful in women who were non-
informative for the Bel I polymorphism. In all women in whom both the Bel I and Xba I
polymorphisms were unhelpful, the Bgl I marker was of little additional benefit. In this
latter group, however the linked Bgl II marker was informative in 31.5% of cases. The
multi-allelic Taq I marker was analysed in very few families but proved to be of benefit in
women homozygous for all other RFLP's.
158
3.2.6. Distribution of the Bel I, Xba I and Bgl I Haplotypes
in Unrelated Women.
The frequencies of the various haplotypes for the three intragenic polymorphisms in non-
related individuals are shown in Tables 27-28 and compared to the distributions expected
in the absence of any linkage disequilibrium and to previously published data.
Table 27. Distribution of the Bel I/Xba I haplotypes in unrelated females.
Bel I/Xba I 2Wionet 2Moodie et Cumulative
haplotype No. Observed Ipredicted al195 al334 summary
(%) (%) No. (%) No. (%) No. (%)
0.8/4.8 25 62.5 37.5 45 61 37 44 107 54
0.8/6.2 9 22.5 37.5 15 20 23 27 47 24
1.1/4.8 0 0 12.5 0 0 8 10 8 4
1.1/6.2 6 15 12.5 14 19 16 19 36 18
Total 40 100 100 74 100 84 100 198 100




Table 28. Distribution of the Bgl I RFLP alleles with the Xba I/Bcl I haplotypes in
unrelated females.
Bel I/Xba I Bgl I 2Moodie et Cumulative
haplotype allele Observed Ipredicted a |334 summary
No. (%) (%) No. (%) No. (%)
0.8/4.8 5.0 22 58 35.25 33 43.4 55 48.2
20 2 5.3 2.25 1 1.3 3 2.6
0.8/6.2 5.0 8 21 35.25 20 26.4 28 24.6
20 1 2.6 2.25 1 1.3 2 1.8
1.1/4.8 5.0 0 0 11.75 4 5.3 4 3.5
20 0 0 0.750 1 1.3 1 0.9
1.1/6.2 5.0 3 7.9 11.75 11 14.4 14 12.3
20 2 5.2 0.75 5 6.6 7 6.1
Total 38 100 100 76 100 114 100
1 Predicted frequency of the various haplotypes in the absence of any linkage
disequilibrium, calculated from the haplotype and allelic frequencies detailed in Tables
27 and 23 respectively.
^Observed haplotype frequencies
The observed haplotype frequencies reported in Table 27 are similar to those published
by Wion et al^5 and indicate linkage disequilibrium - a not unexpected finding as the
two polymorphic sites lie within 18kb of each other. The result for the l.l/4.8kb
haplotype suggests a degree of linkage disequilibrium not found by Moodie.334
In Table 28, the frequencies of the Bgl I alleles with the various Bel I/Xba I haplotypes are
shown both for the observed haplotypes and those predicted to occur in the absence of
any linkage disequilibrium. These results are, in general, similar to those reported by
Moodie^^ although no examples of the 1.1/4.8/5.Okb or l.l/4.8/20kb haplotypes were
found. In addition, the l.l/4.8kb and l.l/6.2kb haplotypes and either of the Bgl I alleles
occur less frequently than predicted suggesting linkage disequilibrium. Overall, the
0.8/4.8/5.0kb and the 0.8/6.2/5.Okb haplotypes accounted for 79% of cases.
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These findings suggest strong linkage disequilibrium between the Bel I, Xba I and the
Bgl I polymorphisms and that the value of the Bgl I RFLP in non-informative Bel I/Xba I
haplotypes will be limited - a finding already shown in Table 26. All women identified
within the study as informative for Bgl I were also heterozygous for Bel I. The value of
the Bgl I polymorphism in the population studied is, therefore, limited.
3.2.7. Linkage of the FVIII Locus to Other Markers.
The major problem with the use of linked, extragenic markers in haemophilia A is the
possibility of a recombination occurring between the FVIII gene and the site of the
polymorphism. The chances of such an event occurring are related to the distance
between the marker used to track the gene and the gene in question and increases as the
distance between the two increases. In this study the linkage of the FVIII locus to the two
extragenic polymorphic loci was studied wherever possible. It should be noted that
paternity testing was not undertaken in any of these studies.
1. Linkage of the DX13 (DXS15) Locus to the Bel I Locus.
There were 40 meioses in which it was possible to establish whether a recombination had
occurred between the Bel I and DX13 loci. Within this study, three families (Pedigree
Nos. 16, 28 and 32: Appendix 1) were identified in which a recombination event was
found to have occurred. This gives an overall recombination rate of 7.5%.
In Pedigree No. 16 the recombination can be shown to have occurred between the
extragenic Bgl II site and the Bel I/Bgl I sites as both intragenic polymorphisms are in
agreement.
2. Linkage of the DX13 (DXS15) Locus to the Xba I Locus.
No recombination events between the Xba I and DX13 loci were found in 12 meioses in
161
which it was possible to study both markers.
3. Linkage of the ST14 (DXS52) Locus to the Bel I and/or Xba I Loci.
In Pedigree No. 39 (Appendix 1) a possible recombination between the ST14 and Bel I
loci was suspected but the genotypic data available was insufficient to allow a definite
decision to be made. The possibility of non-paternity to explain the genotypic findings
in this family is discussed with the Pedigree in Appendix 1.
The data available on ST14/Bcl I recombinations is limited as the ST14 locus was only
examined when the other polymorphisms were non-informative. Only six meioses were
available in which it was possible to study linkage between the ST 14 and Xba I loci but no
recombinations were observed.
4. Linkage of the DX13 (DXS15) Locus to the ST14 Locus (DXS52).
A single family was found in which a recombination event was thought to have taken
place between the DX13 and the ST14 loci - Pedigree No. CI (Appendix 3). Carrier
detection was attempted in this family with X-linked adrenoleukodystrophy (but no
history of haemophilia A or B) using both intragenic and extragenic FVIII gene probes.
The pedigree shows a recombination to have taken place in II-4. Her mother (1-2) has
haplotypes [5.8/4.5] and [2.8/3.9] whilst her father (1-1) has the haplotype [2.8/4.1], II-4
has a [2.8/4.1] haplotype from her father and hence a recombinant [5.8/3.9] chromosome
from her mother.
The ST14(DXS15) and DX13(DXS52) loci are located close to each other on the X-
chromosome; the chances of recombination would appear to be small and it is essential,
therefore, to exclude non-paternity.
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3.3. Genotypic Analysis in Potential Carriers of Haemophilia A.
Pedigree analysis identified 80 potential carriers in whom carrier detection could be
attempted by RFLP analysis. 32 of these potential carriers were from families in which
there was a history of haemophilia A affecting more than a single generation or in which
the birth of two affected children identified their mother as an obligate carrier. The
remaining potential carriers (48) were from families in which there was only a single
isolated affected male. This latter group will be discussed in more detail in a separate
section on sporadic disease.
Of the 80 potential carriers (Table 29), 47 had a normal coagulation phenotype, 27 were
abnormal suggesting carriership and in 6 no coagulation data was available although
genotypic analysis was still possible. From phenotypic studies the potential carriers could,
therefore, be assigned to one of three groups; normal phenotype, abnormal phenotype
and no phenotype data available. Within each of these groups the benefits from
genotypic analysis was examined.
1. Normal phenotype: of the 47 potential carriers with a normal coagulation phenotype
genotypic data allowed 25 to be classified as normal and only 1 to be re-classified as a
carrier. Of the 25 genotypically normal women, 14 were from families in which there was
a history of haemophilia and 11 were from families in which there was no previous
history. In the remaining 21 phenotypically normal women their carrier status could not
be established from the genotypic data either because insufficient family members were
available or individuals were homozygous for the polymorphisms analysed or diagnosis
by exclusion of the potentially abnormal haplotype was not possible.
2. Abnormal phenotype: of the 27 potential carriers in whom the coagulation phenotype
was abnormal, 4/27 were shown to be carriers on the basis of their genotype and all of
these were from families in which there was a history of haemophilia. In 4 cases
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genotypic analysis allowed exclusion of a potential carrier with an abnormal phenotype.
In the remaining 19 women their carrier status could not be confirmed by genotypic
analysis although their coagulation phenotype was abnormal and it is likely that this
group contains some 'true' carriers.
3. No phenotype data: in 6 women, no coagulation data was available to establish their
risk of carriership phenotypically. However, genotypic analysis allowed 2 women to be
classified as carriers, 2 to be excluded as carriers but in the remaining 2 women
carriership could not be established.
From the data summarised in Table 29 it proved impossible to establish the carrier status
in 42/80 (52.5%) of the potential carriers either because key family members were
unavailable, or the polymorphic markers studied were unhelpful or diagnosis by
exclusion of the potentially abnormal haplotype was not possible.. In these individuals,
where the origin of the haemophilic mutation is difficult to establish, exclusion of the
mutant haplotype is the only method of carrier detection by RFLP analysis. Therefore, in
families in which RFLP analysis is unhelpful and ideally in all families seeking carrier
detection, identification of the kindred-specific mutation should be attempted although
this is not always possible.
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3.3.1. Sporadic Haemophilia A.
Estimates of the incidence of sporadic haemophilia A vary widely. In this study there
were 18 families in whom no previous history of haemophilia could be elicited. Prior to
the advent of recombinant DNA technology, pedigree information and phenotypic
analysis were the only methods available to determine the probability of carriership.
In cases in which no family history is available, it is usually only possible to detect non-
carrier status using RFLP analysis ie. haplotype exclusion, as determining carrier status
depends upon knowing in which generation the new mutation arose.
3.3.2. Phenotypic Analysis in Sporadic Haemophilia A.
The eighteen families comprised a total of 86 individuals of whom 38 were males and 48
female. Of the males 10 had severe disease (VIII:C <0.01 iu/dl), 6 had moderately severe
disease, 1 was mild (VIII:C=0.09iu/dl) and the remaining 21 were normal. Of the females
coagulation data was not available on 2 women. Without genotypic analysis all the
women within a kindred with spontaneous haemophilia A must be considered as potential
carriers.
The mean VIII:C for the females was 0.81 iu/dl, the mean vWF:Ag was 1.08iu/dl and the
mean vWF:RCo 1.02iu/dl. Using the VIII:C/vWF:Ag ratio (<0.58) 16/46 (34.8%) of these
potential carriers were classified as carriers and 18/46 (39%) using the VIII:C/vWF:RCo
ratio (<0.49). From these results it was predicted that almost 35% of the potential carriers
from families with sporadic haemophilia A would be carriers.
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3.3.3. Genotypic Analysis in Sporadic Haemophilia A.
The results of genotypic analysis in families with isolated affected male are shown in
Table 29. Using a combination of intragenic and extragenic polymorphisms, carriership
could be excluded in 14/48 (29.2%) of the potential carriers. It was impossible to
establish the carrier status of a further 34 women, either because key family members
were unavailable, the polymorphisms analysed were unhelpful or because the haemophilic
haplotype could not be excluded. It is possible that by studying other family members
and/or increasing the numbers of polymorphisms analysed, the number of potential
carriers in whom carriership could be accurately established could be increased.
3.3.4. Combined Coagulation and RFLP Analysis in Potential
Carriers of Haemophilia A.
Combined phenotypic and genotypic analysis identified 10 potential carriers from
families with an isolated affected male, as carriers. In each case they had a carrier
phenotype and had inherited the potentially abnormal haemophilic haplotype. Overall,
therefore, 24/48 (50%) of the potential carriers could be offered accurate genetic
counselling. (5 potential carriers from families with a history of haemophilia were also
identified as carriers after combined phenotypic/genotypic analysis).
3.3.5. Origin of the Mutant Gene.
In 8 of the 22 families in which haemophilia A affected only a single generation, RFLP
analysis allowed a prediction to be made as to the origin of the mutant gene. In the
remaining families, cither the pedigree data was too limited key family members were
missing or the genotypic data was unhelpful.
Of these 8 families (Pedigree Nos. 5, 9, 11, 12, 20, 25, 31 and 33), in 2 (Pedigree Nos. 5
and 20) the mutation was thought to be unique to the haemophiliac by the finding of a
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normal brother with an identical haplotype and, therefore, excluded carriership in any
females within those kindred. In a further 3 families (Pedigree Nos. 9, 11 and 12) the
mutation could be localised to the maternal grandfather and in each case his daughter ie.
the haemophiliac's mother had an abnormal coagulation phenotype suggestive of
carriership. In a further 2 families (Pedigree Nos. 25 and 33) although genotypic data
was not available on the maternal grandfather, sufficient pedigree data was available to
establish that the mutation was likely to have originated with him. In the remaining
family (Pedigree No. 31) the mutation was thought to be present in the maternal
grandmother and this was supported by an abnormal coagulation phenotype.
These results emphasise the importance of extended pedigree data in families in which the
disease appears to be spontaneous, and in particular genotypic analysis of parents, grand¬
parents and any siblings. It is possible that by extending the family pedigree data, the
number of families in which this type of analysis could be performed could be increased.
3.4. Antenatal Diagnosis.
In addition to establishing the carrier status of potential carriers, the availability of
antenatal diagnosis for both obligate, established and potential carriers was studied using
informative polymorphisms. For the purposes of antenatal diagnosis women could be
divided into three groups:
1. Antenatal diagnosis possible using intragenic polymorphisms.
This is possible for obligatory carriers or potential carriers identified by genotypic
analysis as carriers and involves the use of informative, intragenic polymorphisms and
fetal sexing on chorionic villus samples.
2. Antenatal diagnosis possible using linked, extragenic polymorphisms.
This group of women includes both obligate carriers and genotypically proven carriers
who are non-informative for the intragenic polymorphisms and in addition, includes a
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group of women whose carrier status could not be accurately established. For these
women chorionic villus sampling (CVS) permits early fetal sexing and genotypic analysis
of male embryos might exclude a fetus as a haemophiliac. However, because of the risks
of error due to recombination using linked RFLP's fetal blood sampling is desirable to
confirm the results of genotypic analysis.
3. Antenatal diagnosis possible by fetal blood sampling only.
In some women, non-informative for the polymorphisms analysed, antenatal diagnosis
could only be offered by fetal blood sampling after early fetal sexing. Early fetal sexing
by CVS or amniocentesis would eliminate the need for fetal blood sampling in
approximately 50% of pregnancies.
The availability of antenatal diagnosis and its method for 89 'at-risk' women identified in
the study has been considered. Of these women, 40 were obligatory carriers and the
remainder were potential carriers in whom genotypic analysis had not confidently
excluded carriership.
Tables 34-36 (at the end of this Chapter) summarise the pedigree, phenotypic and
genotypic data for each family and shows the availability of prenatal diagnosis to 'at-
risk' women. Prenatal diagnosis using genotypic analysis exclusively was available to
33/89 (37%) women; using linked, extragenic markers and fetal blood sampling to a




The Results of Carrier Detection Studies in Haemophilia B
(Christmas Disease).
Introduction.
With developments in molecular biology and in particular the Polymerase Chain Reaction
it is now possible to identify and characterise kindred specific defects in haemophilia B,
thereby increasing both the accuracy and availability of carrier detection. However, it is
only relatively recently that such techniques have become widely available and this study
has, therefore, concentrated on the use of RFLP analysis in carrier detection.
Only 5 families with haemophilia B consented to be studied. A history of haemophilia
affecting more than a single generation was obtained in 2 families whilst in a further 2 the
disease appeared to have arisen spontaneously. Of these 4 families (Table 30), 22
individuals were analysed, comprising 11 males and 11 females. There were 5
haemophiliacs, all of whom had IX:C values above O.Oliu/dl. Of the 11 females studied,
from the pedigree data 3 could be classified as obligate carriers and 8 as potential
carriers. A fifth family (Pedigree No. B5) in which a single female was identified with
low levels of both IX:C and IX:Ag but no family history, was studied in some detail and
the findings are presented at the end of this Chapter. No female could be excluded as a
carrier by pedigree analysis alone.
Because of the small number of families available for study, the data on obligatory
carriers is limited. Although fifteen normal females were included as a control group for
the measurement of IX:C, there was no control group of obligatory carriers and no
control data was available for the measurements of IX:Ag.
Table 37 at the end of this Chapter, summarises all the data on the families with
haemophilia B whilst the pedigree, phenotypic and genotypic data is contained in
Appendix 2.
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Haemophiliac: 5 1 IX:C >0.01<0.05iu/d
4 IX:C >0.05iu/dl
Total: 11





NB. A single female identified as having Christmas disease (Pedigree No. B5) is not
included in the above table.
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3.5. Analysis and Interpretation of the Phenotypic Data from
the Haemophilia B Kindred.
3.5.1. IX:C and IX:Ag in Obligatory and Potential Carriers
of Haemophilia B.
IX:C and IX:Ag levels together with their ranges, and means were available for the 3
obligate carriers and 4 of 8 potential carriers (4/8 IX:C; 2/8 IX:Ag) identified within the
study and are shown in Table 31 below and Figure 24. Data on 15 normal females is
included for comparison.
The mean IX:C results for the 3 obligate carriers was 0.52iu/dl and although similar to
that of the potential carriers (0.50iu/dl) is lower than the mean of the normal females
(1.1Oiu/dl). The IX:Ag values were comparable to the IX:C assays in all individuals in
whom both measurements were available and no CRM+ families were detected (Figure








Carriers 3 0.52 0.16-1.20 3 0.48 0.12-0.88
Potential
Carriers 4 0.50 0.32-0.80 2 0.35 0.30/0.40
Normal
Females 15 1.10 0.64-1.61























Figure 24. A) The distribution of IX:C and IX:Ag results in potential and obligate carriers of
haemophilia B identified within the study. B) Correlation between IX:C and IX:Ag assays in
15 individuals in whom both results were measured.




3.5.2. Assessment of the Haemostatic Risk in Carriers of
Haemophilia B using IX:C Assays.
Three of the seven women in whom coagulation data was available had IX:C levels less
than 0.40iu/dl and were, therefore, at risk of haemorrhage after trauma or surgery
including antenatal diagnosis.
3.5.3. Discrimination between Obligate Carriers of
Haemophilia B and Normal Women using IX:C Assays.
Table 33 and Figure 24 show that although the mean IX:C for the obligatory carriers is
lower than that of the control group, there is a considerable overlap of values. Limited
phenotypic data is available but 2 of 3 obligate carriers and 3 of 4 potential carriers have
a IX:C assay below the lowest IX:C value obtained in the control group of 15 normal
women (0.64iu/dl) suggesting carriership. Insufficient data was available to allow
classification by IX:Ag alone or in combination with measurements of IX:C.
3.6. Genotypic Analysis in Haemophilia B.
3.6.1. Genotypic Analysis in Haemophilia B.
DNA was analysed from 23 individuals from 5 families with haemophilia B and carrier
detection was attempted in 8 'at-risk' females. Three intragenic polymorphisms (Taq I,
Xmn I and Dde I) were used for gene tracking studies although only 1 family (Pedigree
No B2) was analysed for the Dde I polymorphism. No linked polymorphisms were




1. Taq I/Xmn I polymorphisms.
The Taq I polymorphism situated 3' of exon D in the FIX gene, comprises a two allele
system. Southern blotting and probing with either a genomic probe (Probe VIII) or the
FIX cDNA, produces a 1.8kb band when the polymorphic site is absent and a 1.3kb
fragment when present.
The Xmn I polymorphism situated 3' of exon C and close to the Taq I polymorphic site,
results in bands of 11.5kb when the site is absent and 6.5kb when the site is present. This
polymorphism is detected using the same probes as those used with the Taq I RFLP.
Because of the close proximity of the two polymorphic sites, they show strong linkage
disequilibrium and as a result each rarely gives any additional information over the other
but as both can be detected using the same probe, both were analysed.
Figure 25 shows a Pedigree No. B3 (Appendix 2) informative for both the Taq I and
Xmn I polymorphisms. The mutant gene is marked by the 6.5kb and 1.3kb fragments of
the Xmn I and Taq I polymorphisms (IV-1 and IV-3) respectively. Females III-2 and II-
2 are both obligate carriers. III-2 has two sons both of whom are affected and a single
son, IV-2 who has inherited the non-haemophilic 1.8/11.5kb haplotype and is, therefore,




































Figure 25. Autoradiograph of leucocyte DNA digested with Taq I and Xmn I and
hybridised with the genomic FIX probe, Probe VIII. The polymorphic fragments at
1.3kb/1.8kb (Taq I) and 6.5kb/11.5kb (Xmn I) are marked.
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2. Dde I polymorphism.
The Dde I polymorphism is situated 5' of exon B in the FIX gene and results in two allelic
forms differing by 50bp of inserted DNA sequence (1.70kb and 1.75kb). Figure 26
shows Pedigree No. B2 (Appendix 2) in which the Taq I and Xmn I polymorphisms were
unhelpful but the Dde I polymorphism proved informative.
In this family the mutant gene is marked by the 1.75kb allele of the Dde I polymorphism
(III-1). From the pedigree, III-3 and II-3 are both potential carriers and both have an
abnormal coagulation phenotype. The finding of low IX:C and IX:Ag values in these two
individuals suggests that II-3 is likely to be a carrier and that the mutation in III-1 is not
unique. If II-3 is a carrier then her daughter (III-3), having inherited the abnormal
haplotype is also a carrier, a suggestion supported by her phenotype.
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Figure 26. Autoradiograph of leucocyte DNA digested with Dde I and hybridised with
the genomic Factor IX probe, Probe XIII. The polymorphic fragments at 1.70kb and
1.75kb are marked. M - Lambda DNA/Hind III markers.
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3.6.3. Frequency of Intragenic Polymorphisms.
The frequencies of the allelic DNA fragments and the number of heterozygous females
for the three intragenic polymorphisms are summarised in Table 32. This shows the data
obtained for all women, unrelated females and the 3 obligate carriers.
The Taq I and Xmn I polymorphisms were informative in 9/11 women studied.
The Dde I polymorphism was only analysed in a single family but was informative in the
2 'at-risk' females.
Table 32. Allelic frequencies for the three intragenic polymorphisms used for the carrier
detection studies in families with haemophilia B.
Allele




































NB. 1. The predicted heterozygosity frequencies for the Taq I, Xmn I and Dde I
polymorphisms are 47.7%, 47.7% and 49% respectively.
2. See Chapter 1 for published heterozygosity frequencies for the 3 intragenic
polymorphisms.
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3.6.4. Genotypic Analysis in Potential and Obligatory
Carriers of Haemophilia B.
RFLP analysis was attempted in 8 potential carriers and 3 obligatory carriers of haemo¬
philia B.
1. Potential carriers: of the 8 potential carriers, the coagulation phenotype was normal in
1, abnormal in 3 and in the remaining 4 women no data was available. The analysis of
the potential carriers and the contribution from genotypic analysis is shown in Table 33
below. In 2 of 3 potential carriers with abnormal phenotypes, genotypic analysis
confirmed them as carriers. However, genotypic analysis was unhelpful in the single
potential carrier with a normal coagulation phenotype, in the four potential carriers in
whom no coagulation data was available and in one of the 'at-risk' females in whom the
coagulation phenotype was abnormal.
Table 33. Potential carriers of haemophilia B classified by coagulation phenotype and
the results of genotypic and combined genotypic/phenotypic analysis.
Carrier status following genotypic Carrier status following combined
analysis phenotypic and genotypic analysis
Non- Non-
Phenotype Carrier Normal informative Carrier Normal informative
Normal - - 1 - - 1
(n=l)
Abnormal - - 3 2 - 1
(n=3)
No Data - - 4 - - 4
(n=4)
2. Obligate carriers: of the 3 obligatory carriers identified, 2 had abnormal coagulation
phenotypes; all 3 were heterozygous for both the Taq I and Xmn I polymorphisms.
Overall, genotypic analysis was helpful in establishing the carrier status of 2 potential
carriers and demonstrating informative polymorphisms for use in prenatal diagnosis in 3
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obligatory carriers. The 2 potential carriers classified as carriers were from the same
pedigree (B2) whilst in the remaining 6 potential carriers whose carrier status could not be
definitively established, 4 came from a single pedigree (B4) in which it was impossible to
establish the origin of the mutation and, therefore, to track it by RFLP analysis.
In 4 women in whom no coagulation data was available, measurement of their IX:C may
prove useful establishing their risk of carriership.
3.6.5. Origin of the Mutant Gene in Families with
Spontaneous Haemophilia B.
With the pedigree data available, it was not possible to establish the origin of the mutant
FIX gene in any of the kindred with sporadic disease. In Pedigree No. B2 (Appendix 2)
although II-3 was identified as a probable carrier from a combination of phenotypic and
genotypic analysis, it was not possible to establish whether the abnormal gene had arisen
with her or in a previous generation.
3.7. Antenatal Diagnosis.
The availability of antenatal diagnosis for both obligatory and potential carriers was
established (Table 37). All of the obligate carriers and the two potential carriers shown
genotypically to be carriers, were informative for one of the intragenic polymorphisms
and could, therefore, be offered accurate and early prenatal diagnosis with chorionic
villus sampling.
In the case of the remaining potential carriers, although they were all informative for one
or more polymorphic markers, their carrier status was not established. It would be
feasible to offer antenatal diagnosis using RFLP analysis and in those cases in which a
male fetus had inherited the same haplotype as an affected male, to perform fetal blood
sampling. If RFLP analysis indicated a male fetus had inherited the other haplotype, the
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pregnancy could be allowed to continue safely. Although this provides a solution, the
detection of kindred specific mutations allows more accurate carrier detection, prenatal
diagnosis and genetic counselling.
3.8. Pedigree No. B5 (Appendix 2).
A single female was identified within this study with low levels of both IX:C (0.16iu/dl)
and IX:Ag (0.12u/dl) but no family history of Christmas disease or of any other bleeding
diathesis. However, she had a life-long history of recurrent bleeding associated with
minor trauma and surgery but denied any spontaneous bleeding episodes. Coagulation
studies on her daughter were entirely normal.
In view of these findings the possibility of an unusual chromosomal karyotype was
considered. Karyotypic analysis demonstrated a mosaic picture with the existence of two
clones:
i. A major clone (85%) with one normal X and one abnormal X chromosome (see
Figure 27).
ii. A minor clone (15%) which had only one normal X chromosome (see Figure 28).
The chromosomal rearrangement of the major clone was interpreted as inversion X(q24-
26) - a linear rearrangement with no loss of genetic material at the level of light
microscopy.
There are a number of possibilities to explain the phenotypic and karyotypic findings:
a) The chromosomal inversion may involve the FIX gene resulting in only a single
functional gene. Extreme Lyonisation of the other X-chromosome could result in
reduced expression and therefore, low FIX levels.
b) The inversion although close to the FIX gene by cytogenetic analysis, at a molecular
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level may lie many millions of bases away from it and the minor clone is the important
abnormality. This clone may involve the hepatocytes such that a proportion of the cells
have only a single functional X chromosome. If this single X-chromosome carried a
mutant gene the cells would produce only defective factor IX.
c) A mutation in one of the FIX genes may occur leading to non-expression of that
gene. Extreme Lyonisation could then result in reduced expression of the remaining FIX
gene.
In an attempt to establish whether there was a mutation in the FIX gene, DNA from the
proposita was isolated from peripheral blood leucocytes. Restriction mapping of the gene
was performed with BamH I, Hind III, EcoR I, Taq I and the FIX cDNA as a probe.
Taq I was used as its recognition sequence (TCGA) occurs at a recognised 'hotspot'
(CpG dinucleotidc) for mutation in the human genome and variations at this site will
result in an altered Taq I map. The remaining enzymes cut commonly throughout the
human genome and it was hoped that a major insertion/deletion within the FIX gene
would alter the pattern of fragments generated. However, in each case a pattern identical
to that of a normal control DNA was seen, indicating that no major rearrangements within
the gene had occurred although not excluding a small deletion, insertion or point
mutation.
Further analysis of the FIX genes in this individual was kindly performed by Prof. F.
Giannelli at Guy's Hospital, London. Using the PCR technique the entire coding region,
intron-exon splice sites and the promoter region of the FIX gene was amplified and
sequenced. This demonstrated a single point mutation (GGA-GTA) resulting in the
substitution of a Glycine by a Valine at position 76. This region, encoded by exon D
(nucleotides 10392-10505) forms part of the connecting region of the FIX protein.
Glycine is the simplest of the amino acids having no side chain whilst valine is larger and
contains 2 methyl group side-chains. Although both are neutral amino acids at
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physiological pH, it is possible that this substitution is sufficient to cause a perturbation in
the FIX molecule resulting in a failure in secretion or its increased removal from the
plasma.
Although a mutation has been demonstrated within a FIX gene, it is still unclear what is
happening at the hepatocyte level. The aetiology of the disease in this lady, therefore,
remains speculative. The finding of a normal karyotype and coagulation phenotype in
the daughter of the propositus does not exclude her as a carrier and characterisation of
her FIX gene is needed to establish her carrier status.
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Figure 27. Karyotype analysis on the propositus from Pedigree No. B5 showing the
major clone demonstrating the inversion on one X chromosome that has occurred in the

















Figure 28. Karyotype analysis on the propositus from Pedigree B5 showing the minor
clone with only a single X-chromosome.
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3.9. The use of FVIII gene probes in X-linked
adrenoleukodystrophy (Pedigree No. CI - Appendix 3).
During this study, help was sought to clarify the carrier status of a female in a family with
X-linked adrenoleukodystrophy (ALD). There was no history of haemophilia A or B.
X-linked ALD is characterised by the progressive accumulation of very long chain fatty
acids (VLCFA) in neural white matter, adrenal glands, fibroblasts and plasma leading to
progressive demyelination and adrenal insufficiency with features resembling Addison's
disease.
The gene for ALD maps close to that of the FVIII gene at Xq28,337,338,339,340 has
been shown to be tightly linked to both the G6PD337 aiKj DXS52339 iocj Auborg and
co-workers analysed 7 families with ALD using the ST14(DXS52) marker. The Lod
score for this data was 13.766 at a maximum likelihood estimate of recombination (0) of
0%. No evidence for recombination between the ALD and ST14(DXS52) loci was found
(confidence limits 0-4%). The use of the ST14 marker may, therefore, be useful in
carrier detection studies in ALD.
Within this kindred III-1 is an affected male and both clinically and biochemically it was
felt that III-2, his brother, was also affected. Their mother, therefore, is an obligatory
carrier of the disease. Information was sought as to whether her sister II-4 might be a
carrier. The two linked Factor VIII polymorphisms - Bgl II (DX13) and Taq I, (ST14)
together with the three intragenic polymorphisms were used in an attempt to track the
mutant gene within the family. The family is non-informative for the three intragenic
probes but informative for the Bgl II marker which suggests that II-4 is a carrier.
However, analysis with the ST14 probe showed a recombination has taken place between
the two linked markers (see Pedigree/genotype data - Appendix 3). However as the ST14
(DXS52) probe is the closest to the adrenoleukodystrophy gene the results reduce the risk
that that II-4 is a carrier. Ideally, further linkage studies with probes closer to or within
the gene are required.
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3.10. Family Pedigree Data.
1. Summary of Pedigree Data for Haemophilia A and B (Tables 34-37).
Tables 34-37 summarise the pedigree, phenotypic and genotypic data from the 44
families with haemophilia A and the 5 families with haemophilia B studied in this Thesis.
2. Family Pedigrees (Appendices 1-3).
The family pedigrees and individual results obtained from the phenotypic and genotypic
analyses are contained in the Appendices 1-3. Two consecutive pages are devoted to each
kindred. The first page shows the full pedigree together with tabulated data from the
phenotypic and genotypic analyses. The pedigree is based exclusively on family data
and does not include any of the results from the carrier detection studies. For each
female their carrier status derived from the pedigree from coagulation testing and finally
from genotypic analysis is shown. The second page contains a limited pedigree showing
only those family members in which genotypic analyses were performed. The haplotype
for each individual is plotted on the family tree. The results from both pages are
summarised and the value of the cumulative data analysed in terms of the availability of
carrier detection and of antenatal diagnosis. Comments for each family highlighting
particularly interesting or unusual findings are included as a separate section at the
bottom of the second page.
Appendix 1 contains pedigree data for the haemophilia A families, Appendix 2 for the
haemophilia B families and Appendix 3 for the non-haemophilia families.
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3.11. Summary of Results.
The results of the phenotypic and genotypic studies in haemophilia A and B are
summarised in Figures 29 and 30.
3.11.1. Haemophilia A.
125 females with haemophilia A were studied. From pedigree analysis 40 were identified
as obligate carriers, 80 as potential carriers and 5 women were considered normal.
A. Obligate carriers: of the 40 obligate carriers, 26 were shown to have an abnormal
coagulation phenotype, 11 to have a normal phenotype and in 3 no coagulation data was
available. Genotypic analysis established 23 as being informative for one or more of the
intragenic polymorphisms and 15 as informative for a linked polymorphism. Two

















Figure 29. Summary of data following phenotypic and genotypic analyses in 125
women from 44 families with haemophilia A.
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B. Potential carriers: of the 80 potential carriers identified within the study, 27 had an
abnormal coagulation phenotype, 47 were normal and in 6 no coagulation data was
available. Combined phenotypic/genotypic analysis classified 17 of the 80 potential
carriers as carriers, 31 as normal but in 32 women genotypic analysis could not establish
their carrier status and they, therefore, remain potential carriers.













Results from combined phenotypic/genotypic analysis of 80 potential
carriers of Haemophilia A
Figure 30. Results following phenotypic and combined phenotypic/genotypic analysis in
80 potential carriers of haemophilia A. (C - carrier; N - normal; ND - no data).
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3.11.2. Haemophilia B.
11 females with haemophilia B (Christmas disease) from 4 families were studied. A single
female with an unusual karyotype was also identified as having haemophilia B. From
pedigree analysis, 3 of the women were identified as obligate carriers and 8 as potential
carriers. Phenotypic data was available on 3 of the obligate carriers and 4 of the potential
carriers. Phenotypic analysis showed 2 of 3 obligate carriers to have a low IX:C and 3 of
4 potential carriers.
Following combined phenotypic/genotypic analysis 2 of 8 potential carriers were
identified as carriers but in the remainder accurate classification was not possible. All 3
of the obligate carriers were informative for one or more of the intragenic
polymorphisms.
















Figure 30. Summary of data from phenotypic and combined phenotypic/genotypic






Over the past 20 years the development of better standardisation of functional assays
(VIII:C, vWF activity), the introduction of immunological assays (VIII:Ag and vWF:Ag)
and the application of molecular biology techniques has improved the ability to
discriminate between carriers of haemophilia A and normal women.
Advances in molecular biology have now made the characterisation of kindred specific
defects in families with haemophilia B a real possibility but the size of the FVIII gene has
precluded such an approach until very recently and RFLP analysis has, therefore,
remained a major technique for both carrier detection and prenatal diagnosis in
haemophilia A.
This Thesis addresses the role of coagulation testing and restriction fragment length
polymorphism (RFLP) analysis in establishing carriership in haemophilia A and B and
how best to provide prenatal diagnosis to 'at-risk' women.
In this Chapter the results from pedigree, phenotypic and genotypic analysis presented in
the previous chapter will be discussed in the context of previously published studies.
Analysis of the family pedigree forms an essential part of carrier detection in families
with a history of a bleeding diathesis and the pattern of inheritance eg. autosomal, X-
linked, dominant or recessive, may suggest specific diseases. Within this study a female
could be classified by pedigree analysis as either an obligate carrier, a potential carrier or
normal.
In some instances, pedigree analysis may allow a female to be excluded as a carrier eg.
the daughter of a normal male in a family with haemophilia. A number of women
identified as obligate carriers had failed to appreciate the importance of being the
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daughter of a haemophiliac. This lack of knowledge emphasises the importance of good
genetic counselling in families with any genetic disorder. However, for many women
pedigree analysis can only establish them as potential carriers and further testing is
required to define their carrier status.
Coagulation testing and phenotypic analysis in families with haemophilia is undertaken
for a number of reasons:
1. To identify within a kindred which males are affected.
2. To identify any women, either potential carriers or obligate carriers with low VIII:C
values and, therefore, at increased risk of haemorrhage.
3. To try and define the carrier status of potential carriers.
4. As an aid to the interpretation of genotypic analysis.
In the carrier detection studies reported in this Thesis, measurement of the coagulation
factors and relevant immunological assays were used to estimate the risk of carriership in
individual females. These results were then compared to those obtained from genotypic
analyses.
Measuring VIII:C and vWF by immunological and biological functional assays to
compare values between obligate carriers and normal women has, until recently been the
principle method for carrier detection in haemophilia A. By applying various
discriminant functions to potential carriers, the likelihood of carriership in a particular
individual can be established although for many, carriership cannot be excluded.
Published studies, reviewed in the Introduction (Chapter 1) to this Thesis have shown that
the measurement of the ratio of VIII:C to vWF:Ag (and possibly VIII:C to vWF:RCo) are
superior to the measurement of VIII:C alone in the detection of haemophilia A carriers.
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In this Thesis, normal ranges for both obligate and normal females were established using
age-matched controls from which the VIII:C/vWF:Ag and VIII:C/vWF:RCo ratios were
derived which correctly classified all of the normal women. These ratios were then used
to analyse both the obligatory carriers and the potential carriers identified within the
study.
The mean VIII:C, vWF:Ag and vWF:RCo values obtained for the control groups were
similar to those reported by other workers (reviewed in Chapter 1) and no differences
were found between vWF:Ag and vWF:RCo values for each group contrary to the results
of Zimmerman et al who found vWF:Ag assays to be higher in carriers.^55 jn addition,
no differences were found between women taking the oral contraceptive pill and those
who were not although this has been reported to cause elevations in both VIII:C and
vWF.247
The VIII:C/vWF:Ag ratio appeared to be a more sensitive discriminant of carriership than
the VIII:C/vWF:RCo ratio as it correctly classified 65.2% of the control obligate carriers
and 56.8% of the study obligate carriers whilst the VIII:C/vWF:RCo ratio correctly
classified only 21.7% of the control obligate carriers and 43.4% of the study obligate
carriers. Our findings that the VIII:C/vWF:Ag ratio correctly classified 65% of the
control obligatory carriers and only 56.8% of the study obligatory carriers are inferior to
many other studies. It is likely that this reflects, to some extent, the method by which the
coagulation data was analysed. A number of studies have reported that the percentage of
obligatory carriers correctly classified by measuring the VIII:C/vWF:Ag ratio ranges from
70-100% (Chapter 1). In 1986 a Multicentre International Study299 concluded that the
inclusion of both age and ABO blood group together with the minimisation of laboratory
assay errors improved the discrimination between normal women and obligatory carriers
but that assays other than VIII:C and vWF:Ag had no effect. Earlier studies have shown
that repeated testing can result in better discrimination between carriers and non-
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carriers.^96
Because many of the families in this study live some considerable distance from the
Centre (both within and outwith the West Midlands Health region) it was only possible to
undertake coagulation factor assay on a single occasion when samples for DNA isolation
were obtained. Because of this statistical analysis has not been applied to carrier
prediction of the study group but the coagulation phenotype has been used as an
indication of carriership and as an aid to the interpretation of the results from genotypic
analysis.
Only 5 families with haemophilia B consented to be studied. The mean IX:C assays in
both the obligate and potential carriers (in whom data was available) was lower than that
of 15 normal women included for comparison but the variation in both groups was large
and there was considerable overlap in results suggesting that carrier detection using IX:C
alone is a poor discriminant between normal women and obligatory carriers. Two of the
three obligate carriers and three of the four potential carriers had IX:C levels below that
of the 15 normal female controls and would, therefore be classified as carriers. However,
the numbers in both these groups are small and the conclusions which can be drawn are
limited. The measurement of IX:Ag has been suggested as a method for increasing the
accuracy of carrier detection either alone or in combination with measurements of
IX:C.310>314,315 measurement of both IX:C and IX:Ag also allows any CRM+
families to be identified. No CRM+ families were detected with IX:Ag testing but
insufficient IX:Ag data was available to determine the efficacy of this assay as a
discriminant in carrier detection.
The method employed to predict carriership is open to major criticism. Although the two
control groups (normal women and obligatory carriers) were matched (for age and
contraceptive usage) and the coagulation data carefully collected, the assignment of an
arbitrary 'cut-off' value to predict carrier status has major limitations. Such an approach
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is very dependent upon sample size and it is probable that increasing the size of the two
control groups would result in an entirely different 'cut-off' value and, therefore, the
assignment of carricrship in the 'at-risk' women. A more logical approach would be to
use Bayesian analysis - this would take into account pedigree, phenotypic and genotypic
information, assigning a final risk of 'carrier' or 'non-carrier' to all 'at-risk' women.
Such an approach has been reviewed in Chapter 1 of this Thesis.
Recent advances in molecular biology eg. PCR, chemical cleavage of mismatches, single-
strand conformation polymorphism analysis, have made the characterisation of individual
mutations more feasible than with previous technology. For haemophilia B the
identification of kindred specific mutations is now possible and this should improve both
the accuracy and the availability of carrier detection. However, in haemophilia A the size
of the FVIII gene (186kb) has made, until very recently, the identification of individual
mutations virtually impossible for all but a small number of individuals. When such
mutations have been characterised it is generally because they have occurred at restriction
enzyme recognition (eg. Taq I) sites known to occur at 'hotspots' (eg. CpG
dinucleotides) for mutation in the human genome, 194,231,341 or are the result of major
gene deletions.
More recently the PCR technique has been used to amplify the small amounts of FVIII
mRNA produced at non-hepatic sites in haemophiliacs342,343,344 an(j this may prove to
be an invaluable approach for identifying mutations in which an abnormal mRNA is
produced. A concern is that some mutations within the FVIII gene arise as a failure of
transcription and, therefore, will not be detected using this technique. In addition, a
recent report indicates that approximately 50% of mutations in severe haemophilia A are
not within the coding regions, the splice junctions, the promoter region or the
polyadenylation region of the factor VIII gene.^ll and are unlikely, therefore, to be
associated with the production of an abnormal ectopic FVIII mRNA.
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The size of the factor IX gene has meant that the detection of kindred-specific mutations
is more feasible and with current techniques, direct carrier detection by identification of
the presence or absence of specific mutations should be possible in most cases of
haemophilia B.242
At present, therefore, the analysis of RFLP's remains an important part of carrier detection
in haemophilia A but to a lesser extent with haemophilia B.
The usefulness of RFLP's in carrier detection is related to their frequency within a
population. A number of the RFLP's used in carrier detection studies in haemophilia A
show racial segregation and the population studied is, therefore important. The families
studied in this Thesis were mainly European with a small number of Asian families and
therefore, polymorphisms shown to be useful in other races were not analysed.
Three intragenic - Bel I, Xba I and Bgl I and two linked polymorphisms - Bgl II and
Taq I were used for genotypic studies in haemophilia A. The Bel I polymorphism was
studied in most women and is now the first of the RFLP's to be analysed as this can be
readily performed by PCR. Gitschier et al!93 predicted that 42% of women would be
heterozygous for this polymorphism - in our study an identical figure (41.8%) was
observed although in unrelated women the number of heterozygotes was less at 36.5%
and similar to that found in obligatory carriers (33%). A number of other
studies334,335,336,345 have reported similar heterozygosity frequencies and our
findings confirm the value of this polymorphism in carrier detection studies.
In women in whom the Bel I polymorphism was non-informative, the intragenic Xba I
polymorphism was analysed. In initial studies, analyses were performed by Southern
blotting but in the latter part of the study, a combination of PCR and Southern blotting
was used. Wion et al^5 predicted from the frequencies of the two alleles that 48% of
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women would be heterozygous for this marker. In our study, a slightly higher frequency
(57.1% in related women, 55.5% in unrelated women and 58% in unrelated obligate
carriers) was observed indicating that the Xba I polymorphism should be a useful marker
in carrier detection studies. A number of other studies have found similar heterozygosity
frequencies334,336 confirming the usefulness of this polymorphism.
In the 45% of women in whom the Bel I polymorphism was non-informative, 52% (of
unrelated women) were heterozygous for the Xba I polymorphism. Therefore, a
combination of these two intragenic polymorphisms will be informative in 78% of
women.
The Xba I and Bel I polymorphisms are situated close to each other within the FVIII gene
and analysis of the haplotype frequencies shows that of 40 unrelated women the
l.l/4.8kb haplotype was not observed. From the allelic frequencies this haplotype should
be found in 12.5% of cases and these findings are consistent with the two polymorphisms
exhibiting a degree of linkage disequilibrium similar to that originally reported by Wion
et al. Moodie reported less linkage disequilibrium between these two sites and
specifically a frequency for the l.l/4.8kb haplotype of 10%. This has not been
confirmed by this study or by that of Wion who also failed to identify this particular
haplotype in any individual. In addition our study has shown an increased frequency for
the 0.8/4.8kb haplotype and a reduced frequency for the 0.8/6.2kb haplotype. The
explanation for these differences is likely to reflect variations in allelic frequencies
between differing populations.
In addition to the Xba I polymorphism reported by Wion et al, a number of additional
polymorphisms recognised by the same probe (p482.6) have been reported.346,347,348
Two of these are intragenic^46 an(j jn a Chinese population (as originally reported) the
frequencies of heterozygotes for the Xba I sites are 0.49 (the site originally described by
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Wion et al), 0.18 and 0.30. The third Xba I polymorphism is extragenic^47 and located
in the area of the X chromosome homologous to that region of the FVIII gene detected
by the p482.6 genomic FVIII probe. This region gives rise to the 6.6kb band during
Southern blot analysis for the Xba I polymorphism and co-amplifies during PCR
detection (generating a 96bp band). It has been mapped to a region within 1.5Mbp of
the FVIII gene at DXS115.349 The frequency of heterozygosity at this locus is reported
as 13% in a German population.347 jhe fourth polymorphism, also extragenic and
detected using the intron 22 specific probe p482.6 is identified with BstX I and also maps
to DXS115.348 These additional polymorphisms will increase the number of
heterozygous women but further work is required to accurately establish their allelic
frequencies and the risk with the extragenic RFLP's of recombination.
In women in whom both the Bel I and Xba I polymorphisms were non-informative, the
intragenic Bgl I marker was analysed. Unfortunately the two alleles of this
polymorphism occur in Europeans with markedly unequal frequencies (5.0kb allele
0.94; 20kb allele 0.06) suggesting that few women will be heterozygous for this marker.
The frequencies for the two alleles found in this study are similar to those reported by
Antonarakis et al*94 ancj others.3 34 From the allelic frequencies it is predicted that
11.3% of women will be informative for this polymorphism, similar to the observed
frequency of 13%. However, when those women who were heterozygous for the Bgl I
polymorphism were analysed for heterozygosity at other sites, all women informative for
the Bgl I marker were also informative for the Bel I polymorphism suggesting strong
linkage disequilibrium between the two sites. No women were identified who were
homozygous for the Bel I and Xba I polymorphisms but heterozygous for the Bgl I
polymorphism. In American Blacks, the frequency of Bgl I heterozygotes approaches
40% making it an extremely useful marker and emphasising the importance of
establishing allelic frequencies in local populations.
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Analysis of the Xba I, Bel I and Bgl I haplotypes shows that the several of the haplotypes
occur more frequently than predicted from the allelic frequencies whilst others occur less
frequently and indicates linkage disequilibrium. The finding of low heterozygosity
frequency and linkage disequilibrium with the Bel I and Xba I polymorphisms for the
Bgl I polymorphism indicate that it has limited value in our local population. Analysis of
the linked RFLP's (Bgl II and Taq I) would be more appropriate in women homozygous
for the Bel I and Xba I polymorphisms.
The DNA from women in whom the intragenic markers were non-informative was
analysed using two polymorphisms tightly linked to the FVIII gene - Bgl II and Taq I
both situated centromeric to the FVIII locus. The Bgl II polymorphism was the first
RFLP to be reported and used for carrier detection in haemophilia A^O an(| was the first
for which a probe was available at the start of this study and, therefore, results are
available on the majority of women. Harper reported a heterozygosity frequency of 50%
in their population for the Bgl II RFLP and predicted a 9% recombination rate between
the polymorphic site and the FVIII gene. Within this study the frequency of observed
heterozygotes (58.9% all women, 67% unrelated women, 65% unrelated obligate carriers)
is similar although slightly higher than that reported in previous studies334,335,345
suggesting it will be a useful marker and in view of its distance from the previously
identified intragenic polymorphisms, is unlikely to show significant linkage
disequilibrium. Importantly, for unrelated women in whom both the Bel I and Xba I
polymorphisms were unhelpful, heterozygosity for the Bgl II polymorphism was found
in 56% of cases. Therefore, 90% of women will be informative for one of the two
intragenic polymorphisms or the linked Bgl II polymorphism.
In occasional women, homozygous for all the intragenic and the linked Bgl II
polymorphisms, the multi-allelic Taq I marker was analysed. This polymorphism has at
least 10 alleles, and as many as 90% of 'at-risk' females will be informative. 191 within
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this study, in the 10 women analysed, 8 were found to heterozygous, although in the case
of unrelated women they were all informative.
The Taq I polymorphism has proved to be a useful marker in RFLP studies in
haemophilia A but there are potential problems in the interpretation of Southern blots
when supposedly constant bands may migrate with polymorphic bands obscuring
important data. Experience with the interpretation of this polymorphism is essential
before its use in carrier detection studies and prenatal diagnosis.
In women in whom carrier detection is only possible using linked polymorphic markers,
a combined approach using the results from phenotypic analysis may increase the
accuracy of diagnosis.350 Finally, in potential carriers in whom genotypic analysis is
unhelpful, it may still be possible to establish carrier status from phenotypic analysis.
Therefore, even with RFLP analysis, the data from phenotypic analysis forms an essential
part of carrier detection.
A number of studies have shown that carrier detection in haemophilia B can be readily
performed by DNA analysis using intragenic polymorphisms, 137-146,149 an(j many of
these RFLP's can now be rapidly analysed by PCR. 142,143,146,147 Despite significant
linkage disequilibrium between closely positioned intragenic polymorphisms, it is
estimated that RFLP analysis can provide a diagnosis in 89% of 'at-risk' womenJ 44
Unfortunately, the factor IX RFLP's show marked ethnic variation (See Chapter 1) which
limits their usefulness in some populations.
In this Thesis only three intragenic polymorphisms were analysed - Taq I, Xmn I and
Dde I and all women studied were heterozygous for one or more. The observed
heterozygosity frequencies are based on a small sample and as a result have large
sampling errors. Previously published studies show that 45% of women will be
206
heterozygous for the Taq I polymorphism, 120 41% for the Xmn I polymorphism ^35
and 37% for the Dde I polymorphism. *35
Unfortunately the Taq I and Xmn I polymorphisms lie within 4.5kb of each other and
show strong linkage disequilibrium and the additional data obtained from analysing both
is small although sometimes useful.252 The Dde I polymorphism is also situated close to
the Taq I and Xmn I sites*25 an(j has been shown to be in linkage disequilibrium with
both. However, in spite of this linkage disequilibrium, approximately 16% of women,
homozygous for the Taq I/Xmn I polymorphisms will be informative for the Dde I
polymorphism. ^25
Within this study, analysing the Xmn I polymorphism yielded no additional information
over that derived from the Taq I polymorphism. Only a single family in whom the
Taq I/Xmn I polymorphisms were non-informative, was analysed for the Dde I
polymorphism and both 'at-risk' females were found to be heterozygous. Therefore,
RFLP analysis by Southern blotting identified informative polymorphisms in all the 'at-
risk' women.
Haplotype frequencies were not calculated for the three RFLP's used in this study as the
number of unrelated individuals in whom data was available was small. Previous
studies^25 have shown that the 11.5/1.8kb and 6.5/1.3kb haplotypes represent over 90%
of chromosomes analysed. Analysis of linkage of the Dde I polymorphism to the Xmn I
polymorphism showed that the rare 1.75kb Dde I allele was always associated with the
frequently occurring 11.5kb Xmn I allele and that the 6.5/1.75kb haplotype was not
observed although it was predicted to account for almost 5% of haplotypes - a finding
consistent with linkage disequilibrium between the two polymorphic sites.
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A number of potential problems with RFLP analysis are recognised which can limit their
usefulness in carrier detection studies:
1. Correct paternity: when a polymorphism is used to track the inheritance of a mutation,
correct identification of the biologic father is essential for test accuracy. False
assumptions of paternity can result in identification of the wrong polymorphism as being
associated with the mutant gene and therefore, in a mistake in both carrier detection and
possibly prenatal diagnosis. As the number of family members necessary for establishing
a linkage phase increases, the greater the chances of error due to false paternity. For X-
linked diseases false paternity in a fetus or male offspring is not a source of error in
diagnosis but false paternity can cause an error in the determination of carrier status and
the establishment of linkage phases in females. Although difficult to discuss with families
seeking genetic counselling, they must be made aware of the problems that false paternity
can cause. Paternity testing should be ascertained whenever information from paternal
RFLP's is used and in addition when a recombination event is suspected. In these
situations, genetic fingerprinting using minisatellite probes may prove to be extremely
useful.
2. Missing 'key' family members: in some families and in particular those in which there
is only a single isolated affected male, analysis of all family members may be essential in
establishing the origin of the mutant gene and, therefore, in identifying which females are
at risk of being carriers.
3. Homozygosity for all polymorphisms: the X chromosome appears to be less
polymorphic than the autosomes, and a number of individuals will, therefore, be
homozygous for all the available polymorphisms. In these women, the only possible
hope for carrier detection is identification of the underlying genetic mutation.
4. Linkage disequilibrium.
5. Recombination: the risk of a recombination occurring in genetic analyses is directly
related to the distance between the locus of the polymorphism and the gene of interest
and increases as the distance between the two increases. These risks can be incorporated
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into Bayesian analysis (See Chapter 1).
In this study three recombinations were found to have occurred between the DXS15
(Bgl II) and Bel I loci. In one of these families the recombination occurred between the
Bgl I/Bcl I loci and the DXS15 locus. Harper in his original paper! 90 estimated the
recombination rate between the FVIII gene and the DXS15 locus would be less than 9%.
Further studies1^,334,353,354 haye estjmate(j this at between 3-5%. Within this
study, a recombination rate of 7%, slightly higher than previously published figures, was
found between the DXS15 and Bel I loci. No recombinations were found between the
Xba I and DXS15 loci.
Although a number of recombinations have been reported between the FVIII gene and
the DXS52 (ST14) loci334'355,356 no definite cross-overs were found within this study
although in one family (Pedigree No. 39) the limited genotypic data suggested that this
was a possibility although false paternity is more likely. The number of women in whom
the DXS52 locus was studied is small and the data is, therefore, limited. However, a single
recombination between the DXS15 and DXS52 loci was identified in a family with X-
linked adrenoleukodystrophy (Pedigree No. CI: Appendix 3) although again accurate
paternity was not established.
Despite these problems RFLP analysis has dramatically improved carrier detection in
haemophilia A and B increasing both the availability and the accuracy of diagnosis. In
this study, combined phenotypic/genotypic assessment of carrier status was possible in
48/80 (60%) of potential carriers and informative polymorphisms were identified in
38/40 (95%) obligate carriers.
One of the principal objectives of carrier detection studies in haemophilia is to clarify the
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carrier status of potential carriers. Whilst phenotypic analysis is based on probabilities,
genotypic analysis using intragenic RFLP's allows a definite decision to be made
increasing the accuracy of genetic counselling and allows individuals to make decisions
about whether or not to have antenatal diagnosis and terminate an affected pregnancy.
By combining the results from phenotypic and genotypic studies and using Bayesian
analysis a final probability of carriership can be established for all 'at-risk' women.
Within this study 80 potential carriers of haemophilia A were identified, 32 were from
families in which there was a history of haemophilia for more than a single generation or
in whom the birth of a second affected child established the mother as an obligate carrier
and the remainder were from families in whom there was no previous history of
haemophilia.
From the results of coagulation phenotype analysis it was possible to assign a potential
carrier to one of two groups - normal coagulation phenotype or abnormal coagulation
phenotype. (This assignment is based upon an arbitrarily assigned 'cut-off' value and is,
therefore, open to criticism.) In a small group of women no phenotypic data was
available, although genotypic analysis was still possible.
Following RFLP studies, potential carriers could be reclassified into definite carriers,
normal women or if the results were inconclusive - they remained potential carriers. Of
the 80 potential carriers studied, it was possible to definitively establish the carrier status
in 48 women. Of these 48 women, 17 were shown to be carriers and of these 12 had an
abnormal coagulation phenotype. The remaining 31 women were shown to be normal
and of these 25 had a normal coagulation phenotype. Within the first group, genotypic
analysis reclassified 2 women with normal phenotypes as carriers, whilst in the second
group, subsequent analyses reclassified 4 women as normal. In 32 women, genotypic
analysis could not establish their carrier status either because they were homozygous for
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the polymorphisms analysed or key family members were missing.
From the 4 families with haemophilia B, 8 potential carriers were identified.
Phenotypic/genotypic analysis allowed the carrier status of 2 to be established as carriers
but in the remainder analyses were inconclusive and these women remain potential
carriers. In this situation, the identification of a kindred specific defect should allow
clarification of the carrier status of all 'at-risk' women.
Although fatal without treatment, the frequency of haemophilia is maintained within a
population indicating that new mutations are continually arising. Haldane in 1935 was
the first person to examine the possibility of a sex difference in mutation rates during
gematogenesis.357 His formulation suggested that for an X-linked lethal disorder, if the
mutation rates are equal in both sexes, then the probability of an isolated case being the
result of a new mutation is:
(1-/)"
m = —
2 u + v
where/= biological fitness, p = mutation rate in females and v = the mutation rate in
males. If the biological fitness equals zero ie. no patients reproduce and the mutation
rate in male and female gametes is the same then the probability of an isolated case being






However, in haemophilia the mutation rate in male gametes is estimated to be
approximately 10X that in female gametes and the biological fitness is estimated at
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between 0.3 and 0.7.324 Using these variables in the formula the proportion of isolated
cases which are due to new mutations lies between 2.5 (f-0.3) and 5.8% (/=0.7). This is
significantly less than the figure of 30% which has been suggested by Bennett and
Ratnoff 282 but in keeping with the findings of Biggs and Rizza.358 xhis has important
implications for genetic counselling as it suggests that the vast majority of women with an
isolated affected haemophilic child are carriers and, therefore, at risk of having a further
affected child.
Within a kindred with a single isolated affected male it may be possible to identify the
origin of the haemophilic gene by a combination of genotypic and phenotypic analysis
greatly facilitating carrier detection.
Within this study there were 18 families comprising 48 potential carriers in whom there
was a single isolated affected male. Phenotypic analysis identified 17 women as having
an VIII:C/vWF:Ag ratio consistent with that of a carrier, 29 as normal and in 2 no
coagulation data was available. Combined phenotypic/genotypic analysis allowed 24/48
(50%) of these potential carriers to be reclassified as either normal or carriers. In the
remaining 24 women, carriership could not be established either because insufficient
pedigree data was available or the polymorphisms studied were non-informative.
In sporadic haemophilia A, establishing carrier status usually depends upon
demonstrating that an 'at-risk' female has not inherited the potentially abnormal
haplotype ie. a diagnosis of exclusion. A number of studies have evaluated the role of
RFLP analysis in sporadic haemophilia A. Grover in 1987359 using two intragenic
(Bel I and Bgl I) and two linked RFLP's (Taq I, Bgl II) assessed the carrier status of 30
women from 5 families with an isolated affected male. In 3 families they were able to
assign a low risk to 10 women based on genotypic analysis, in a further 2 families
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genotypic analysis suggested the mutation originated in either the maternal
grandmother's or maternal grandfather's germ cells thereby limiting the risk to their
descendants. In the remaining family a large gene deletion was identified enabling
carrier detection by densitometric analysis. In the same year Bernardino using three
intragenic and two linked RFLP's studied 17 families with isolated affected males. In 8 of
these families they were able to show that the mutated genes originated with one of the
maternal grandparents; in six families of these families the mutations derived from the
maternal grandfather whilst in the remaining two families from the maternal
grandmother. This data suggested a higher mutation rate in male rather than female
germ cells and may be explained by the many more cell divisions which occur in the
maturation of spermatozoa (10-20X) than in oocytes.361
Lillicrap in 1988^50 studied the benefits of combined RFLP and coagulation testing in
sporadic haemophilia A and was able to establish 23 women as normal but 27 remained
at risk after RFLP analysis. Of these 27, 14 had coagulation test results which indicated a
high probability of carriership. They concluded that an optimal service for haemophilia
A carrier detection must offer coagulation testing in addition to DNA marker analysis.
Antonarakis and Kazazian362 were abie t0 characterise the mutation in 13 apparently
spontaneous cases of haemophilia A. In 11/13 cases they could identify the origin of the
mutation; 5/11 occurred in the maternal grandfathers and the remaining 6 in either the
mother or grandmother.
Within this study, the origin of the mutation could be predicted in 8 of the 18 families by
RFLP analysis. In 2 families the mutation appeared to be unique to the affected
haemophiliac. In 3 families it appeared to have originated with the maternal grandfather
and in each case his daughters had abnormal coagulation phenotypes. In a further 2
families although the grandfather could not be definitely established as the origin of the
mutations the genotypic data favoured him as the source. In the remaining family the
213
mutation could be tracked as far as the maternal grandmother implicating her as a
possible carrier and this was substantiated by an abnormal coagulation phenotype. These
findings strengthen the general impression that the maternal grandfather appears to be
the source of the haemophilic mutation in spontaneous haemophilia A more frequently
than the grandmother or mother.
Mutations in families with sporadic haemophilia A are presumed to arise at the level of
the germ line and the majority probably occur during the development of the germ cells
so that a mutated gamete is unique. Consequently, the siblings of individuals with new
mutations are unaffected. If, however, the mutation occurs early in embryogenesis before
differentiation of the germ line, then the individual with the mutation will be a mosaic and
if a gonadal mosaic may have several types of germ cells. In some cases of mosaicism, in
which a high proportion of the somatic cells contain the mutation eg. leucocytes, this may
be detectable by Southern Blotting - but if the defect is not readily detectable then this is
not possible. As a result, the recurrence risk in some families with apparent sporadic
disease will be higher than expected. Although mosaicism in haemophilia A has been
reported^63 jt js unclear how often it accounts for spontaneous disease and further work
is required to clarify this area.
Tracking the haemophilic haplotype through various generations of a pedigree
emphasises the importance of extended pedigree data in families in whom the disease
appears to be spontaneous and in particular genotypic analysis of parents, grandparents
and any siblings. It is possible that by extending the family pedigree data, the number of
families in which this type of analysis could be performed could be increased. Tracking
the mutation by RFLP analysis is extremely important in families with sporadic
haemophilia A as it allows more accurate carrier detection studies and increases the
information which can be given to 'at-risk' females during genetic counselling.
However, such studies require extensive pedigree, phenotypic and genotypic data. In
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sporadic haemophilic families in which genotypic analysis fails to establish the carrier
status of potential carriers, phenotypic analysis may still allow their risk of carriership to
be predicted.
Unfortunately, in the 2 families with sporadic haemophilia B, only limited data was
available and the origin of the mutation could not be identified. With the identification
of kindred specific mutations in haemophilia B the origin of the mutation can be
accurately predicted and accurate genetic counselling given.
The logical conclusion of carrier testing in haemophilia A and B and the identification of
informative polymorphisms is to be able to accurately identify carriers and to offer
antenatal diagnosis if requested. Conventional techniques for prenatal diagnosis in 'at-
risk' women involves fetal sexing followed by blood sampling at a relatively late stage in
pregnancy. Genotypic analysis which can be performed on chorionic villus samples
(CVS), therefore allows the early and rapid detection of affected fetus and by using PCR
in previously tested informative families results can be available within 24 hours. Within
this study the availability of carrier detection using genotypic data, phenotypic data or a
combination of the two was assessed.
In haemophilia A prenatal diagnosis could be offered to all 'at-risk' women studied
using either informative intragenic polymorphisms (33/89), a combination of extragenic
polymorphisms and fetal blood sampling (39/89) or by fetal blood sampling alone
(17/89). In women in whom carrier detection studies fails to establish their carrier status,
fetal sexing and genotypic analysis (if informative) can identify 'at-risk' pregnancies but
confirmation of an affected male by fetal blood sampling will be required. In general,
fetal blood sampling usually involves the measurement of VIII:C although the
measurement of VIII :Ag has been shown to correlate well with VIII:C in CRM"
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families. *^9
The value of VIII:Ag measurements in carrier detection has not been assessed in this
Thesis - such assays were not available commercially and previous studies have shown no
improvements over measurements of VIII:C.296 However, VIII:Ag is more stable than
VIII:C it can be measured in serum and may, therefore have a role in prenatal diagnosis
based on fetal blood sampling and in assessing FVIII levels from geographically distant
centres when measurements of VIII:C are not possible.
In an analogous situation to that of haemophilia A, antenatal diagnosis can be offered to
all the women in the haemophilia B families. All of the obligate carriers and the two
potential carriers shown by combined phenotypic/genotypic analysis to be definite
carriers, were informative for one or more intragenic polymorphisms. However, for the
remaining potential carriers although prenatal diagnosis is possible using intragenic
polymorphisms and chorionic villus sampling, carriership in the mothers has not been
definitively established necessitating confirmation of an affected pregnancy by fetal
blood sampling. With the development of techniques for rapidly identifying kindred
specific defects, genotypic analysis of carriers will be readily available allowing both
accurate carrier detection and prenatal diagnosis.
During the course of this study into carrier detection in haemophilia, two particularly
interesting families were identified. In the first of these - Pedigree No. 42 (Appendix 1),
although there was no history of haemophilia A the coagulation results were consistent
with a diagnosis of a heterozygous female ie. a haemophilia A carrier. However, an
unusual form of von Willebrand's disease affecting the VIII:C binding site could not be
excluded.364 It is obviously vital to diagnose these individuals with variant vWD as both
the treatment and genetic counselling are entirely different to that of classical
haemophilia A. FVIII binding studies to clarify whether this variant vWF is present in the
family reported in this Thesis are currently in progress.
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In the second family - Pedigree No. B5 (Appendix 2), although there was no family
history of haemophilia B, a single female was identified as having low levels of both IX:C
and IX:Ag in association with both an abnormal karyotype and a point mutation within
one FIX gene.
The commonest explanation for the finding of low factor VIII or IX levels in a woman is
extreme Lyonisation in a heterozygote. However, additional possibilities include
misdiagnosed von Willebrand's disease (low VIII:C); genetic abnormality in a phenotypic
female with one X-chromosome carrying an abnormal FVIII or FIX gene eg. testicular
feminisation (46,XY), Turner's Syndrome (XO) or Turner's mosaic (XX/XO) and
genetic abnormality in a phenotypic female (deletions, inversions, translocations
involving one of the two X-chromosomes with extreme Lyonisation of the other.
In the female identified within the study, the cause of the low FIX levels could not be
established as she has both an abnormal karyotype and a mutation within her FIX gene.
Interestingly, she has a daughter in whom both FIX assays and karyotypic analysis are
normal although DNA was not available for molecular analysis.
A single family with X-linked adrenoleukodystrophy (ALD) was analysed during this
study. Previous work has shown that the linked DXS52 (ST 14) marker is useful in carrier
detection studies in ALD and appears to be associated with a low risk of recombination.
Analysis of this marker reduced the risk to one potential carrier of carriership and in
addition, identified a recombination between the DXS15 and DXS52 loci. Such a
recombination is likely to be a rare event as these two markers are physically close to one
another on the X-chromosome and non-paternity must, therefore, be excluded.
217
The Future of Carrier Testing In Haemophilia.
Improvements in coagulation testing and development of genotypic analysis using the
study of RFLP's has radically improved the detection of haemophilia carriers. Whilst
progress in RFLP analysis continues to be made eg. direct detection of RFLP's by PCR,
the use of variable number tandem repeats (VNTR's), the future of carrier testing must lie
with the molecular characterisation of the mutant gene in specific families. Identification
of the mutation in affected individuals will allow rapid carrier detection in 'at-risk'
females, allow for early, accurate antenatal diagnosis and in addition, will increase our
understanding of the molecular basis of both haemophilia A and B. This approach will
be of benefit to all families but in particular those with sporadic disease in whom RFLP
analysis is unhelpful. However, such an approach is likely to be demanding in terms of
technical expertise, equipment and the interpretation of the results and may indicate a
need for the establishment of a small number of laboratories where families may be
referred for further investigation.
The ultimate hope for haemophilia is that some form of gene therapy may provide a
'cure'. Meanwhile, advances in in vitro fertilisation may allow the selection of non-
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Appendix 1.
Pedigree, Phenotypic and Genotypic Data on Families with
Haemophilia A.
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Index member (or members)
N/A Not applicable
Roman numerals indicate generation number.
CD - Carrier detection
AND - Antenatal diagnosis
Restriction Fragment Length Polymorphisms.





















Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status
No RCo vWF: Ag vWF:RCo Pedigree
III F 1.50 2.30 1.00 0.65 1.50 Obligate carrier
II-2 M 1.10 1.25 1.05 0.88 1.04
III-l M 0.02 0.72 1.00 - - Propositus
m-2 M 0.80 0.70 1.00 1.14 0.80
III-3 M 1.20 1.30 - 0.92 -
Phenotype
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status from
No Genotype
II-1 F 0.8/0.8 5.0/5.0 6.2/6.2 5.8/2.8 N/A - Obligate carrier
II-2 M 0.8 5.0 6.2 2.8
in-i M 0.8 5.0 6.2 2.8 Propositus
III-2 M 0.8 5.0 6.2 5.8
III-3 M 0.8 5.0 6.2 5.8
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Family No. 1 (continued).






Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.


















In this pedigree the haemophilic gene is marked by the 2.8kb Bgl II allele. 13-1 is the daughter of
a severely affected haemophiliac and is, therefore, an obligate carrier. She is informative for the
linked Bgl II polymorphism which could be used for antenatal diagnosis but with a 5% chance of








Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/


































Family No. 2 (continued).








Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 3
Gen. Status from Status from
No Pedigree Phenotype
n-5 Potential carrier Normal












Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the 1 .lkb Bel I allele. III-5 and II-5 cannot be
excluded as carriers by either pedigree, phenotypic or genotypic analysis. Both are informative for
the Bel I polymorphism and could be offered prenatal diagnosis if requested. It is unclear if the
mutation in IV-1 is unique or inherited. It is possible that by extending the pedigree data the
origin of the abnormal gene could be predicted allowing a more accurate assessment of carrier
status in the 'at-risk' women. However, within this limited pedigree ideally, the mutation in IV-1














































N/A - Obligate carrier





Family No. 3 (continued).







Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 4
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data
CD AND
n-i Obligate carrier Carrier Informative Bgl II: N/A Yes
Obligate carrier
n-2 Obligate carrier Normal Informative Bgl II: N/A Yes
Obligate carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [4.8/2.8kb] Xba I/Bgl n haplotype.
n-1 and II-2 are both daughters of a severely affected haemophiliac and are, therefore, both
obligatory carriers. Although phenotypic data supports II-1 as being a carrier it is normal in the
case of H-2, emphasising the differences in Lyonisation which must have occurred. They are both
informative for the linked Bgl II polymorphism which could be used for prenatal diagnosis







Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status
No RCo vWF: Ag vWF :RCo Pedigree
II-1 M 1.20 1.30 1.10 0.92 1.10
n-2 F 1.00 1.25 0.96 0.80 1.04 Obligate carrier
mi M 1.00 0.82 0.36 1.22 2.70
III-2 M 0.08 0.93 0.90 - - Propositus
m-3 M 1.10 0.89 - 1.24 -
ni-4 M 1.05 0.70 1.30 1.50 0.81
III-5 M 0.08 0.91 0.70 - - Propositus
III-6 F 1.00 0.85 1.00 1.18 1.00 Potential carrier
III-7 F 0.80 0.75 0.35 1.07 2.29 Potential carrier
Genotype Data.
Gen. Sex Bel I Bgl II Carrier status from
No Genotype
II-1 M 0.8 5.8
II-2 F 0.8/1.1 2.8/5.8 N/A - Obligate carrier
III-l M 1.1 5.8
III-2 M 0.8 2.8 Propositus
III-3 M 1.1 5.8
III-4 M 1.1 5.8
III-5 M 0.8 2.8 Propositus
III-6 F 0.8/1.1 5.8/5.8 Normal
III-7 F 0.8/1.1 5.8/5.8 Normal
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Family No. 4 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 9
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype data genotypic data to:
CD AND
n-2 Obligate carrier Normal Informative Bel V N/A Yes
Bgl II: Obligate carrier
m-6 Potential carrier Normal Informative Bel I: Yes N/A
Normal
m-7 Potential carrier Normal Informative Bel I: Yes N/A
Normal
Implications and interpretations from these studies.
II-2 is an obligate carrier having two affected sons and a family history of haemophilia A. ILI-6
and III-7 are both potential carriers from the pedigree although their coagulation phenotypes are
normal.
The haemophilic gene in this kindred is associated with the 0.8kb allele of the Bel I
polymorphism. III-6 and III-7 have inherited this allele from their father rather than their carrier






Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status
No RCo vWF: Ag vWF :RCo Pedigree
n-2 M 1.00 0.54 0.75 1.85 1.33
II-3 F 0.64 0.75 1.00 0.85 0.64 Potential carrier
III-l M 0.94 0.52 1.00 1.81 0.94
III-3 M 0.02 1.00 0.75 Propositus
Genotype Data.
Gen. Sex Bel I Bgl I Bgl II Carrier status from
No Genotype
II-2 M 0.8 5.0 5.8
II-3 F 0.8/0.8 5.0/5.0 2.8/5.8 Normal
III-l M 0.8 5.0 5.8
III-3 M 0.8 5.0 5.8 Propositus
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Family No. 5 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 4
Gen. Status from Status from Genotypic
No Pedigree Phenotype Data/Status
n-3 Potential carrier Normal Informative Bgl II:
Normal
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is associated with the 5.8kb allele of the Bgl II poly¬
morphism. n-3 is a potential carrier having a single affected son. The coagulation phenotype is
normal. However, both ffl-1 and III-3 have the same haplotype indicating the mutation in HI-3 is












Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/














Gen. Sex Bel I Xba I Bgl II Carrier status from
No Genotype
II I F 0.8/0.8 4.8/6.2 5.8/2.8 N/A - Obligate carrier
III-l M 0.8 6.2 2.8 Propositus
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Family No. 6 (continued).









Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 2
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data to:
CD AND
n-1 Obligate carrier Carrier Informative Xba V N/A Yes
Bgl II: Obligate carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [2.8/6.2kb] haplotype of the Xba I/Bgl II
polymorphisms. II-l is an obligate carrier having a single affected son and a family history of
haemophilia. Her coagulation phenotype is abnormal. She is informative for both the Xba I and







Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VlllrC/ Carrier status from:
N o RCo vWF: Ag vWF:RCo Pedigree Pheno
1-2 F 0.35 0.65 0.70 0.54 0.50 Obligate carrier Carrier
II-1 M 0.00 1.25 0.32 - - Propositus
II-2 F 0.48 0.62 ' 0.78 " Potential carrier Carrier
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status from
No Genotype
1-1 M l.l 5.0 6.2 2.8
1-2 F l.l/i.l 5.0/5.0 6.2/6.2 5.8/2.8 N/A - Obligate carrier
II-1 M l.l 5.0 6.2 5.8 Propositus
II-2 F i.i/l.i 5.0/5.0 6.2/6.2 5.8/2.8 Carrier
II-3 M l.l 5.0 6.2 5.8 Propositus
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Family No. 7 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.










1-2 Obligate carrier Carrier
D-2 Potential carrier Carrier
Informative Bgl II: N/A Yes
Obligate carrier
Informative Bgl II: Yes Yes
Carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the 5.8kb Bgl II allele. 1-2 is an obligate
carrier having 2 affected sons and in addition has an abnormal coagulation phenotype. She is
informative for only the linked Bgl II polymorphism but which could be used in prenatal
diagnosis.
II-2 is a potential carrier from the pedigree and has a low VIILC suggestive of carriership although
a normal VIII:C/vWF:Ag ratio. Genotypic analysis shows she has inherited the abnormal 5.8kb
Bgl II allele from her carrier mother Both 1-2 and II-2 are informative for the Bgl n
polymorphism which could be used for prenatal diagnosis although with a 10% chance of error due








t>T-0' [ 3□ Vk
Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status
No RCo vWF:Ag v\VF:RCo Pedigree
IV-5 M 0.90 0.48 1.15 1.88 0.78
IV-6 F 0.95 0.76 0.84 1.25 1.13 Obligate carrier
V-l F 0.95 1.00 0.61 0.95 1.56 Potential carrier
V-2 M 0.19 1.00 " " " Propositus
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status from
No Genotype
IV-5 M 1.1 _ _ 2.8
IV-6 F 0.8/0.8 20/20 4.8/4.8 2.8/5.8 N/A - Obligate carrier
V-l F 0.8/1.1 - - 2.8/2.8 Potential carrier
V-2 M 0.8 20 4.8 - Propositus
Phenotype
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Family No. 8 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 4
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data
CD AND
IV-6 Obligate carrier Normal Informative Bgl II: N/A Yes
Obligate carrier
V-l Potential carrier Normal Informative Bgl II/ Yes Yes
Bel I: Potential carrier
Implications and interpretations from these studies.
IV-6 is an obligate carrier having a single affected son and a family history of haemophilia
although her coagulation phenotype is normal. She is informative for only the linked Bgl II
polymorphism which could be used for prenatal diagnosis but with a 5% chance of error due to
recombination.
V-l is a potential carrier although phenotypically normal. Insufficient DNA was available on the













Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
No RCo vWF: Ag vWF:RCo Pedigree Phenotype
II-3 F 0.92 1.30 0.83 0.71 1.11 Potential carrier Normal
II-4 M No data Clinically normal
III-l F 1.45 1.53 1.48 0.95 0.98 Potential carrier Normal
III-3 F 0.20 0.68 1.00 0.29 0.20 Potential carrier Carrier
III-4 M 1.00 1.52 - 1.52 -
III-5 M 0.90 2.60 1.60 0.34 0.56
rv-2 F 1.05 1.20 - 0.87 - Potential carrier Normal
IV-3 M 0.00 0.40 0.60 - - Propositus
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status
No Genotype
II-3 F 0.8/0.8 4.8/6.2 2.8/5.8 Normal
II-4 M 0.8 - - 5.8
III-l F 0.8/0.8 - - - Normal
III-3 F 0.8/0.8 5.0/5.0 4.8/6.2 2.8/5.8 Potential carrier
III-5 M 0.8 - 4.8 5.8
IV-2 F 0.8/0.8 - - 2.8/5.8 Potential carrier






Pedigree showing informative polymorphisms in investigated
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 7
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data to:
CD AND
n-3 Potential carrier Normal Informative Xba I/ Yes N/A
Bgl II: Normal
m-i Potential carrier Normal Normal Yes N/A
m-3 Potential carrier Carrier Informative Xba 1/ Yes Yes
Bgl II: Obligate carrier
IV-2 Potential carrier Normal Informative Bgl II: Yes Yes
Potential carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [4.8/5.8kb] haplotype of the Xba I/Bgl II
polymorphisms. III-5 has inherited the [4.8/5.8] haplotype from his mother - II-3 but is
phenotypically normal. Therefore, the mutation must be unique to III-3 excluding n-2, III-l and
IV-1 as carriers.
IH-3 has a carrier phenotype strongly suggesting she is a carrier. She is informative for both the
Bgl II and Xba I polymorphisms and this has been used for prenatal diagnosis - an affected fetus
was detected and the pregnancy terminated.
IV-2 is a potential carrier - unfortunately DNA was not available from her father and, therefore,




Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
No RCo vWF: Ag vWF :RCo Pedigree Phenotype
1-2 F 1.30 0.80 1.63 Obligate carrier Normal
II-6 F 0.70 1.20 1.10 0.64 1.09 Obligate carrier Normal
11-10 F 0.96 1.00 1.36 0.96 0.71 Obligate carrier Normal
III-5 M 0.10 1.45 1.05 - -
III-6 M 1.00 1.00 0.74 1.00 1.35
m-9 M 0.05 1.26 - - - Propositus
Genotype Data.
Gen. Sex Bel I Bgl II Carrier status from
No Genotype
1-2 F 0.8/0.8 2.8/5.8 N/A - Obligate carrier
II-6 F 0.8/1.1 2.8/5.8 N/A - Obligate carrier
11-10 F 0.8/1.1 2.8/5.8 N/A - Obligate carrier
III-5 M 0.8 5.8
III-6 M 1.1 2.8
m-9 M 0.8 5.8 Propositus
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Family No. 10 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
©2 0.8/0.82.8/5.8
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 6
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data to:
CD AND
1-2 Obligate carrier Normal Informative Bgl II: N/A Yes
Obligate carrier
n-6 Obligate carrier Normal Informative Bel 1/ N/A Yes
Bgl II: Obligate carrier
n-io Obligate carrier Normal Informative Bel 1/ N/A Yes
Bgl II: Obligate carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [0.8/5.8kb] haplotype of the Bel I/Bgl II
polymorphisms. The family is unusual in that two of the affected individuals studied (1H-5 and
III-9) have differing VIII:C levels. H-6 and 11-10 are both obligate carriers as each has a single
affected son and there is a family history of haemophilia. Their mother (1-2) is also an obligate
carrier having 3 affected sons. 1-2, II-6 and 11-10 all have normal coagulation phenotypes. They
are informative for one or more polymorphisms and could be offered prenatal diagnosis if
requested.
The explanation for the differing VIII:C values in the 2 haemophiliacs is unclear as presumably
the underlying mutation is identical in each case.




Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
No RCo vWF: Ag vWF: RCo Pedigree Pheno
1-1 M 0.74 0.60 0.52 1.23 1.42
1-2 F 0.84 0.80 0.27 1.05 3.11 Potential carrier Normal
II-1 F 1.00 0.80 0.98 1.25 1.02 Potential carrier Normal
II-2 F 0.22 0.84 0.30 0.26 0.73 Potential carrier Carrier
III-l M 0.00 0.64 0.89 - - Propositus
III-2 F 1.10 0.72 0.87 1.52 1.26 Potential carrier Normal
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status; from
No Genotype
1-1 M 0.8 5.0 6.2 5.8
1-2 F 0.8/1.1 5.0/5.0 4.8/6.2 2.8/2.8 Normal
II-1 F 0.8/1.1 5.0/5.0 4.8/6.2 2.8/5.8 Normal
II-2 F 0.8/1.1 5.0/5.0 4.8/6.2 2.8/5.8 Potential carrier
III-l M 0.8 5.0 6.2 5.8 Propositus
III-2 No DNA sample available
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Family No. 11 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 5
Gen. Status from Status from Genotypic










m-2 Potential carrier Normal
Heterozygous Bel I Yes N/A
Xba I/Bgl II: Normal
Heterozygous Bel 1/ Yes N/A
Xba I/Bgl II: Potential
carrier
Heterozygous Bel 1/ Yes N/A
Xba I/Bgl II: Potential
carrier
No genotypic data available
Implications and interpretations from these studies.
II-2 has an abnormal coagulation phenotype consistent with being a carrier The haemophilic
haplotype [0.8/6.2/5.8] is derived from 1-1 who was clinically normally. Therefore, the mutation
appears to be unique to D-2 excluding II-1 and 1-2 as carriers. II-2 is informative for both the
Xba I and Bel I polymorphisms and could be offered prenatal diagnosis if requested.
DNA was not available on IH-2 for carrier studies.
It is possible that 1-1 is a germ-line mosaic and, therefore, that II-1 is at risk of being a carrier
Alternatively the mutation may be unique to II-2 excluding II-1 as a carrier Ideally




Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII :C/ Carrier status from:
No RCo vWF:Ag vWFiRCo Pedigree Phenotype
1-1 M 1.00 1.25 0.94 0.80 1.06
1-2 F 1.00 1.00 0.80 1.00 1.25 Potential carrier Normal
II-1 M 0.68 1.03 - 0.67 -
II-7 F 0.50 1.35 1.00 0.38 0.37 Potential carrier Carrier
III-2 M 0.00 1.23 1.90 - - Propositus
III-3 M 0.00 1.25 0.76 Propositus
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status from
No Genotype
1-1 M 0.8 5.0 _ 5.8
1-2 F 0.8/1.1 5.0/5.0 - 2.8/5.8 Normal
II-1 M 0.8 - - -
II-7 F 0.8/0.8 5.0/5.0 6.2/6.2 5.8/5.8 N/A - Obligate carrier
III-2 M 0.8 5.0 6.2 5.8 Propositus
III-3 M 0.8 5.0 6.2 5.8 Propositus
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Family No. 12 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
0.8 I I1 2 0.8/1.1






Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 6







1-2 Potential carrier Normal
D-7 Obligate carrier Carrier





Implications and interpretations from these studies.
II-7 is an obligate carrier having 3 affected sons - her coagulation phenotype is also abnormal. It
is not clear whether the haemophilic haplotype [0.8/5.8] is derived from the maternal grandfather
or grandmother, although the finding of a 0.8kb allele in II-1 (phenotypically normal) suggests
that 1-2 is not a carrier and that the mutation has originated with 1-1 (maternal grandfather). This
is important in the genetic counselling of other potential carriers within the pedigree as 1-1 may be
a mosaic. Ideally, identification of the underlying defect in III-2 or III-3 is required which could




Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:CI Carrier status from:
No RCo vWF: Ag vWF:RCo Pedigree Phenotype
n-i M 1.00 0.78 0.50 1.28 2.00
n-2 F 0.46 0.68 0.62 0.68 0.74 Obligate carrier Carrier
III-I M 0.01 0.62 1.00 0.02 0.01 Propositus
III-2 F " " " " " Potential carrier No Data
Genotype Data.
Gen. Sex Bel I Bgl II Carrier status from
No Genotype
II-1 M 0.8 5.8
II-2 F 0.8/1.1 2.8/5.8 N/A - Obligate carrier
m-i M 0.8 5.8 Propositus
III-2 F 0.8/0.8 5.8/5.8 Carrier
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Family No. 13 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.






















Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [0.8/5.8kb] Bel I/Bgl II haplotype. n-2 is
an obligate carrier as she is the daughter of a severely affected haemophiliac. She is informative
for the Bel I and Bgl II polymorphisms and can, therefore, be offered prenatal diagnosis if
requested. III-2 is a potential carrier from the pedigree although no phenotypic data was available.
She has inherited a 0.8kb allele from her father and the other 0.8kb allele from her mother and is,
therefore, a carrier.








Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII :C/ Carrier status
No RCo vWF: Ag vWF :RCo Pedigree
III F 0.85 0.85 0.60 0.94 1.42 Potential carrier
II-2 M 1.00 0.90 1.00 1.11 1.00
III-l M 0.00 1.58 - - - Propositus
Phenotype
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status
No Genotype
II-1 F 0.8/0.8 5.0/5.0 4.8/4.8 2.8/5.8 Potential carrier
II-2 M 0.8 5.0 4.8 2.8 Normal
m-i M 0.8 5.0 4.8 2.8 Propositus
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Family No. 14 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
II 2.8/5.8 ( ) 2.8
m1*
s
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 3
Gen. Status from Status from Genotypic
No Pedigree Phenotype Data/Status
D-l Potential carrier Normal Heterozygous Bgl II:
Potential carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the 2.8kb allele of the Bgl II polymorphism.
II-l is a potential carrier but has a normal phenotype. Although heterozygous for the Bgl II
polymorphism her carrier status cannot be established. Ideally a kindred specific defect should be


















Pedigree and Phenolype Data.
Gen. Sex VIII:c vWF:Ag vWF: VIII:c/ VIII:ct Carrier status
No RCo vWF:Ag vWF: RCo Pedigree
n-8 f 0.32 0.47 0.49 0.68 0.65 Potential carrier
in-i m 0.00 - - - - Propositus
m-7 f 0.52 0.78 - 0.67 - Potential carrier
m-9 F 0.16 1.02 0.88 0.16 0.18 Potential carrier
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status; from
Phenotype
No Genotype
n-8 F 0.8/0.8 5.0/5.0 4.8/6.2 5.8/5.8 Potential carrier
III-I M 0.8 5.0 4.8 5.8 Propositus
ra-7 F 0.8/0.8 5.0/5.0 6.2/6.2 5.8/2.8 Normal
m-9 F 0.8/0.8 5.0/5.0 2.8/5.8 Potential carrier
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Family No. 15 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members




Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 4
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data
CD AND
n-8 Potential carrier Carrier Informative Xba I: Yes Yes
Potential carrier
m-7 Potential carrier Normal Informative Bgl II: Yes N/A
Normal
m-9 Potential carrier Carrier Heterozygous Bgl II: No Yes
Potential carrier
Implications and interpretations from these studies.
The haemophilic gene in this family is associated with the [4.8/5.8kb] Xba I/Bgl II haplotype.
H-8 has a low VIII:C suggesting she is a carrier and genotypic analysis indicates she has inherited
the [4.8/5.8kb] haplotype. Assuming this haplotype in II-8 indicates she is a carrier then III-7 has
not inherited this haplotype and is, therefore, not a carrier. This is supported by a normal
coagulation phenotype. Xba I analyses on III-9 were unsatisfactory and repeat samples were not




Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from
No RCo vWF: Ag vWF :RCo Pedigree Pheno
III M 0.56 0.82 _ 0.68 _ Normal
II-2 F 0.27 1.65 1.65 0.16 0.16 Obligate carrier Carrier
III-l F 0.53 1.56 - 0.34 - Potential carrier Carrier
III-3 M 1.18 1.14 1.53 1.04 1.77 Normal
III-4 F 0.69 0.63 0.63 1.10 1.10 Potential carrier Normal
IV-1 M 1.60 1.50 1.04 1.06 1.54 Normal
IV-4 M 0.82 0.51 - 1.61 - Normal
IV-5 F 0.65 0.90 - 0.72 - Potential carrier Normal
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status from
No Genotype
II-1 M 0.8 5.0 _ _
II-2 F 0.8/1.1 - - 2.8/5.8 N/A - Obligate carrier
III-l F 0.8/1.1 5.0/20 6.2/6.2 2.8/5.8 Carrier
III-3 M 0.8 5.0 - 2.8
III-4 F 0.8/0.8 - - 2.8/5.8 Normal
IV-1 M 0.8 5.0 6.2 2.8
IV-4 M 0.8 - - 2.8
IV-5 F 0.8/1.1 - - 2.8/5.8 Normal
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Family No. 16 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 8
Gen. Status from Status from
No Pedigree Phenotype
H-2 Obligate carrier Carrier
m-1 Potential carrier Carrier
m-4 Potential carrier Normal




Bgl n/Bgl I: Carrier
Informative Bel 1/
















Implications and interpretations from these studies.
In this kindred, no index member was available. However, II-2 is an obligate carrier as she is the
daughter of a haemophiliac. Her son - III-3 is phenotypically normal and genotype analysis shows
him to have inherited the [0.8/2.8/5.0kb] Bel I/Bgl II/Bgl I haplotype. Therefore, the haemophilic
gene in this kindred is associated with the other maternal haplotype [l.l/5.8/20.0kb].
From Bel I and Bgl I analyses, III-l has inherited the haemophilic haplotype (supported by an
abnormal phenotype) whilst III-4 has inherited the normal haplotype (normal coagulation
phenotype) excluding both herself and her daughter - IV-5 as carriers. However, using the linked
Bgl II polymorphism shows that both III-l and III-4 have inherited the normal 2.8kb Bgl n allele
excluding them as carriers. This family illustrates one of the problems associated with the use of
linked RFLP analyses - a recombination (cross-over) has taken place between II-2 and III-l. Non¬
paternity to explain these findings has not been excluded.




Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
No RCo vWF: Ag vWF :RCo Pedigree Phenotype
1-2 F 0.70 0.71 1.65 0.99 0.42 Potential carrier Normal
II-2 F 0.86 1.38 1.60 0.62 0.53 Potential carrier Normal
II-1 M 0.83 1.00 0.78 - -
III-l F 0.52 0.46 0.86 1.13 0.60 Potential carrier Normal
III-2 M 0.01 1.08 1.12 ~ ~ Propositus
Genotype Data.
Gen. Sex Bel I Bgl II Carrier status from
No Genotype
1-2 F 0.8/1.1 2.8/5.8 Potential carrier
II-2 F 0.8/1.1 2.8/5.8 Potential carrier
III M 0.8 2.8
III-l F 0.8/0.8 2.8/5.8 Normal
III-2 M 1.1 2.8 Propositus
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Family No. 17 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 5
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data
CD AND
1-2 Potential carrier Normal Heterozygous Bel 1/ Yes Yes
Bgl II: Potential carrier
n-2 Potential carrier Normal Heterozygous Bel V No Yes
Bgl II: Potential carrier
m-i Potential carrier Normal Normal Yes N/A
Implications and interpretations from these studies.
II-2 is a potential carrier with a normal coagulation phenotype. Is it unclear whether the
haemophilic haplotype f 1.1/2.8] is inherited from the maternal grandfather or grandmother
However, III-l has inherited the non-haemophilic haplotype from her mother and is, therefore,
normal.
This family emphasises that although it may be impossible to clarify the carrier status of some







Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status
No RCo vWF: Ag vWF :RCo Pedigree
III-3 F 0.72 0.52 0.50 1.38 1.44 Potential carrier
III-4 M 1.25 1.90 0.90 0.66 1.39





















Family No. 18 (continued).








Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.












m-3 Potential carrier Normal Heterozygous Xba 1/ N/A
Bgl II: Potential carrier
Yes
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [2.8/4.8kb] haplotype of the Xba I/Bgl II
polymorphisms. III-3 is a potential carrier from the pedigree but has a normal coagulation
phenotype. She is informative for the Xba I and Bgl II polymorphisms which could be used for
prenatal diagnosis although these do not establish her carrier status. Ideally the mutation in the





Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:CI Carrier status from:
No RCo vWF: Ag vWF:RCo Pedigree Pheno
1-2 F 0.46 0.62 1.06 0.74 0.43 Potential carrier Carrier
II-1 M 0.00 0.74 1.24 - - Propositus
II-2 F 0.54 1.28 0.74 0.42 0.73 Potential carrier Carrier
II-3 F 0.46 1.00 0.46 0.46 1.00 Potential carrier Carrier
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Taq I Carrier status
No Genotype
1-1 M 0.8 5.0 6.2 5.8 3.9
1-2 F 0.8/0.8 5.0/5.0 4.8/4.8 2.8/2.8 3.9/4.5 Potential carrier
II-1 M 0.8 5.0 4.8 2.8 4.5 Propositus
n-2 F 0.8/0.8 5.0/5.0 4.8/6.2 2.8/5.8 3.9/4.5 Potential carrier
n-3 F 0.8/0.8 5.0/5.0 4.8/6.2 2.8/5.8 3.9/4.5 Potential carrier
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Family No. 19 (continued).


















Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.












I-2 Potential carrier Carrier
II-2 Potential carrier Carrier










Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [4.8/2.8/4.5kb] haplotype of the Xba 1/
Bgl II/Taq I polymorphisms.
1-2, II-2 and II-3 arc all potential carriers and all have abnormal coagulation phenotypes. The
carrier status of 1-2 cannot be definitely established by RFLP analysis, however, she has an
abnormal coagulation phenotype suggestive of carriership.
Assuming 1-2 is a carrier, then both II-2 and II-3 have inherited the haemophilic haplotype and are,
therefore, carriers. This is supported by the finding of abnormal coagulation phenotypes in both
these individuals. The finding of a carrier phenotype in both II-2 and II-3 (both with the
haemophilic haplotype] reinforces the suggestion that 1-2 is a carrier.
Both II-2 and II-3 are informative for the Xba I polymorphism which could be used for prenatal
diagnosis. However, 1-2 is informative for only the linked Taq I polymorphism and although this




Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII :C/ VIII:C/ Carrier status from:
N o RCo vWF: Ag vWF:RCo Pedigree Phenotype
1-2 F 1.10 2.30 1.00 0.48 1.10 Potential carrier Carrier
II-1 F 1.20 1.35 - 0.89 - Potential carrier Normal
n-2 F 1.00 2.00 1.70 0.50 0.58 Potential carrier Carrier
III-l M 0.00 1.00 - - - Propositus
III-2 M 1.30 0.90 0.66 1.4 2.1
Genotype Data.
Gen. Sex Bel I Bgl II Carrier status
No Genotype
1-2 F 0.8/0.8 2.8/2.8 Normal
n-i F 0.8/1.1 2.8/5.8 Normal
n-2 F 0.8/1.1 2.8/5.8 Normal
mi M 0.8 2.8 Propositus
III-2 M 0.8 2.8
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Family No. 20 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 5
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data
CD AND
1-2 Potential carrier Normal Normal Yes N/A
n-i Potential carrier Normal Heterozygous Bel 1/
Xba I: Normal Yes N/A
n-2 Potential carrier Normal Heterozygous Bel 1/
Xba I: Normal Yes N/A
Implications and interpretations from these studies.
In the pedigree the haemophilic gene is marked by the [0.8/2.8kb] haplotype of the Bel I/Bgl II
polymorphisms.
1-2, II-1 and II-2 are all potential carriers and although their VIII:C values are normal, 1-2 and II-2
have low VIII:C/vWF:Ag ratios. However, genotypic data shows that III-1 and III-2 have
inherited the same haplotype [0.8/2.8] from their mother. As III-2 is phenotypically normal, this
indicates that the mutation is unique to III-l and therefore, the carrier status of the three potential




Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII :C/ VIII:C/ Carrier status from:
No RCo vWF: Ag vWF :RCo Pedigree Phenotype
1-1 M No coagulation data available
1-2 F 1.00 1.85 1.08 0.54 0.92 Potential carrier Carrier
n-3 F 0.68 0.99 1.40 0.69 0.48 Potential carrier Carrier
II-4 M 0.74 1.02 0.94 0.73 0.79
III-l F 0.17 0.62 0.62 0.27 0.27 Potential carrier Carrier
III-2 M 0.02 0.94 ' ' ' Propositus
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier statusi from
No Genotype
1-1 M 0.8 5.0 _ 5.8
1-2 F 0.8/0.8 - 2.8/5.8 Potential carrier
II-3 F 0.8/0.8 5.0/5.0 4.8/6.2 5.8/5.8 Potential carrier
II-4 M 0.8 5.0 4.8 5.8
III-l F 0.8/0.8 5.0/5.0 - 5.8/5.8 Potential carrier
III-2 M 0.8 5.0 6.2 5.8 Propositus
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Family No. 21 (continued).




Vy 20/5.05.0 I '
0.8/0.8 3 1 4 0.15 .8/5 .8 ( \ I 51








Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 6
Gen. Status from Status from
No Pedigree Phenotype
1-2 Potential carrier Carrier
n-3 Potential carrier Carrier















Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [0.8/5.8/5.0/6.2] Bel I/Bgl II/Bgl I/Xba I
haplotype. However, the origin of this haplotype is unclear as Xba I data was available only on
limited family members. The finding of an abnormal coagulation phenotype in all 3 'at-risk'
females suggests they may be carriers. If II-3 is a carrier, then III-l has inherited the haemophilic
haplotype suggesting carriership. II-3 and III-2 are informative for the intragenic Xba I





Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
No RCo vWF: Ag vWF:RCo Pedigree Phenotype
II-4 F 0.50 1.10 0.85 0.45 0.59 Obligate carrier Carrier
III-2 F 0.27 0.60 0.88 0.45 0.31 Obligate carrier Carrier
III-4 F 0.33 1.00 0.89 0.33 0.37 Obligate carrier Carrier
III-6 M 0.61 0.58 0.72 1.05 0.85
IV-3 F 0.18 0.56 0.41 0.32 0.44 Obligate carrier Carrier
V-l M 0.00 1.20 0.50 - - Propositus
V-2 F 0.41 0.62 0.61 0.66 0.67 Potential carrier Carrier
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status from
No Genotype
II-4 F 0.8/0.8 5.0/5.0 4.8/6.2 2.8/5.8 N/A - Obligate carrier
III-2 F 0.8/0.8 5.0/5.0 4.8/6.2 2.8/5.8 N/A - Obligate carrier
m-4 F 0.8/0.8 5.0/5.0 4.8/6.2 2.8/5.8 N/A - Obligate carrier
III-6 M 0.8 5.0 - 5.8
IV-3 F 0.8/1.1 5.0/5.0 4.8/6.2 2.8/5.8 N/A - Obligate carrier
V-l M 0.8 5.0 - 2.8 Propositus
V-2 F 0.8/0.8 5.0/5.0 4.8/6.2 2.8/5.8 Potential carrier
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Family No. 22 (continued).



























Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 7
Gen. Status from Status from
No Pedigree Phenotype
11-4 Obligate carrier Carrier
m-2 Obligate carrier Carrier
m-4 Obligate carrier Carrier
IV-3 Obligate carrier Carrier







Bgl II: Obligate carrier
Informative Xba 1/
Bgl II: Obligate carrier
Informative Xba 1/
Bgl II: Obligate carrier
Informative Xba V
Bel I, Bgl II: Obligate carrier
Heterozygous Xba V Yes









Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [0.8/2.8/4.8kb] Bel I/Bgl n/Xba I
haplotypc. HI-2, III-4 and IV-3 are all obligate carriers and have abnormal coagulation phenotypes.
They are all informative for one or more intragenic polymorphisms and could be offered prenatal
diagnosis if requested. V-2 is a potential carrier but a DNA sample was not available from her













Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:a VIII:C/ Carrier status from:
No R Co vWF: Ag vWF:RCo Pedigree Phenotype
ID-7 M 0.11 1.28 0.82 0.09 0.13
III-8 F 1.00 0.62 0.84 1.61 1.12 Normal Normal
IV-7 F 0.35 0.80 - 0.44 - Obligate carrier Carrier
IV-8 F 0.19 0.43 0.56 0.44 0.34 Obligate carrier Carrier
V-3 M 0.14 0.40 0.59 " - Propositus
Genotype Data.
Gen. Sex Bel I Xba I Bgl I Bgl II Carrier status from
No Genotype
III-7 M 0.8 4.8 5.0 5.8
III-8 F 0.8/0.8 4.8/6.2 5.0/5.0 5.8/5.8 Normal
IV-7 F 0.8/0.8 4.8/4.8 5.0/5.0 5.8/5.8 N/A - Obligate carrier
IV-8 F 0.8/0.8 4.8/6.2 5.0/5.0 5.8/5.8 N/A - Obligate carrier
V-3 M 0.8 4.8 5.0 5.8 Propositus
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Family No. 23 (continued).







Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.






















Obligate carrier N/A No
Informative Xba I: N/A Yes
Obligate carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [4.8kb] Xba I RFLP. IV-7 and IV-8 are
both obligate carriers being the daughters of a severe haemophiliac. IV-8 is informative for the
Xba I polymorphism which could be used in prenatal diagnosis. However, IV7 is non-









Gen. Sex VIII: C vWF:Ag vWF: VIII :CI VIII:C/ Carrier status
No RCo vWF:Ag vWF:RCo Pedigree
II-1 M 1.40 0.65 0.70 2.15 2.00
n-2 F 0.52 1.35 2.00 0.39 0.26 Obligate carrier
m-i M 0.07 1.17 1.17 - - Propositus
III-2 M 0.04 0.87 0.80 - - Propositus
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status from
No Genotype
n-i M _ 5.0 4.8 2.8
n-2 F 0.8/0.8 5.0/5.0 4.8/4.8 2.8/5.8 N/A - Obligate carrier
mi M 0.8 5.0 4.8 2.8
III-2 M 0.8 5.0 4.8 2.8
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Family No. 24 (continued).






Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.












n-2 Obligate carrier Carrier Informative Bgl II:
Obligate carrier
N/A Yes
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the 2.8kb Bgl II allele. II-2 is an obligate
carrier as she has 2 affected sons. Her coagulation phenotype is abnormal. She is informative for
only the linked Bgl II polymorphism and although could be offered prenatal diagnosis there would




Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
N o RCo vWF: Ag vWF :RCo Pedigree Phenotype
n-i F 0.40 1.42 1.12 0.28 0.36 Potential carrier Carrier
n-2 F 0.65 1.37 1.25 0.47 0.52 Potential carrier Carrier
II-3 F 0.70 0.98 0.66 0.71 1.06 Potential carrier Normal
n-5 F 0.75 1.05 1.25 0.71 0.60 Potential carrier Normal
m-i M 0.00 2.40 0.71 Propositus
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status
No Genotype
II-1 F 0.8/0.8 5.0/5.0 4.8/4.8 2.8/2.8 Carrier or Normal
II-2 F 0.8/0.8 5.0/5.0 4.8/4.8 2.8/2.8 Carrier or Normal
n-3 F 0.8/0.8 - 4.8/4.8 2.8/5.8 Carrier or Normal
II-5 F 0.8/0.8 - - 2.8/5.8 Potential carrier
in-i M 0.8 - - 2.8 Propositus
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Family No. 25 (continued).
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Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 5
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data to:
CD AND
n-i Potential carrier Carrier Heterozygous Bgl II: Yes N/A
Potential carrier
n-2 Potential carrier Carrier Heterozygous Bgl II: Yes N/A
Potential carrier
n-3 Potential carrier Normal Heterozygous Bgl II: Yes N/A
Potential carrier
n-5 Potential carrier Normal Heterozygous Bgl II: Yes N/A
Potential carrier
Implications and interpretations from these studies.
The mutant gene is marked by the 2.8kb allele of the Bgl II polymorphism which by implication
must be derived from 1-1 as this is the only common allele in his daughters. II-1, II-2, II-3 and II-
5 are all potential carriers, although only II-l and II-2 have abnormal coagulation phenotypes.
The origin of the mutation in this family is unclear and although 1-1 is clinically normal it is
possible that he is a germ line mosaic and, therefore, all his daughters are at risk of being carriers.
Differences in Lyonisation would explain the variations in VIII:C found in
II-l - II-5. Ideally such a situation requires clarification by demonstrating the kindred specific
mutation and screening of the 'at-risk' females for its presence or absence. II-5 could be offered
prenatal diagnosis using the Bgl II polymorphism but would require confirmation of an affected
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VIII:C/ VIII:C/ Carrier status from:
vWF:Ag vWF:RCo Pedigree Phenotype
II-5 F 1.01 0.64 - 1.58 - Obligate carrier Normal
III-l F 0.46 0.70 - 0.66 - Obligate carrier Carrier
III-6 F 1.83 1.42 - 1.29 - Potential carrier Normal
III-7 M 0.95 2.00 - 0.47 -
IV-1 M 0.00 1.77 0.40 - - Propositus
IV-2 F 1.20 0.64 0.35 1.87 3.40 Potential carrier Normal
IV-3 M 0.64 2.10 - 0.30 -
IV-4 F 0.69 0.70 - 0.99 - Potential carrier Normal
IV-5 F 0.56 0.45 - 1.24 - Potential carrier Normal


























































N/A - Obligate carrier








Family No. 26 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 10
Gen. Status from Status from Genotypic Applications of
N o Pedigree Phenotype Data/Status genotypic data to:
CD AND
n-5 Obligate carrier Normal Informative Xba I: N/A Yes
Obligate carrier
m-i Obligate carrier Carrier Informative Xba I: N/A Yes
Obligate carrier
m-6 Potential carrier Normal Normal Yes No
IV-2 Potential carrier Normal Heterozygous Bel 1/ Yes Yes
Xba I: Potential carrier
IV-4 Potential carrier Normal Normal Yes N/A
rv-5 Potential carrier Normal Normal Yes N/A
IV-6 Potential carrier Normal Normal Yes N/A
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [0.8/5.0/6.2/5.8] haplotype. II-5 and III-l
are both obligate carriers although only III-l has an abnormal phenotype. The haemophilic
haplotype [0.8/5.0/6.2/5.8] has not been inherited by III-6 and therefore, excludes both herself and
her offspring as carriers. The father of IV-2 was not available for study and her carrier status




Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
No RCo vWF: Ag vWF:RCo Pedigree Phenotype
1-3 F 0.30 2.05 1.00 0.15 0.30 Potential carrier Carrier
II-1 M 0.68 0.72 0.70 0.94 0.97
n-2 F 1.00 1.90 1.74 0.53 0.57 Obligate carrier Carrier
II-4 F 0.88 1.42 1.20 0.62 0.73 Obligate carrier Normal
II-5 M 0.74 1.08 - 0.69 -
II-6 F 1.05 2.10 1.25 0.50 0.84 Potential carrier Carrier
III-l F 0.94 1.10 1.25 0.85 0.75 Potential carrier Normal
HI-2 M 0.00 1.66 0.84 - - Propositus
III-3 M 1.25 1.30 1.40 0.96 0.89
III-4 M 0.00 1.05 1.18 - - Propositus
Genotype Data.
Gen. Sex Bel I Bgl I Bgl II Carrier status from
No Genotype
1-3 F 0.8/1.1 5.0/20.0 5.8/5.8 Carrier
II-1 M 0.8 - 5.8
II-2 F 0.8/1.1 - 5.8/5.8 N/A - Obligate carrier
II-4 F 0.8/1.1 - 5.8/5.8 N/A - Obligate carrier
II-6 F 1.1/1.1 5.0/20.0 5.8/5.8 Normal
III-l F 0.8/1.1 - 5.8/5.8 Normal
III-2 M 0.8 - 5.8 Propositus
III-3 M 1.1 - 5.8
III-4 M 0.8 - 5.8 Propositus
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Family No. 27 (continued).











Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 9
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data to:
CD AND
1-3 Potential carrier Carrier Informative Bel I: Yes Yes
Carrier
n-2 Obligate carrier Carrier Informative Bel I: N/A Yes
Obligate carrier
11-4 Obligate carrier Normal Informative Bel I: N/A Yes
Obligate carrier
n-6 Potential carrier Normal Normal Yes N/A
m-i Potential carrier Normal Informative Bel I: Yes N/A
Normal
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the 0.8kb Bel I allele. II-2 and II-4 are
obligate carriers each having a single affected son and a family history of haemophilia. II-2 has a
carrier phenotype but II-4 is normal. From the pedigree it is not clear whether the mutant gene
has originated with the maternal grandfather or maternal grandmother although the coagulation data
suggests the latter (1-3) and this is supported by genotypic analysis. From this data it is possible
to confidently exclude II-6 as a carrier as she has not inherited the 0.8kb allele. In addition it is
possible to exclude III-l as a carrier as she has inherited the normal l.lkb allele from her mother
and the 0.8kb allele from her father. II-4 and II-2 are both informative for the Bel I RFLP which




Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:CI Carrier status from:
No RCo vWF: Ag vWF:RCo Pedigree Phenotype
1-6 F 1.05 1.41 1.65 0.74 0.64 Normal Normal
II-2 F 0.45 0.94 1.30 0.48 0.35 Obligate carrier Carrier
n-4 F 0.32 1.30 1.20 0.25 0.27 Obligate carrier Carrier
n-7 F 0.50 1.75 1.30 0.29 0.38 Obligate carrier Carrier
ni-4 M 0.05 - - - - Propositus
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status from
No Genotype
1-6 F 0.8/1.1 _ - 2.8/5.8 N/A - Normal
II-2 F 1.1/1.1 20/20 6.2/6.2 2.8/5.8 N/A - Obligate carrier
II-4 F 0.8/1.1 - - 2.8/5.8 N/A - Obligate carrier
II-7 F 1.1/1.1 20/20 6.2/6.2 2.8/2.8 N/A - Obligate carrier
ra-4 M 1.1 20 6.2 2.8 Propositus
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Family No. 28 (continued).





Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.





















Informative Bel I: N/A Yes
Obligate carrier
Informative Bel I: N/A Yes
Obligate carrier
Informative Bel I: N/A Yes
Obligate carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [1.1/2.8] Bel I/Bgl II haplotype. 1-6 is a
normal female. II-2, II-4 and II-7 are all obligate carriers being the daughters of a severely affected
haemophiliac and all have a coagulation phenotype consistent with carriership. They are all
informative for the Bel I polymorphism and can, therefore, offered prenatal diagnosis.
Analysis of the family using the Bel I and Bgl II RFLP's shows a recombination between 1-6 and
II-2. The [1.1/2.8] haplotype is common to both II-2, II-4 and II-7 and is derived from 1-5. II-4
and II-7 have inherited either a [0.8/5.8] or a [1.1/2.8] haplotype from their mother but II-2 has
inherited a [1.1/5.8] indicating a cross-over between the Bel I and Bgl II loci. Non-paternity to






Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status
No RCo vWF:Ag vWF :RCo Pedigree
1-1 M 1.00 1.00 1.00 1.00 1.00
1-2 F 0.60 1.00 1.40 0.60 0.43 Obligate carrier
III M 0.00 1.10 0.67 - - Propositus
n-2 M 0.00 1.60 1.50 Propositus
Genotype Data.
Gen. Sex Bel I Bgl II Carrier status from
No Genotype
1-1 M 1.1 5.8
1-2 F 0.8/1.1 5.8/5.8 N/A - Obligate carrier
II-1 M 1.1 5.8 Propositus
II-2 M 1.1 5.8 Propositus
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Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.












1-2 Obligate carrier Normal Informative Bel I:
Obligate carrier
N/A Yes
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the 1.1 kb allele of the Bel I RFLP. 1-2 is an
obligate carrier having 2 affected sons although a normal coagulation phenotype. Unfortunately,
she is adopted and no previous family history was obtainable. However, she is informative for the










Pedigree and Phenotype Data.
6-i-n'
□
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
No RCo vWF:Ag vWF:RCo Pedigree Phenotype
II-1 F 0.41 0.76 2.20 0.54 0.19 Obligate carrier Carrier
II-2 M 1.00 - - -
III-l F 0.41 1.10 0.46 0.37 0.89 Potential carrier Carrier
m-2 M 0.01 - - - Propositus
Genotype Data.
Gen. Sex Bel 1 Bgl I Xba I Bgl II Carrier status from
No Genotype
II-1 F 0.8/0.8 5.0/5.0 4.8/4.8 2.8/5.8 N/A - Obligate carrier
II-2 M 0.8 5.0 6.2 5.8
III-l F 0.8/0.8 5.0/5.0 4.8/6.2 5.8/5.8 Carrier







Pedigree showing informative polymorphisms in investigated
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 4
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data t
CD AND
n-i Obligate carrier Carrier Informative Bgl II: N/A Yes
Obligate carrier
m-i Potential carrier Carrier Informative Xba I: Yes Yes
Carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [4.8/5.8] Xba I/Bgl II haplotype. 13-1 is an
obligate carrier and has a carrier phenotype. III-l is a potential carrier and has a carrier phenotype.
m-1 has inherited the haemophiliac haplotype [4.8/5.8] from her mother and is therefore, a carrier.
II-l is informative for the Bgl II polymorphism and III-l for the Xba I polymorphism and both,












Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII :C/ VIII:C/ Carrier status
No RCo vWF: Ag vWF :RCo Pedigree
1-1 M 0.72 0.50 0.80 1.40 0.90
1-2 F 0.30 0.66 0.69 0.45 0.43 Potential carrier
II-4 F 0.82 0.69 0.65 1.19 1.26 Potential carrier
II-6 F 0.56 0.76 1.40 0.74 0.40 Potential carrier
III-3 M 0.00 0.74 0.62 - -
III-4 F 1.00 0.70 0.70 1.43 1.43 Potential carrier
Genotype Data.
Gen. Sex Bel I Bgl I Bgl II Carrier status
N o Genotype
1-1 M 1.1 _ 2.8
1-2 F 0.8/1.1 5.0/5.0 2.8/5.8 Carrier
II-3 M 0.8 - 2.8
II-4 F 0.8/1.1 - 2.8/2.8 Potential carrier
II-6 F 0.8/1.1 - 2.8/2.8 Carrier
III-3 M 0.8 5.0 2.8
III-4 F 0.8/1.1 - 2.8/2.8 Normal
from
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Family No. 31 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 7
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data to:
CD AND
1-2 Potential carrier Carrier Heterozygous Bel V N/A Yes
Bgl II: Carrier
11-4 Potential carrier Normal Heterozygous Bel I: N/A Yes
Carrier
n-6 Potential carrier Normal Heterozygous Bel I: Yes Yes
Carrier
m-4 Potential carrier Normal Heterozygous Bel I: Yes Yes
Normal
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [0.8/2.8] Bel I/Bgl II haplotype and
genotypic analysis shows that this is derived from 1-2. 1-2 is a potential carrier and has an
abnormal coagulation phenotype.
Assuming 1-2 to be a carrier then II-6 has inherited the haemophilic haplotype and is, therefore a
carrier. III-4 is also a potential carrier although her coagulation phenotype is normal. She has
inherited the non-haemophilic haplotype [1.1/2.8] from her mother (II-4) and is therefore normal.











Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII :C/
No RCo vWF: Ag vWF:RCo
1-2 F 0.50 1.02 _ 0.49 _
II-1 F 0.60 0.64 0.68 0.94 0.88
II-3 M 0.00 - - - -
III-l F 0.70 0.91 0.80 0.77 0.87








Gen. Sex Bel I Bgl I Bgl II Carrier status from
No Genotype
1-2 F 0.8/1.1 5.0/5.0 2.8/5.8 Potential carrier
II-1 F 0.8/0.8 5.0/5.0 2.8/2.8 Potential carrier
II-3 M 0.8 5.0 5.8 Propositus
III-l F 0.8/1.1 5.0/5.0 2.8/2.8 Potential carrier
III-2 M 0.8 5.0 2.8
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Family No. 32 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 6
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data to:
CD AND
1-2 Potential carrier Carrier Heterozygous Bel 1/ No Yes
Bgl II: Potential carrier
n-i Potential carrier Normal Non-informative: Yes No
Potential carrier
III-I Potential carrier Normal Heterozygous Bel I/ Yes Yes
Potential carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [0.8/5.8] Bel I/Bgl II haplotype. 1-2 is a
potential carrier and has an abnormal coagulation phenotype. II-1 is a potential carrier although
her coagulation phenotype is normal.
Establishing the carrier status of II-l using the linked Bgl II polymorphisms suggests she is
normal as she has inherited the 'normal' 2.8kb Bgl II allele. However, the intragenic Bel I
polymorphism indicates she is a carrier as she has inherited the 'abnormal' 0.8kb allele. This
difference represents a cross-over or recombination between the Bel I and Bgl n loci and again
emphasises the problems associated with the use of linked RFLP's. Non-paternity to explain
these findings has not been excluded.
The carrier status of III-l cannot be established from the available data and ideally an informative




Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
No RCo vWF:Ag vWF: RCo Pedigree Pheno
II-3 F 1.00 1.65 1.30 0.61 0.77 Potential carrier Normal
III-l F 1.00 1.45 1.50 0.69 0.67 Potential carrier Normal
III-4 F 1.10 1.25 1.30 0.88 0.85 Potential carrier Normal
III-3 M 1.20 0.78 0.86 1.54 1.40
IV-3 M 1.00 0.90 0.94 1.11 1.06
IV-4 F 1.00 0.86 0.86 1.16 1.16 Potential carrier Normal

































Family No. 33 (continued).
















Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 6
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data to:
CD AND
n-3 Potential carrier Normal Heterozygous Bel I: Unhelpful Yes
Potential carrier
irr-i Potential carrier Normal Heterozygous Bel I/ Unhelpful Yes
Bgl II: Potential carrier
m-4 Potential carrier Normal Heterozygous Bel I: N/A Yes
Potential carrier
Implications and interpretations from these studies.
The haemophilic haplotype [1.1/2.8] has been inherited from the maternal grandfather. Although
clinically normal it is possible that he is a germ line mosaic in which case there is a risk that
HI-1 is a carrier.
Although the coagulation phenotype is normal in III-l and ni-4, ideally the mutation in the FV1H




Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
N o RCo vWF: Ag vWF:RCo Pedigree Phenotype
IV-3 M 1.05 1.28 1.40 0.82 0.75
rv-4 F 0.40 0.41 0.22 0.98 0.18 Obligate carrier Carrier
V-l M 0.00 - - - - Propositus
V-2 M 0.80 0.74 - 1.08 -
V-3 F 0.70 0.56 0.55 1.25 1.27 Potential carrier Normal
V-4 M 0.00 - - - - Propositus
V-5 M No data - - - - Clinically normal
Genotype Data.
Gen. Sex Bel I Bgl II Xba I Carrier status from
N o Genotype
IV-3 M 0.8 2.8 4.8
IV-4 F 0.8/0.8 5.8/2.8 4.8/6.2 N/A - Obligate carrier
V-l M 0.8 5.8 4.8 Propositus
V-2 M 0.8 6.2
V-3 F 0.8/0.8 2.8/5.8 4.8/4.8 Carrier
V-4 M 0.8 5.8 4.8 Propositus
V-5 M 0.8 2.8 6.2
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Family No. 34 (continued).





















Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 7
Gen. Status from Status from Genotypic




IV-4 Obligate carrier Carrier
V-3 Potential carrier Normal
Informative Xba 1/ N/A Yes
Bgl II: Obligate carrier
Informative Bgl II: Yes Yes
Carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [0.8/2.8/6.2] haplotype. IV-4 is an
obligate carrier and has an abnormal coagulation phenotype. She is informative for both the
Bgl II and Xba I polymorphisms and can be offered prenatal diagnosis if requested. V-3 has
inherited the haemophilic haplotype [4.8/5.8] from her mother and is, therefore, a carrier. She is




Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF: Ag vWF: VIII:C/ VIII:C/ Carrier status from:
No RCo vWF:Ag vWF:RCo Pedigree Phenotype
n-2 F _ _ _ _ _ Normal N/A
III-I F 0.35 0.64 - 0.55 - Obligate carrier Carrier
III-2 M 1.20 - - - -
III-3 F 0.73 0.64 - 1.14 - Obligate carrier Normal
III-5 M 0.01 ' " " " Propositus
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Taq I Carrier status from
No Genotype
II-2 F 0.8/0.8 5.0/5.0 4.8/6.2 5.8/5.8 4.8/5.2 N/A
III-l F 0.8/0.8 5.0/5.0 4.8/6.2 5.8/5.8 4.8/4.8 N/A - Obligate carrier
III-2 M 0.8 5.0 6.2 5.8 5.2
III-3 F 0.8/0.8 5.0/5.0 6.2/6.2 5.8/5.8 4.8/5.2 N/A - Obligate carrier
III-5 M 0.8 5.0 6.2 5.8 4.8 Propositus
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Family No. 35 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 5
Gen. Status from Status from Genotypic Applications of
No Pedigree Phenotype Data/Status genotypic data
CD AND
n-2 Normal N/A N/A N/A N/A
m-i Obligate carrier Carrier Informative Xba I: N/A Yes
Obligate carrier
III-3 Obligate carrier Normal Informative Taq I: N/A Yes
Obligate carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [4.8/6.2] Xba I/Thq I haplotype.
III-l and ni-3 are obligate carriers as both are the daughters of a severely affected haemophiliac
(now deceased) although only III-l has a carrier phenotype. III-l is informative for the intragenic
Xba I polymorphism whilst III-3 is homozygous for all markers except the linked Hq I
polymorphism. Both could be offered prenatal diagnosis but in the case of III-3 there would be a




























Bel I Bgl IGen. Sex
No
1-1 M 0.8 5.0
I-2 F No Data available
H-l F 0.8/0.8 5.0/5.0
II-2 F 0.8/0.8 5.0/5.0







N/A - Obligate carrier
N/A - Obligate carrier
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Family No. 36 (continued).





Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.












m-1 Obligate carrier No data





Implications and interpretations from these studies.
n-1 and H-2 are both obligate carriers being the daughters of an affected haemophiliac. They were













II-l M No data available - clinically normal
VIII:C/ Carrier status from:
vWF:RCo Pedigree Phenotype
H-2 F 0.65 1.02 0.56 0.64 1.16 Potential carrier Normal
III-l M 0.09 0.92 1.16 - - Propositus
m-2 F 1.80 1.60 1.10 1.12 1.64 Potential carrier Normal
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status
No Genotype
n-i M 0.8 4.8 5.8
II-2 F 0.8/0.8 5.0/5.0 4.8/4.8 2.8/5.8 Potential carrier
III-l M 0.8 5.0 4.8 5.8 Propositus
m-2 F 0.8/0.8 4.8 2.8/5.8 Normal
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Family No. 37 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
ill
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.




















Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the 5.8kb allele of the Bgl IIRFLP.
II-2 and III-2 are potential carriers and both have a normal coagulation phenotype. III-2 has
inherited a normal 2.8kb allele from her mother and a normal 5.8kb allele from her father and is,
therefore, not a carrier. There is a 10% chance of error due to two possible recombinations.
This family illustrates that in sporadic haemophilia, haplotype exclusion can be extremely




Pedigree and Phenotype Data.
Gen. Sex VIII:C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
No RCo vWF: Ag vWF :RCo Pedigree Phenotype
1-2 F No data available- _ _ _ Potential carrier
II-2 F No data available - - - Potential carrier
III-l F 0.58 0.66 1.12 0.88 0.52 Obligate carrier Normal
III-2 M 1.60 1.15 0.97 1.39 1.65
III-3 F 1.00 1.00 1.40 1.00 0.71 Obligate carrier Normal
IV-1 M 0.01 1.20 - - - Propositus
IV-2 F 1.50 0.90 0.92 1.67 1.63 Potential carrier Normal
IV-3 F 1.50 0.84 0.90 1.79 1.67 Potential carrier Normal
IV-4 M 0.01 - - - - Propositus
IV-5 F 1.70 1.10 1.40 0.55 1.21 Potential carrier Carrier
IV-7 F 2.00 1.80 0.78 1.11 2.56 Potential carrier Normal
Genotype Data.
Gen. Sex Bel I Xba I Bgl II Carrier status from
No Genotype
1-2 F 0.8/0.8 _ 5.8/5.8 Potential carrier
II-2 F 0.8/0.8 - 2.8/5.8 Potential carrier
III-l F 0.8/1.1 - 2.8/5.8 N/A - Obligate carrier
III-2 M 0.8 - 5.8
III-3 F 0.8/1.1 4.8/6.2 2.8/5.8 N/A - Obligate carrier
IV-1 M 0.8 4.8 2.8 Propositus
IV-2 F 0.8/1.1 - 5.8/5.8 Normal
rv-3 F 0.8/1.1 - 5.8/5.8 Normal
IV-4 M 0.8 - 2.8 Propositus
IV-5 F 0.8/1.1 - 2.8/5.8 Normal
IV-7 F 0.8/1.1 - 2.8/5.8 Normal
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Family No. 38 (continued)



















f 0.8 0.8/1.1 0.8/0.8 0.8/1.1
* 2.8 2.8/5.8 2.8/5.8 2.8/5.8
4.8
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 11
Gen. Status from Status from Genotypic




1-2 Potential carrier No data Non-informative:
Potential carrier
No Yes
n-2 Potential carrier No data Heterozygous Bgl II:
Potential carrier
No Yes








IV-2 Potential carrier Normal Heterozygous Bel I:
Normal
Yes N/A
rv-3 Potential carrier Normal Heterozygous Bel I:
Normal
Yes N/A
IV-5 Potential carrier Normal Heterozygous Bel I:
Normal
Yes N/A
rv-7 Potential carrier Normal Heterozygous Bel I: Yes N/A
Normal
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Pedigree No. 38 (continued).
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is marked by the [0.8/2.8/4.8] Bel I/Bgl n/Xba I haplotype.
III-l and m-3 are both obligate carriers although their coagulation phenotypes are normal. The
haemophilic haplotype has not been inherited by IV-2, IV-3, IV-5 or IV-7 and they are, therefore,
normal. Both IIt-1 and IH-3 are informative for the Bel I and Xba I polymorphisms and can be









Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status
No RCo vWF: Ag vWF:RCo Pedigree
II-1 F 0.72 0.68 0.86 1.06 0.84 Obligate carrier
II-3 F 0.15 0.74 0.86 0.20 0.17 Obligate carrier
m-1 M 0.00 1.24 1.10 - - Propositus
m-2 M 0.00 1.36 1.34 - - Propositus






Gen. Sex Bel I Bgl I Xba I Bgl II Taq I Carrier status froi
No Genotype
II-1 F 0.8/0.8 _ _ 5.8/5.8 4.8/5.25 N/A - Obligate carrier
II-3 F 0.8/0.8 5.0/5.0 4.8/4.8 5.8/5.8 4.8/5.2 N/A - Obligate carrier
m-i M 0.8 5.0 4.8 5.8 4.8 Propositus
III-2 M 0.8 5.0 4.8 5.8 4.8 Propositus
III-4 F 0.8/1.1 - - 5.8/5.8 Potential carrier
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Family No. 39 (continued).








Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 5
Gen. Status from Status from Genotypic




n-1 Obligate carrier Normal
n-3 Obligate carrier Carrier
m-4 Potential carrier Nomial
Informative Bel I: N/A Yes
Obligate carrier




Implications and interpretations from these studies.
In this family the haemophilic gene is marked by the [0.8/4.8] Bel I/Taq I haplotype.
II-1 and II-3 are both obligate carriers although only II-3 has an abnormal phenotype. II-1 is
informative for the Bel I polymorphism and 1-3 for the T&q I polymorphism. No data was
available on the father of III-4.
This family illustrates the differences in Lyonisation which can occur in obligatory carriers (II-l
VIII:C 0.72; D-3 VIII:C 0.15) and highlights the problems in phenotypic based methods of carrier
detection.
The finding of identical Taq I alleles in II-1 and n-3 but different Bel I alleles suggests either 1-2 is
homozygous [5.2/5.2] or a recombination has occurred between the Bel I and Taq I loci. DNA was
not available on the maternal grandparents to clarify this.
An alternative explanation and more plausible for these findings is non-paternity. As II-I and II-3
are both obligate carriers and their putative father is normal, the difference in their Bel I markers
suggests they have different fathers as the maternal Bel I marker (she must be an obligate carriers)
should be the same in the two women. These findings emphasise the necessity for paternity




Pedigree and Phenotype Data.
Gen. Sex VIII: C vWF:Ag vWF: VIII:C/ VIII:C/ Carrier status from:
No RCo vWF: Ag vWF:RCo Pedigree Pheno
1-1 M 0.83 0.90 1.00 0.92 0.83
1-2 F 0.43 0.66 0.79 0.65 0.54 Potential carrier Carrier
II-1 M 0.00 1.00 - - - Propositus
II-2 F 1.00 0.90 0.77 1.11 1.30 Potential carrier Normal
Genotype Data.
Gen. Sex Bel I Bgl I Xba I Bgl II Carrier status from
No Genotype
1-1 M 1.1 5.0 6.2 5.8 Propositus
1-2 F 0.8/0.8 5.0 4.8/6.2 2.8/5.8 Potential carrier
III M 0.8 5.0 6.2 5.8
n-2 F 0.8/1.1 5.0/5.0 4.8/6.2 2.8/5.8 Normal
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Family No. 40 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 4
Gen. Status from Status from Genotypic








Heterozygous Xba V No Yes
Bgl II: Potential carrier
Heterozygous Xba 1/ Yes N/A
Bgl 11/ Bel I: Normal
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is associated with the [0.8/6.2/5.8] Bel I/Xba I/Bgl II
haplotype. 1-2 and II-2 are both potential carriers although only 1-2 has an abnormal coagulation
phenotype. Genotypic analysis shows the haemophilic haplotype [0.5/6.2/5.8] has not been
























VIII:C/ VIII:C/ Carrier status from:
vWF:Ag vWF:RCo Pedigree Phenotype
0.23 - Obligate carrier Carrier
Propositus
1.30 - Potential carrier Normal
Genotype Data.
Gen. Sex Bel I Xba I
No
II-2 M 0.8 6.2
III F 0.8/0.8 4.8/6.2
m-2 M 0.8 6.2
m-1 F 0.8/0.8 4.8/6.2
Bgl II Carrier status from
Genotype
2.8




















Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 4
Gen. Status from Status from Genotypic




n-1 Obligate carrier Carrier
m-1 Potential carrier Normal
Informative Xba 1/ N/A Yes
Bgl II: Obligate carrier
Heterozygous Xba U Yes N/A
Bgl II: Normal
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is associated with the [2.8/6.2] Bgl Il/Xba I haplotype.
II-1 is an obligate carrier as she is the daughter of a haemophiliac. III-l is a potential carrier but
has a normal coagulation phenotype. She has inherited the normal [5.8/4.8] haplotype from her
mother rather that the haemophilic [2.8/6.2] haplotype and is therefore normal. II-l is informative


































Gen. Sex Bel I Xba I Bgl I Bgl II Carrier status from
No Genotype
III M 0.8 4.8 5.0 2.8
II-2 F 0.8/1.1 4.8/6.2 5.0/20 2.8/2.8 Propositus
III-l M 1.1 6.2 20 2.8
m-2 F 0.8/0.8 4.8/4.8 5.0/5.0 2.8/2.8 Carrier
* See following page and text.
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Family No. 42 (continued).


















Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.


















Implications and interpretations from these studies.
II-2 was found to have an abnormal coagulation profile consistent with carriership of
haemophilia A, although there was no positive family history. The possibility of an unusual
form of von Willebrand's disease affecting the VIII :C binding site has not been excluded. Studies
to clarify this is are currently in progress.
From RFLP analysis, as II-l is normal the other maternal haplotype [0.8/2.8/4.8] must be
associated with the proposed haemophilic gene and as ni-2 has inherited this we can infer that if II-
2 is a carrier of haemophilia A then so is her daughter - a finding supported by the abnormal
coagulation phenotype. These findings do not exclude vWD - if vWF binding studies are normal
then identification of any mutations in the FVIII gene should be attempted. Although the
genotypic and phenotypic data in this family are in agreement, variant von Willebrand's disease




Pedigree and Phenotype Data.
Gen. Sex Carrier status from:
No Pedigree
1-1 F No data available Potential carrier
1-2 M No data available Normal
IT-1 M 0.01 Propositus
II-2 F No data available Potential carrier
Genotype Data.












Family No. 43 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 4
Gen. Status from Status from Genotypic Applications of
N o Pedigree Phenotype Data/Status genotypic data
CD AND
1-1 Potential carrier No Data Heterozygous Bel I: N/A Yes
Potential carrier
n-2 Potential carrier- No Data Homozygous: Yes N/A
Normal
Implications and interpretations from these studies.
Although no phenotypic data was available on this family, from the pedigree 1-1 and II-2 are both
potential carriers. Genotypic analysis shows that the mutant gene is marked by the 0.8kb Bel I
allele. II-2 can be excluded as a carrier as she has inherited a normal 1.1 kb allele from her father
and a normal 1 .Ikb allele from her mother.
1-1 is informative for the Bel I polymorphism and although her carrier status has not been
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Gen. Sex Bel I Xba I Bgl I Bgl II
No
II-1 M 0.8 4.8 5.0 5.8
n-2 F 0.8/0.8 4.8/4.8 5.0/5.0 2.8/5.8
III-l M 0.8 4.8 5.0 2.8
m-2 F 0.8/0.8 4.8/4.8 5.0/5.0 2.8/5.8
Carrier status from
Genotype




Family No. 44 (continued).





Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.
Number of Family members studied: 4
Gen. Status from Status from Genotypic




n-2 Obligate Carrier No Data
m-2 Potential carrier No Data
Informative Bgl II: N/A Yes
Obligate carrier
Informative Bgl II: Yes Yes
Carrier
Implications and interpretations from these studies.
In this pedigree the haemophilic gene is associated with the 2.8kb Bgl II allele.
II-2 is an obligate carrier and informative for the linked Bgl II marker III-2 has inherited the
abnormal 2.8kb Bgl II allele from her mother and is, therefore, probably a carrier. The Bgl II
RFLP could be used for prenatal diagnosis in both II-2 and III-2 if requested although with a 5%
chance of error due to possible recombination.
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Appendix 2.
Pedigree, Phenotypic and Genotypic Data on Families with





































N/A - Obligate carrier
Propositus
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Family No. B1 (continued).







Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.












m-3 Obligate carrier Normal Informative Taq 1/ N/A
Xmn I: Obligate carrier
Yes
Implications and interpretations from these studies:
III-3 is an obligate carrier of haemophilia B having a single affected son and a family history.
She is informative for both the Taq I and Xmn I polymorphisms and either of these could be used







Pedigree and Phenotype Data.
Gen. Sex IX:C IX: Ag Carrier status from:
No Pedigree Phenotype
n-2 M 1.20 1.30
n-3 F 0.40 0.30 Potential carrier Carrier
m-i M 0.15 0.12 Propositus
m-2 M 0.94 0.56
m-3 F 0.32 0.40 Potential carrier Carrier
Genotypic Data.
Gen. Sex Taq I Xmn I Dde I Carrier status
No Genotype
n-2 M 1.8 11.5 1.70
n-3 F 1.8/1.8 11.5/11.5 1.70/1.75 Potential carrier
m-i M 1.8 11.5 1.75 Propositus
m-2 M 1.8 11.5 1.70
III-3 F 1.8/1.8 11.5/11.5 1.70/1.75 Carrier
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Family No. B2 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members.
Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.












n-3 Potential carrier Carrier Heterozygous N/A Yes
Dde I: Carrier
m-3 Potential carrier Carrier Heterozygous Yes Yes
Dde I: Carrier
Implications and interpretations from these studies:
In this pedigree the haemophilic gene is marked by the 1,75kb allele of the Dde I polymorphism.
II-3 and III-3 are potential carriers of haemophilia B and both have abnormal coagulation
phenotypes. Assuming II-3 is a carrier then III-3 has inherited the haemophilic haplotype
(supported by the abnormal phenotype). Both II-3 and III-3 are informative for the Dde I
polymorphism and could be offered prenatal diagnosis if requested. This family illustrates the
value of a combined approach to carrier detection in apparently sporadic disease utilising both




Pedigree and Phenotype Data.
Gen. Sex IX:C IX: Ag Carrier status from:
No Pedigree Phenoi
1-2 F No data Potential carrier No data
n-i M 1.00 -
n-2 F 0.25 - Obligate carrier Carrier
m-i M 1.00 1.00
m-2 F 0.48 0.60 Obligate carrier Carrier
IV-1 M 0.06 0.07 Propositus
rv-2 M 1.00 0.80
















6.5/11.5 N/A - Obligate carrier
11.5





Family No. B3 (continued).




Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.

































Implications and interpretations from these studies:
In this pedigree the haemophilic gene is marked by the [1.3/6.5] Taq I/Xmn I haplotype. El-2 and
III-2 are both obligate carriers, have abnormal coagulation phenotypes and are informative for both
the Taq I and Xmn I polymorphisms either of which could be used in prenatal diagnosis. The
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Pedigree and Phenotype Data.
Gen. Sex IX:C Carrier status from:
No Pedigree Phenotype
n-i F 0.50 Potential carrier Carrier
n-2 M -
n-3 F 0.80 Potential carrier Normal
n-5 F - Potential carrier
n-7 F - Potential carrier
UI-l F - Potential carrier
ffl-2 M 0.15 Propositus
Genotypic Data.













6.5/11.5 Potenti al carrier
6.5/11.5 Potential carrier
6.5/11.5 Potential carrier
6.5/11.5 Potenti al carrier
11.5 Propositus
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Family No. B4 (continued).












Summary of pedigree, phenotypic and genotypic data in obligate and potential
carriers.












H-l Potential carrier Normal
D-3 Potential carrier Normal
n-5 Potential carrier Normal
H-7 Potential carrier Normal





















Implications and interpretations from these studies:
In this kindred the haemophilic haplotype [1.8/11.5] is found in all 5 potential carriers (II-1, II-3,
II-5, II-7 and III-1). Unfortunately, they all have a normal coagulation phenotype and it is
impossible to accurately assign carrier status. Ideally the kindred specific defect should be




Pedigree and Phenotype Data.
Gen. Sex IX:C IX:Ag
No
n-1 F 0.16 0.12
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Family No. B5 (continued).
Abbreviated Pedigree showing informative polymorphisms in investigated
members.
Number of Family members studied: 1
Implications and interpretations from these studies:
This family is discussed in detail on at the end of Chapter 3.
II-l was found to have low levels of both IX:C and IX:Ag although no family history of
Christmas disease. Further investigations demonstrates an unusual chromosomal karyotype -
XO/XXinv. Amplification and sequencing of the FIX gene demonstrated a single point mutation
at codon 76 resulting in the substitution of a glycine by a valine. Coagulation testing and
karyotype analysis in III-l were entirely normal.
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Appendix 3.
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Results from genotypic investigations.
Gen. Sex Bel I Xba I Bgl I Bgl II Taq I
No
1-1 M 0.8 4.8 5.0 2.8 4.1
1-2 F 0.8/0.8 4.8/4.8 5.0/5.0 5.8/2.8 4.5/3.9
n-i F 0.8/0.8 4.8/4.8 5.0/5.0 5.8/2.8 4.5/4.1
n-3 M 0.8 4.8 5.0 2.8 3.9
n-4 F 0.8/0.8 4.8/4.8 5.0/5.0 2.8/5.8 4.1/3.9
m-i M 0.8 4.8 5.0 5.8 4.5
m-4 M 0.8 4.8 5.0 5.8 4.5
346
Pedigree No. CI (continued)
Summary of the pedigree, phenotypic and genotypic data.
Number of Family members studied: 7
Gen. Status from Status from Genotypic
No Pedigree Phenotype data
1-2 Potential carrier No data available Heterozygous Bgl II/Tkj I:
Potential carrier
n-i Obligate carrier Carrier Heterozygous Bgl II/Taq I:
Obligate carrier
II-4 Potential carrier No data available Heterozygous Bgl II/Taq I
?Normal
Implications and interpretations from these studies:
In this family a single boy (III-l) was found to be suffering from X-linked adrenoleukodystrophy.
Subsequent investigations on his brother (III-2) showed that he was also affected. Studies on their
mother (II-1) showed abnormal long chain fatty acids consistent with carriership of the disease.
The finding of two affected individuals with the same mother (II-l) establishes her as an obligate
carrier. As the gene maps close to that of the FVIII locus, the use of the FVm gene probes allows
carrier detection studies using RFLP's (See Chapter 2). Genotypic analysis of this family shows
them to be non-informative for the three intragenic RFLP's but informative for the linked Bgl II
and Taq I polymorphisms. The abnormal haplotype [4.5/5.8] is derived from 1-2.
II-4 shows a recombination between the Bgl II (Probe DX13 (DXS15)) and Taq I (Probe Stl4
(DXS52)) loci. However, despite this recombination, the DXS52 loci, which is thought to be
closest to the ALD locus reduces the risk that II-4 is a carrier.
Correct paternity is assumed in this family but was not confirmed. The DXS52 and DXS15 loci
are physically close to each other and, therefore, recombination is unlikely.
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